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ABSTRACT
Chromatin remodelling provides a key mechanism for the regulation of gene expression
through dynamic alterations in nucleosome occupancy at promoters and enhancers.
Haploinsufficiency for the ATP-dependent chromatin remodeller chromodomain-helicase-DNA-
binding protein 7 (CHD7) causes human CHARGE syndrome. CHARGE is characterised by a
distinct pattern of congenital anomalies, including cardiovascular malformations, and has
traditionally been considered a neurocristopathy. However, a number of the congenital heart
defects associated with CHARGE cannot be attributed to disruption to the neural crest alone.
This thesis therefore addresses the tissue-specific requirements and roles for CHD7 during
cardiogenesis.
CHD7 protein is shown to be present throughout the developing heart until E13.5. Conditional
ablation of Chd7 in the early cardiogenic mesoderm results in embryonic lethality due to
severe cardiovascular defects. These include haemorrhaging and oedema, major venous and
arterial pole malformations, and disruption to cardiac innervation and vascularisation. To
further dissect tissue-specific requirements for CHD7, cardiomyocyte-, second heart field- and
endothelial-specific knockdowns were also performed. Each cross results in a milder subset of
the cardiac defects observed after mesodermal ablation, indicating that CHD7 is required in
multiple lineages within the cardiogenic mesoderm.
Microarray analysis and validation by in situ hybridisation were used to identify genes
dysregulated in the heart following mesodermal Chd7 ablation. These included components of
the Semaphorin and Slit-Robo signalling pathways, which have known roles in heart
development. Furthermore, aberrant expression of genes involved in calcium handling within
cardiomyocytes is seen. Excitation-contraction coupling is disrupted in mutant embryonic
cardiomyocytes, demonstrating relevance of the gene expression changes at the cellular level.
This work reveals a requirement for CHD7 in mesodermal cardiac progenitors for both inflow
and outflow tract development. Novel pathways are identified downstream of CHD7 activity in
the developing heart, including the extracellular Semaphorin and Slit-Robo pathways, as well
as components of the excitation-contraction coupling machinery.4
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CHAPTER ONE
INTRODUCTION
1.1 Heart and great vessel development
The heart is the first functional organ to form in the embryo, and is essential for embryonic
survival. The development of the heart involves a series of tightly-regulated morphological
changes, from establishment of a linear myocardial-endocardial tube to looping, chamber
formation and septation. Cells from a range of developmental origins contribute to its
formation. This section will provide an overview of these complex morphological events in the
mouse embryo and the cellular contributions to the developing cardiac structures.
1.1.1 The cardiogenic mesoderm and formation of the linear heart tube
Mesodermal myocardial progenitor cells emerge from the primitive streak at around
embryonic day (E)6.5 and migrate in an anterior-lateral direction (Garcia-Martinez and
Schoenwolf, 1993) (Figure 1-1, A). As these cells then extend across the midline they form the
characteristic ‘cardiac crescent’ by around E7.5, which sits just under the head fold and
comprises differentiated myocardial cells (Figure 1-1, B). These cells then fuse at the midline at
E8.0 to form the early heart tube, which from a frontal view resembles an inverted Y (Figure
1-1, C). Already this early structure consists of an interior layer of endocardial cells and an
exterior layer of myocardial cells, separated by extracellular matrix, known as cardiac jelly, that
is important for signalling between the two layers (Srivastava, 2006). Marking studies using
iron oxide have shown that the ‘arms’ of the Y, which are continuous with the developing
venous tributaries of the embryo, are fated to become the atrial chambers, whilst the ‘stem’
will become the left ventricle (Maria V. de la Cruz, 1991).
The pool of cardiogenic mesodermal cells that forms this primary heart tube is known as the
first heart field (FHF) (Buckingham et al., 2005). There is also a more recently-discovered
second source of myocardial cells, termed the second heart field (SHF), that lies medially to the
FHF and extends into the mesodermal layer of the pharyngeal arches (Kelly et al., 2001;
Mjaatvedt et al., 2001; Waldo et al., 2001) (Figure 1-1, B). It is proposed the FHF-myocardial
cells provide a scaffold onto which the SHF cells migrate to both poles of the heart in order to
extend the heart tube (Kodo and Yamagishi, 2011), where they then contribute to the right
ventricle, both atria and the outflow tract (OFT, Figure 1-1, B-E, and Figure 1-5, A).18
Concomitant with the extension of the heart tube by SHF cells, the heart tube begins to loop in
a rightward direction, from about E8.5 (Figure 1-1, D-E). This looping is initiated by the
detachment of the developing left ventricle from the mediastinum, so once liberated the heart
tube is able to bend (Moorman et al., 2003). The heart loops in a rightward direction, which is
usually considered the first visible sign of asymmetry in the early embryo, although the
establishment of the left-right axis occurs much earlier during the gastrulation stage of the
embryo (Shiratori and Hamada, 2006).
Figure 1-1: Formation and looping of the early heart tube
(A) Migration of mesodermal cardiogenic cells from the primitive streak (PS) at E7.5.
(B) The cardiac crescent (CC, orange) of FHF progenitors is located below the head folds at E7.75, with
the SHF (pale green) seen medially.
(C) The primary heart tube of FHF myocardial cells is seen at E8.0, with extension at both poles of
myocardium derived from the SHF (dark green). The frontal view (left) shows clearly the inverted Y
shape, whilst the lateral view (right) highlights the linear tube. Tbx18
+ cells that form the sinus venosus
are shown in purple.
(D) At E8.5 the heart starts to loop in a rightward direction, and cardiac neural crest cells (cNCC, yellow)
start to migrate from the dorsal neural tube towards the heart.
(E) By E9.5 further looping and ballooning of chambers has occurred, and further extension of the heart
tube from the SHF. The proepicardial organ (PEO, blue) has also attached to the myocardium and the
cardiac NCCs are migrating through the pharyngeal arches towards the arterial pole.
Taken from Vincent (2010). PS indicates primitive streak; CC, cardiac crescent; PA, pharyngeal arch; AP,
arterial pole; VP, venous pole; cNCC, cardiac neural crest cells; PEO, proepicardial organ.19
1.1.2 Chamber formation and septation
As the linear heart tube undergoes looping, it is segmented into atrial, ventricular and OFT
components, with a distinct atrioventricular canal (AVC) separating the atria and ventricles
(Figure 1-2, A and B). The apical parts of both right and left regions of the emerging ventricular
loop balloon from the outer heart curvature and become trabeculated, which gives each
ventricle its characteristic morphology (Moorman and Christoffels, 2003). Similarly, the
supero-lateral walls of the atrial component of the primary heart tube also balloon out to both
sides of the OFT to give the atrial appendages. By around E10.5-E11.5, once looping is
complete, the recognisable chamber components are assembled (Figure 1-2, C). However, the
AVC opens to the developing left ventricle, whilst the OFT is supported above the developing
right ventricle, so further rearrangement and separation of the right and left sides of the heart
is required in a process known as septation.
Figure 1-2: Localised chamber formation in the early heart tube
(A) Left view of a model linear heart tube at E8.0. Primary myocardium is shown in gray, the aortic sac
with arterial branches is in green at the arterial (oft) pole and the systemic venous tributaries are
marked in green at the inflow tract (ift). Anteroposterior (A-P) and dorsoventral (V-D) axes are shown.
(B) A model of the chamber-forming heart at ~E9.5 (also left view). Ventricular (red) and atrial (blue)
myocardial appendages have been added to the ventricular loop and primary atrium, and the ventricular
and atrial components are seprated by the atrioventricular canal (avc). The orange arrows indicate the
ventricular and atrial inner curvatures.
(C) Frontal view of model of chamber-forming heart at ~E10.5, with same colour scheme as (A) and (B),
highlights the ballooning atrial and ventricular appendages.
Taken from Christoffels et al. (2004). oft indicates outflow tract; ift, inflow tract; rv, right ventricle; lv, left
ventricle; avc, atrioventricular canal; at, atrium; san, sinoatrial node; avn, atrioventricular node.20
Local tissue swellings known as endocardial cushions are formed from the cardiac jelly in the
lumen of the AVC, in between the endocardium and the myocardium, and are populated by
mesenchymal cells of endocardial origin (Lin et al., 2012). These cushions play a key role in the
septation of the atria, the AVC and the ventricles. Prior to septation of the atria, the systemic
venous tributaries are re-orientated to the right side of the common atrial chamber, whilst a
newly-formed pulmonary vein gains entrance to the left side (Webb et al., 2001). The primary
atrial septum then forms as a muscular shelf descending from the roof of the atrial chamber
into the atrial cavity, in between the systemic and pulmonary veins. A mesenchymal cap is
present on the leading edge of this developing septum (Anderson et al., 2002). At the same
time, another mass of mesenchyme enters the heart from the posterior mediastinum, which is
referred to as the vestibular spine (also described in the literature as the dorsal mesenchymal
protrusion) (Webb et al., 1998). It is the fusion of these mesenchymal primordia that both
separates the right and left atria and divides the common AVC into its right and left
components: the mesenchymal cap of the primary atrial septum first fuses with the vestibular
spine, followed by fusion with the superior and inferior endocardial cushions, which
themselves have also grown towards each other and fused (Anderson et al., 2003a).
The muscular inter-ventricular septum forms concomitantly with the ballooning of the apical
components of the ventricles from the primary heart tube. As it grows into the apical cavity of
the ventricles, it separates entirely the inlet component of the right ventricle from the left
ventricle, as the right ventricle instead now has direct continuity from the developing right
atrium. The crest of the inter-ventricular septum finally fuses with the proximal OFT cushions
(see next section) by around E14.5, to ensure the aorta arises exclusively from the left ventricle
and the pulmonary trunk from the right ventricle.
1.1.3 Septation of the outflow tract
The common OFT arising from the right ventricle after heart looping (Figure 1-2, C) also needs
to be separated into the aorta and pulmonary trunk, which constitutes the arterial pole of the
mature heart. The OFT can be arbitrarily divided into distal and proximal portions, which are
separated by a characteristic ‘dog-leg bend’ (Figure 1-3, A). At this stage, the walls of the OFT
have an exclusively myocardial phenotype, whilst the lumen is lined with cardiac jelly, which
concentrates into two pairs of endocardial cushions that spiral around each other along the full
length of the OFT (Figure 1-3, B). These cushions are populated by both mesenchymal cardiac
neural crest cells (NCCs), which have delaminated from the dorsal neural tube and migrate
through the pharyngeal arches to enter the distal and then proximal endocardial cushions21
(Jiang et al., 2000; Kirby et al., 1983), and cells of endocardial origin that transform into
mesenchyme to contribute to the more proximal cushions (Lincoln et al., 2004).
Septation of the OFT appears to be initiated by the major rearrangements in the pharyngeal
region that occurs as the great vessel configuration is established (see Section 1.1.4). Although
the precise mechanism underlying septation remains controversial, a septal structure known
as the aorto-pulmonary (AP) septum seems to play a key role (Webb et al., 2003). The AP
septum is a wedge of tissue in the dorsal wall of the aortic sac that separates the origins of the
4
th and 6
th pharyngeal arch arteries (PAAs, see Figure 1-4). It is proposed that the remodelling
of the PAAs initiates fusion of the AP septum with the most distal end of the OFT endocardial
cushions. Septation then proceeds in a ‘zipper-like’ fashion in a distal-to-proximal direction,
through fusion of the endocardial cushions as they approach each other across the OFT lumen
(Hutson and Kirby, 2007). The aortic blood becomes directed through the left 4
th PAA, which
becomes part of the aortic arch, whilst the pulmonary blood exits through the left 6
th PAA.
Finally, the proximal OFT cushions fuse with the AVC cushions where they span the
ventricular septum, closing the inter-ventricular foramen and completing both septation of the
OFT and the ventricles (Anderson et al., 2003b).
As septation occurs, the distal OFT region (now the intrapericardial components of the aorta
and pulmonary trunk) rapidly becomes arterialised. The most proximal region instead is
‘myocardialised’ through invasion of the cushions by cardiac myocytes from the parietal walls
of the OFT, so that as fusion with the ventricular septum is completed the aorta is completely
walled into the left ventricle (van den Hoff et al., 1999). Septation of the cardiac chambers and
OFT to form the well-characterised four-chambered heart ensures separation of the right and
left sides of the mature heart (see Figure 1-5, B). The pulmonary trunk arises exclusively from
the right ventricle to carry blood to the lungs, from which oxygenated blood can return
through the left atrium and then ventricle, where it is pumped to the systemic circulatory
system through the aorta. Correct septation is therefore essential for keeping the pulmonary
and systemic systems separated. The development of the atrioventricular (mitral and tricuspid)
valves and the semilunar (aortic and pulmonic) valves, also from the AVC and OFT endocardial
cushions respectively (de Lange et al., 2004), plays a further important role in ensuring blood
flows in a single direction from the atria to the ventricles and then to the arteries.22
Figure 1-3: Septation of the outflow tract
(A) Scanning electron micrograph of a ventral view of a human embryonic heart at Carnegie stage 15
(approximately E11.5 in the mouse), shows a ventral view of the heart. A characteristic ‘dog-leg bend’
separates the distal and proximal segments of the unseptated OFT.
(B) Reconstruction of the heart to show the spiralling endocardial cushions extending along the full
length of the distal and proximal OFT. A represents the aortic intercalated cushion, B the septal cushion,
C the pulmonary intercalated cushion and D the parietal cushion. The mesenchymal contribution from
the cardiac neural crest is indicated in purple.
Images taken from Webb et al. (2003).
1.1.4 Great vessel development
Another key process in the development of the cardiovascular system is the remodelling of the
PAAs to form the mature aortic arch with right and left common carotid and subclavian
arteries. Primitive pharyngeal vessels form as a result of local differentiation of mesodermal
cells to endothelial cells (Graham, 2003), to which NCCs migrate and differentiate to form a
layer of vascular smooth muscle cells surrounding the vessel endothelium (Jiang et al., 2000)
(Figure 1-4, A). By E10.5 the 3
rd, 4
th and 6
th PAAs have formed and connect the aortic sac to the
left and right dorsal aortas in a symmetric arrangement (Figure 1-4, B). These PAAs then
undergo a complete remodelling process involving programmed asymmetrical expansion,
regression and spatial rearrangements of the vessels, so that by E14.5 the final aortic arch
structure, derived from the aortic sac, PAAs and the left dorsal aorta, is completed (Hiruma et
al., 2002) (Figure 1-4, C-E). During this process, the pharyngeal surface ectoderm plays a key
role in signalling to the neural crest for aortic arch patterning (Basch and Bronner-Fraser, 2006;
Kameda, 2009). After birth, the ductus arteriosus, which during development links the right
ventricle to the aortic arch as part of the fetal circulation, regresses so the pulmonary and
systemic circulatory systems are completely separated.23
Figure 1-4: Remodelling of the Pharyngeal Arch Arteries to form the Great Vessels
(A) Ventral view shows at E9.5, only the 1
st and 2
nd PAAs have formed, which connect the aortic sac
(light grey) at the arterial pole of the heart to the paired dorsal aortas (dark grey).
(B) By E10.5, the 1
st and 2
nd PAAs have formed the capillary beds of their pharyngeal arches. The aortic
sac is now connected to the dorsal aortas via the 3
rd, 4
th and 6
th PAAs, which have formed symmetrically
in a rostro-caudal direction.
(C) At E11.0 the pulmonary arteries (yellow) can be clearly seen. The overall arrangement is still
symmetrical at this time point.
(D) From E11.5 increased blood flow through the left 6
th PAA drives asymmetrical remodelling,
stabilising the aortic arch on the left and leading to its loss on the right. Segments of the dorsal aortas
between the 3
rd and 4
th PAAs on both sides degenerate to allow individualisation of the common carotid
arteries that are formed from the left and right 3
rd PAAs. The right dorsal aorta is also degenerating
below the regressing right 6
th PAA.
(E) By E14.5 the mature configuration of the great vessels is seen. The right 6
th PAA is lost completely,
along with most of the right dorsal aorta. The aortic arch derived from the aortic sac and the left 4
th PAA
is connected solely to the (left) dorsal aorta, whilst the right 4t PAA connects the brachycephalic trunk
to the right subclavian artery. The left 6
th PAA has formed the ductus arteriosus, which connects the
(left) dorsal aorta to the pulmonary trunk in the embryo, but will regress at birth to separate the
systemic and pulmonary circulations.
Taken from Vincent (2010). PAA indicates pharyngeal arch artery; RSA, right subclavian artery; RCC, right
common carotid; LSC, left subclavian artery; LCC, left common carotid; BT, brachycephalic trunk; Ao,
aorta; DA, ductus arteriosus; PT, pulmonary trunk; PA, pulmonary arteries; T, trachea.24
1.1.5 Contribution of different lineages to the developing heart
As mentioned in Section 1.1.1, within the cardiogenic mesoderm there are two fields of
progenitor cells with myocardial potential: the FHF that forms the primary cardiac tube, and
the SHF (also referred to as the anterior heart field) that contains cells recruited to both poles
of the tube. This distinct second source of myocardial progenitors was first visualised in the
mouse embryo using a lacZ transgene under the control of an Fgf10 gene regulatory element.
Cells with lacZ expression were seen in the pharyngeal mesoderm anteriorly and dorsally to
the cardiac tube, which then contributed to the myocardium at the anterior pole of the heart
(Kelly et al., 2001). This was confirmed by DI-I labelling, which also demonstrated this SHF
population contributes to the right ventricle (Zaffran et al., 2004), whilst lineage tracing of
Islet1-expressing cells showed the SHF extends further posteriorly to contribute to the venous
pole as well (Cai et al., 2003).
Retrospective clonal analysis has confirmed that the FHF and SHF contain distinct myocardial
lineages (Meilhac et al., 2004). This experiment was based on random labelling of precursor
cells, whereby a lacZ reporter carrying a non-functional duplication (laacZ) is randomly
rendered functional again by very rare spontaneous intragenic recombination events that
remove the duplication, allowing clonal analysis by β-galactosidase staining. Evaluation of β-
galactosidase positive cells at E8.5 identified two distinct lineages, one that contributed to
both ventricles, the AVC and both atria, whilst the other contributed to the right ventricle,
AVC, atria and the OFT (summarised in Figure 1-5, A). Therefore, the distinct first and second
clonal lineages correspond directly with the cells from the FHF and SHF. Furthermore, this
retrospective clonal analysis indicated that the first and second lineages segregate from a
common mesodermal precursor before the cardiac crescent stage (Buckingham et al., 2005;
Meilhac et al., 2004).
In addition to the cardiogenic mesoderm, there are two further developmental origins for cells
that make up the heart: cardiac neural crest cells (NCCs) and the proepicardium (PE). The
contributions of each cell type is summarised in Figure 1-5. Cardiac NCCs originate from the
dorsal neural tube, between the mid-otic placode and the caudal boundary of the 3
rd somite,
where they undergo an epithelial-to-mesenchymal transition (EMT) to then migrate along the
pharyngeal arches (Hutson and Kirby, 2007). Some cardiac NCCs contribute to the OFT, where
they play a critical role in formation of the endocardial cushions for septation (as discussed in
Section 1.1.3). Others are targeted to the 3
rd, 4
th and 6
th pharyngeal arch arteries (PAAs) where
they are important for the development of the aortic arch and great vessels (Waldo et al.,
2005).25
The importance of the cardiac NCCs is reflected in the OFT and great vessel defects that arise
when the neural crest is ablated, which include common arterial trunk (CAT, also referred to as
persistent truncus arteriosus) and interrupted aortic arch (Kirby and Waldo, 1990). Mapping of
NCCs in the Splotch
2H (Sp
2H) NCC-deficiency mouse model, in relation to the OFT defects
observed, provided valuable insights into the etiology of these defects (Bradshaw et al., 2009).
Absence of NCCs in the pharyngeal region resulted in failure of the posterior PAAs to stabilise,
leading to their early loss. There was also a notable reduction in the AP septum formation in
the aortic sac, which is derived from NCC mesenchyme, preventing initiation of OFT septation.
This resulted in CAT in 75% of Sp
2H/Sp
2H embryos. Furthermore, double outlet right ventricle
(DORV) developed in those embryos in which the OFT was septated, which was attributed to
an additional role for the NCCs in influencing the distribution of SHF cells in the pharyngeal and
OFT regions (Bradshaw et al., 2009).
The PE is a transitory structure that develops near the venous pole of the heart tube, which in
the chick appears to occur in response to liver-bud-derived signals to the coelomic
mesothelium to drive PE-specific expression patterns including Wt1, Tbx18 and Tcf21 (Ishii et
al., 2007; Manner et al., 2001). However, this inductive relationship with the liver is not
conserved in zebrafish, as PE development is not affected in Hnf1ba
hi2169 mutant embryos that
lack a liver (Liu and Stainier, 2010), and it remains to be seen whether this applies to the
mouse embryo.
The PE extends towards the heart, attaches and spreads across the entire myocardial surface
to form the epicardium (Dettman et al., 1998). Cells derived from the epicardium undergo EMT
to then migrate into the myocardium to give rise to both fibroblasts and smooth muscle cells
for the coronary vasculature system (Merki et al., 2005). Coronary vascular defects occur when
the epicardium is disrupted: for example, in Wt1 mutant mice epicardial cells cannot undergo
EMT due to the activation of the Snail gene by Wt1, leading to loss of the coronary arteries,
pericardial haemorrhage and embryonic lethality (Martinez-Estrada et al., 2010). It was
thought that the endothelial cells of the coronary vasculature also had an epicardial origin,
although this is now contested as genetic tracing indicates that they are derived from the
venous plexus at the sinus venosus (Red-Horse et al., 2010). The epicardium also provides
factors that promote development and expansion of the myocardium, with disruption to this
signalling leading to a thin myocardium (Chen et al., 2002; Lavine et al., 2005).
Overall, it is clear that the development of the heart is an extremely complex process, with
perturbation of any of the cells that contribute to it resulting in congenital cardiac
malformations.26
Figure 1-5: The heart before and after septation, showing the multiple cellular origins of the
cardiac components
(A) Myocardium derived from the FHF (red) exclusively makes up the left ventricle, whilst cells from the
SHF (green) exclusively form the myocardium of the outflow tract. Cells from both the FHF and SHF
contribute to the right ventricle and both atria. The epicardium (blue) envelopes the heart, whilst the
endocardial cushions (yellow) are forming in the outflow tract, with contribution from the cardiac NCCs.
(B) The heart is fully septated and the great vessels are in their mature configuration by E14.5.
Epicardium and epicardial derivatives are shown in blue, the contribution of the cardiac neural crest in
yellow, SHF derivatives in green, and the most posterior Tbx18
+ SHF derivatives in purple.
Taken from Vincent (2010). OFT indicates outflow tract; RA, right atrium; LA, left atrium; RV, right
ventricle; LV, left ventricle; SVC, superior caval vein; IVC, inferior caval vein; AA, aortic arch; Ao, aorta.27
1.2 Chromatin structure and the regulation of transcription
This thesis addresses the role of a chromatin remodelling protein, CHD7, during heart
development. Cardiovascular development requires the dynamic regulation of gene expression
programmes in the correct cell lineage, at the correct time and in the correct order. Alterations
to chromatin structure, through both nucleosome sliding and post-translational modifications,
provide key mechanisms through which such coordinated wholesale gene change can be
achieved. The next two sections will therefore introduce these concepts in more detail, and
give an overview of what is already known about the transcriptional regulation of heart
development.
1.2.1 Chromatin structure
Genomic DNA is organised with specific proteins into chromatin: a dense, highly organised
tertiary structure that allows compaction of the vast lengths of DNA in the nucleus. The basic
structural and functional repeating unit of chromatin is the nucleosome (Kornberg, 1974), a
length of 145-147bp of DNA wrapped twice around a histone protein octamer core comprised
of two H2A-H2B dimers and a H3-H4 tetramer (Figure 1-6, A). Nucleosomes are held together
largely by electrostatic interactions between the positively-charged histone proteins and the
negative charges on the deoxyribose-phosphate DNA backbone (Luger et al., 1997; Van Holde
et al., 1974). A number of histone variants have been identified, which can undergo different
post-translational modifications to affect the local chromatin structure (reviewed in (Luger et
al., 2012)).
Nucleosomes are joined by an average of 20bp of DNA ‘linker’ sequence, and their positioning
can be highly dynamic: multiple enzymes can modify and alter nucleosome positioning and
chromatin structure, which can occur either on a global scale or at individual genes in response
to developmental cues or environmental changes (Smith and Peterson, 2005). The N-terminal
‘tails’ of the histones extend from the nucleosome to form contacts not only with DNA and
other histones, but also other non-histone proteins through epigenetic post-translational
modifications to specific residues on these tails. These interactions can contribute to the
folding of the lengths of nucleosomal structures into complex, highly-compacted tertiary
structures (Figure 1-6, B and C), or to the unwinding of these dense structures to allow access
for DNA-binding enzymes (Becker and Horz, 2002). Higher-order chromatin structures are
stabilised by architectural proteins such as linker histone H1, heterochromatin protein 1 (HP1),
high mobility group (HMG) proteins, Polycomb group proteins and many more (Luger et al.,
2012).28
Figure 1-6: Primary, secondary and tertiary chromatin structure
(A) The primary “beads on a string” chromatin structure consists of individual nucleosomes made up
with either canonical histones (indicated in light blue and yellow) or combinations of different histone
variants (green, purple and pink), which are joined by a length of ‘linker’ DNA.
(B) Short-range nucleosome–nucleosome interactions result in folded chromatin, forming the secondary
“30nm fibre” chromatin structure.
(C) Further fibre–fibre interactions, which are defined by long-range interactions between individual
nucleosomes, form tertiary higher-order chromatin fibres. The primary structure, including histone
variants, nucleosome spacing and post-translational histone modifications, affects both secondary and
tertiary chromatin structure.
The double arrows indicate transitions between the different structural chromatin states. These can be
regulated through a number of mechanisms, including changes in histone modification patterns, binding
or displacement of architectural proteins (indicated by orange triangles), chromatin remodelling and
exchange of histone variants.
Figure from Luger et al. (2012).
1.2.2 Epigenetic mechanisms for the regulation of transcription
In addition to its ‘packaging role’, highly dynamic chemical and structural alterations to
chromatin enable a layer of tissue-specific regulation of transcription, replication and repair.
Three main processes have been described that influence chromatin structure: DNA
methylation at CpG dinucleotides, histone modification and ATP-dependent chromatin
remodelling (Figure 1-7). All are dynamic and intrinsically reversible, and a complex inter-play
is thought to exist between them to direct tissue-specific gene expression.
The methylation status of CpG dinucleotides are mostly stably propagated during mitosis,
except during primordial germ cell specification and post-fertilisation in the early embryo,
when global methylation levels are reset (Smith and Meissner, 2013). Methylation of DNA
cytosines was traditionally seen as a marker of irreversible repression of gene expression.29
However, technological improvements that have allowed large-scale mapping of DNA
methylation have revealed that in fact during development promoter methylation can be
highly dynamic in some contexts, and in many organisms DNA methylation can be found in the
bodies of active genes (Suzuki and Bird, 2008). The DNA methyltransferase enzymes DNMT1,
DNMT3A and DNMT3B are highly conserved, and their roles in the formation and maintenance
of methylation states are essential for normal development (Li et al., 1992; Okano et al., 1999).
A wide range of post-translational modifications to histone tails have been reported, including
methylation, acetylation, phosphorylation, ubiquitination and sumoylation. The properties of
these chemical groups, added or removed by histone-modifying enzymes, affect the charges
on the histone tails, which can lead to electrostatic repulsion between neighbouring
nucleosomes, as well as affecting the affinity of the histones to the negatively-charged DNA.
Thus, histone modifications alter the accessibility to DNA for transcription factors and co-
regulatory proteins (Atkinson and Armstrong, 2008). Histone modifications also have a role in
the recruitment of regulatory factors, through their recognition of specific combinations of
post-translational modifications. Together, this results in a so-called ‘histone code’ for the
regulation of chromatin structure and accessibility for DNA-processing enzymes (Wang et al.,
2004a). For example, the addition of trimethyl (me3) groups to lysine (K) residues in the
histone tails, such as H3K4me3 and H3K27me3, has been linked with the maintenance of a
pluripotent state in embryonic stem cells and regulation of developmental genes. The
presence of both of these chemical markers within the same region of chromatin is associated
with a ‘poised’ transcriptional state (Bernstein et al., 2006; Mikkelsen et al., 2007), in which
genes can be rapidly activated or repressed, whilst acetylation of histone residues is generally
associated with active genes (Marmorstein and Roth, 2001). Therefore, the dynamics of
histone modifiers, particularly those with opposing functions such as acetyltransferases and
deacetylases, is very important during development and in disease states.
Figure 1-7: Epigenetic mechanisms for regulation of gene expression
Chromatin-level gene regulation can be achieved through methylation of the DNA strand, nucleosome
rearrangements by chromatin remodellers and post-translational histone modifications. These
processes require a number of different factors that influence the chromatin structure.
Image from Chang and Bruneau (2012).30
1.2.3 Chromatin remodelling and nucleosome sliding
Chromatin structure can also be altered by enzymes that utilise energy from ATP-hydrolysis to
disengage DNA-histone contacts for nucleosome sliding, displacement, or histone exchange
(Becker, 2002; Becker and Horz, 2002). About 30 mammalian genes are known that encode the
ATPase subunits found in chromatin remodelling protein complexes (Ho and Crabtree, 2010),
and the activity of these enzymes can alter the chromatin structure to modulate DNA
accessibility. Chromatin remodelling complexes alter nucleosome positioning and histone-DNA
contacts, so in combination with other processes such as DNA methylation, chromatin in a
non-permissive heterochromatic state can be changed to a permissive open euchromatic
state, preparing specific genomic loci for replication, repair, recombination, or transcription
(Hargreaves and Crabtree, 2011; Persson and Ekwall, 2010).
There are four main protein families of these ATP-dependent chromatin-remodelling
complexes: SWI/SNF (switching defective/sucrose non-fermenting), ISWI (imitation switch),
CHD (chromodomain, helicase, DNA binding) and INO80 (inositol requiring 80) complexes (Ho
and Crabtree, 2010). All share an evolutionarily-conserved ATPase enzymatic domain, with
additional functional domains that alter their activity and specificity. Chromatin-remodellers
not only direct local changes to nucleosome positioning or composition in conjunction with co-
activators or co-repressors of gene transcription, but may also regulate long-range inter- and
intra-chromosomal interactions and organise the tertiary architecture of chromatin consistent
with specific gene programmes (Morrison and Shen, 2009).31
1.3 Transcriptional and epigenetic regulation of heart development
1.3.1 Transcription factors and congenital heart disease
Many inherited forms of congenital heart disease have been shown to be the result of
mutations in cardiovascular transcription factors (Table 1-1). Heart development relies on a
complex network of these evolutionarily-conserved transcription factors and molecular
pathways, which are inter-linked, mutually reinforcing and often re-utilised at different stages
of heart development (see Figure 1-8). A group of “core cardiac transcription factors” have
been described that are critical for heart development (McCulley and Black, 2012), some
examples of which will be discussed in more detail here. Key cardiac transcription factors
include Nkx2-5, MEF2 factors, the zinc finger proteins GATA4, GATA5 and GATA6, the T-box
factors Tbx1, Tbx2, Tbx3, Tbx5, Tbx18 and Tbx20, the Lim-homeodomain protein Islet1, and
the basic helix-loop-helix proteins Hand1 and Hand2. The earliest identified molecular marker
for cardiac progenitors, however, is the transiently-expressed MESP1 transcription factor.
MESP1 is expressed as the mesoderm emerges from the primitive streak, and is required for
the anterior migration of these mesodermal progenitors (Saga et al., 1999). All myocardial cells
are thought to descend from early Mesp1-expressing cells (Bondue and Blanpain, 2010),
although large regions of other mesoderm-derived structures, such as the components of the
skull vault and its connective tissues, also descend from Mesp1 lineages. (Yoshida et al., 2008).
A recent clonal analysis study by Lescroart and colleagues found that there are two temporally
distinct pools of Mesp1 cardiovascular progenitors: the earlier pool is restricted to the FHF and
the later pool is restricted to the SHF. The FHF progenitors were shown to be unipotent, with
all Mesp1-derived clones in the left ventricle and atria differentiated into either
cardiomyocytes or endothelial cells. Interestingly, by contrast the SHF progenitors could be
either unipotent or bipotent. SHF clones either differentiated into cardiomyocytes or
endothelial cells, or differentiated into both cardiomyocytes and endothelial cells, or
cardiomyocytes and smooth muscle cells. Molecular analysis also confirmed that these distinct
lineages, whilst sharing some key cardiogenic MESP1 targets such as Gata4 and Gata6, were
molecularly heterogeneous (Lescroart et al., 2014).
The GATA family of zinc finger transcription factors have important roles in the differentiation,
proliferation and survival of a number of cell types, including cardiomyocytes. GATA-4, GATA-5
and GATA-6 are expressed in the developing heart in partially-overlapping patterns32
(Molkentin, 2000; Nemer and Nemer, 2003; Patient and McGhee, 2002), and mutations in
GATA-4 and GATA-6 are associated with septal and OFT defects in humans (see Table 1-1).
Complete knockdown of Gata4 and Gata6 in murine models leads to loss of cardiac
differentiation and acardia (Zhao et al., 2008), whilst compound heterozygous Gata4
+/-
/Gata6
+/- mice die around E13.5 due to vascular defects, common arterial trunk (CAT), and
myocardial thinning (Xin et al., 2006). These results suggest functional interactions between
GATA4 and GATA6. Loss of these genes individually also results in cardiovascular defects:
haploinsufficiency of Gata4 leads to common AV canal, DORV and hypoplastic ventricular
myocardium (Pu et al., 2004), whilst Gata6 ablation specifically in NCCs causes CAT through its
role in the regulation of Semaphorin 3C (Lepore et al., 2006). Interactions between GATA5 and
both GATA4 and GATA6 also appears to be important during formation of the OFT: compound
heterozygous Gata5
+/-/Gata4
+/- and Gata5
+/-/Gata4
+/- mouse mutants die embryonically or
perinatally of severe OFT defects, including double outlet right ventricle (DORV), ventricular
septal defects (VSDs) and hypertrophied mitral and tricuspid valves (Laforest and Nemer,
2011). The expression of genes for key cardiac transcription was disrupted, including Tbx20,
Mef2c, Hey1 and Hand2.
GATA factors also act combinatorially with a number of other key transcription factors during
cardiogenesis. GATA4 and GATA6 interact synergistically with MEF2C for the activation of a
number of cardiac genes, including Nppa and α-MHC (Morin et al., 2000), whilst a direct
interaction between GATA4 and Tbx5 activates expression of Cx30.2, which encodes an AV
node gap junction protein required for AV delay (Munshi et al., 2009). GATA4 and Islet1 also
act together at an enhancer region of Mef2c to drive its expression in the second heart field
(Dodou et al., 2004).33
Table 1-1: Genes encoding transcription factors with mutations in human patients with
congenital heart defects
Gene: Congenital Heart Defects: References:
CITED2 VSD, ASD (Sperling et al., 2005)
FOXH1 TGA, TOF (Roessler et al., 2008)
GATA4 ASD, AVSD, VSD, TOF,
HRHS
(Garg et al., 2003), (Okubo et al., 2004), (Sarkozy et
al., 2005), (Garg et al., 2003), (Nemer et al., 2006),
(Tomita-Mitchell et al., 2007), (Rajagopal et al.,
2007), (Schluterman et al., 2007), (Kodo et al., 2012)
GATA6 CAT, PS, AVSD (Kodo et al., 2009), (Lin et al., 2010), (Maitra et al.,
2010), (Kodo et al., 2012)
HAND1 TOF, AI (Hatemi et al., 2011), (Wang et al., 2011)
HAND2 TOF (Shen et al., 2010)
HOXA1 DORV, TOF, VSD, IAA, PDA (Bosley et al., 2008)
MEF2C PAVSD (Kodo et al., 2012)
NKX2.5 TOF, ASD, DORV, VSD,
HLHS, CoA, IAA, TGA
(Schott et al., 1998), (Hosoda et al., 1999),
(Goldmuntz et al., 2001), (Ikeda et al., 2002),
(Watanabe et al., 2002), (Elliott et al., 2003),
(Hirayama-Yamada et al., 2005), (Akcaboy et al.,
2008), (Pabst et al., 2008), (Gioli-Pereira et al., 2010),
(Kodo et al., 2012)
NKX2.6 CAT (Heathcote et al., 2005)
PITX2 AF (Franco et al., 2011; Gudbjartsson et al., 2007)
TBX1* VSD, IAA, PAVSD (Yagi et al., 2003), (Momma, 2010), (Rauch et al.,
2004), (Gong et al., 2001)
TBX5** ASD, VSD, AVSD (Basson et al., 1997), (Reamon-Buettner and Borlak,
2004), (Liu et al., 2009)
TBX20 ASD, CoA, VSD, PDA, MS,
HLHS
(Liu et al., 2008), (Kirk et al., 2007), (Posch et al.,
2010)
ZIC3 TGA, ASD, PS (Chhin et al., 2007), (Megarbane et al., 2000), (Ware
et al., 2004)
AF indicates atrial fibrillation; AI, atrial isomerism; ASD, atrial septal defect; AVSD, atrioventricular septal
defect; CAT, common arterial trunk; CoA, coarctation of aorta; DORV, double outlet right ventricle;
HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right heart syndrome; IAA, interrupted aortic
arch; MS, mitral valve stenosis; PAVSD, pulmonary atresia with ventricular septal defect; PDA, persistent
ductus arteriosus; PS, pulmonary valve stenosis; TGA, transposition of the great arteries; TOF, tetralogy
of Fallot; VSD, ventricular septal defect.
* TBX1 is associated with DiGeorge syndrome, **TBX5 is associated with Holt Oram syndrome
Table adapted from Kodo and Yamagishi (2011) and McCulley and Black (2012).34
The NK homeobox gene Nkx2.5 is a predicted homologue of the Drosophila master cardiac
regulator gene tinman (Azpiazu and Frasch, 1993; Bodmer, 1993). Nkx2-5 is also a key
transcription factor for the regulation of cardiogenesis, with roles in cardiomyocyte
differentiation, chamber identity and OFT formation (Harvey et al., 2002). Nkx2.5 is expressed
under the regulation of GATA factors, SMAD proteins in response to BMP signalling, and by
Nkx2-5 in an auto-regulatory loop (Liberatore et al., 2002; Lien et al., 1999; Searcy et al., 1998).
In the anterior SHF it is also under the regulation of Islet1 (Takeuchi et al., 2005). Nkx2-5
regulates a number of other key cardiac genes, including Mef2c, Hand1 and Jarid2 (Barth et al.,
2010; Tanaka et al., 1999), with mouse knockdown models showing early embryonic lethality
due to lack of cardiac looping and poor blood vessel development (Lyons et al., 1995; Tanaka
et al., 1999). Mutations of NKX2.5 are also associated with a range of congenital heart defects
in humans (Table 1-1). Similarly to the GATA proteins, Nkx2-5 cooperates with a number of
other core cardiac transcription factors in its multiple roles during cardiogenesis: interactions
between Nkx2-5 and both Hand2 and MEF2C are required for determining ventricular identity
(Vincentz et al., 2008; Yamagishi et al., 2001); Nkx2-5 and GATA4 interact to drive expression
of cardiac sarcomeric protein expression (Sepulveda et al., 2002); and it regulates the
expression of the transcriptional repressor Jarid2 during OFT development (Barth et al., 2010).
Members of the T-box family of transcription factors also have critical and widely-varied roles
in heart development, including cardiac fate and differentiation (Plageman and Yutzey, 2005).
Overlapping expression of 7 Tbx genes in the FHF and SHF have been reported in amniotes
(Kodo and Yamagishi, 2011), with mutant models providing further evidence of non-redundant
roles: for example, defects in the posterior region of the heart tube, which develops into the
atria, are reported in Tbx5-null mice, whilst the mouse model of DiGeorge syndrome that is
haploinsufficient for Tbx1 displays aortic arch defects. Tbx2 and Tbx3 meanwhile have roles in
repression of chamber myocardium and in the development of the conduction system
(Moorman and Christoffels, 2003), and Tbx18 is required for venous pole development, in a
population of cells at the posterior region of the SHF that are Tbx18
+ and Nkx2-5
- (Christoffels
et al., 2006). Mutations to a number of TBX genes are associated with a range of congenital
heart defects in humans, reflecting these diverse roles (Table 1-1).
Clearly there are many more transcription factors involved in heart development, as well as
many signalling pathways that provide key spatial and temporal information, including BMP,
Wnt and FGF pathways. Figure 1-8 shows a gene regulatory network of both transcription
factors and some key signalling pathways, which gives a good summary of the complexity of
the process. With so many inter-connected components, it is evident why the system is so
sensitive to disruption of any of the genes involved.35
Figure 1-8: Gene regulatory network during early murine cardiac development
Published temporal and spatial expression data of cardiac genes and interactions information was combined by Herrmann and colleagues to generate a gene regulatory network,
which was validated by running simulations in a Boolian computational model (Herrmann et al., 2012). Genetic interaction in the FHF and SHF are shown, as well as incorporating
the influence of signals from the early mesoderm and endoderm. Genes are represented by their regulatory region and their transcriptional start site. Arrow heads indicate
activation and bar heads inhibition of gene transcription. Broken lines represent intercellular signalling with an integrated signal transduction cascade.
Figure taken from Herrmann et al. (2012).36
1.3.2 Histone modifying genes
It has more recently become apparent that the epigenetic landscape also plays a key role in
the transcriptional regulation of heart development. Increasing numbers of interactions
between chromatin modifiers or remodellers and key cardiac transcription factors are being
reported, whilst human mutations or mutant mouse models also show a range of
cardiovascular defects as a result of loss of epigenetic modifiers. For example, a recent study
used exome sequencing of parent-offspring trios to compare 362 severe congenital heart
defect patients with unaffected parents and 264 control cases, identifying an excess of de novo
mutations in genes involved in the production, removal or reading of H3K4 methylation (Zaidi
et al., 2013). Furthermore, mutations were also found in genes associated with ubiquitination
of H2BK120, which is required for H3K4 methylation, as well as two different de novo
mutations in SMAD2, which regulates H3K27 methylation (see Figure 1-9).
The human disease Wolf-Hirschhorn syndrome, which includes heart defects, is associated
with a deletion mutation of a critical region of chromosome 4q16.3 (Bergemann et al., 2005).
The deleted region includes the candidate gene encoding WHSC1, which contains SET domains
highly homologous to the yeast H3K36 methyltransferase Set2. WHSC1 has been shown to
modulate mono-, di- and tri-methylation of H3K36 on nucleosomes in HeLa cells (Sun et al.,
2005), whilst mice with homozygous knockout of Whsc1 die within 10 days of birth due to
atrial and ventricular septal defects. This was attributed to functional overlap between WHSC1
and a number of key developmental transcription factors, including Nkx2-5 (Nimura et al.,
2009).
Figure 1-9: de novo mutations in the H3K4
and H3K27 methylation pathways
identified in patients with congenital heart
defects
An over-representation of genes that affect the
production, removal or reading of H3K4
methylation, H3K27 methylation and H2BK120
ubiquitination was found in a study of de novo
mutations in patients with sporadic congenital
heart defects. A nucleosome is shown with DNA
wrapped around a histone octamer, with
mutated genes shown. Genes with nonsense,
frameshift or splice site mutations are shown in
red, and those with missense mutations are in
blue, with those known to interact together in
the same complex enclosed in boxes.
Taken from Zaidi et al. (2013)37
Expression of the key cardiac transcription factor Nkx2-5 is mediated by the Polycomb group
protein Rae28 (Shirai et al., 2002), which catalyses mono-ubiquitinylation of histone H2A and
regulates gene silencing. Homozygous ablation of Rae28 results in defects similar to those seen
in Nkx2.5 knockout mice. Another histone modifier Jumonji (also known as Jarid2), is involved
in development of the OFT, under the transcriptional regulation of Nkx2-5 (Barth et al., 2010).
Jumonji is a component of a protein complex with histone demethylase and methyltransferase
activities, which regulates cardiomyocyte proliferation through the repression of CyclinD1
expression (Toyoda et al., 2003). Germline deletion of Jumonji results in VSD, DORV and
myocardial non-compaction (Lee et al., 2000).
Histone deacetylases (HDACs), which are usually associated with repression of gene
expression, also have multiple, often overlapping roles during heart development. For
example, HDAC1 and HDAC2 function redundantly, with deletion of both Hdac1 and Hdac2 in
the myocardium resulting in neonatal death within 2 weeks due to arrhythmias and dilated
cardiomyopathy (Montgomery et al., 2007). HDAC5 and HDAC9 also function redundantly in
the repression of Mef2, SRF factors and myocardin, with double mutants showing VSDs, thin
myocardium and embryonic lethality from E15.5, (Chang et al., 2004). Histone
acetyltransferases (HATs) such as p300 are also important: germline deletion of p300 is
embryonic lethal at E9.5-11.5, with thin myocardium and reduced trabeculation observed (Yao
et al., 1998), whilst a point mutation that inactivates its acetyltransferase activity results in
ASD, VSD, reduced coronary vessels and lethality at E12.5-15.5 (Shikama et al., 2003).
1.3.3 Chromatin remodelling during heart development
ATP-dependent chromatin remodelling complexes also have multiple critical roles during heart
development. The chromatin remodeller CHD7 is haploinsufficient in the human disorder
CHARGE syndrome, which is associated with a range of heart defects (see Sections 1.4, 1.5 and
1.6). This thesis aims to investigate further the tissue-specific role(s) of CHD7 during
cardiovascular development, as this is not yet well understood.
Mutations to a number of components of the BAF complex, a major SWI/SNF ATP-dependent
chromatin remodelling complex, also produce a range of congenital heart defects. The ATPase
subunit of this complex is encoded by either Brg1 or Brm, and whilst Brm-null mice seem to
develop normally, Brg1 is required in multiple tissues during heart morphogenesis (Griffin et
al., 2008; Reyes et al., 1998). Briefly, in the myocardium Brg1 promotes proliferation, so
conditional ablation driven by Sm22α-Cre leads results in thin myocardium and absence of the
inter-ventricular septum (Hang et al., 2010), whilst endocardial ablation driven by Tie2-Cre38
result in hypotrabeculation of the myocardium and absence of the cardiac jelly (Stankunas et
al., 2008). It also has roles in OFT and great vessel development, with persistent ductus
arteriousus (PDA) resulting from Brg1 deletion in smooth muscle cells driven by smMHC-Cre
(Zhang et al., 2011). Furthermore, it has a critical role in the maintenance of a multipotent NCC
reservoir, so ablation of Brg1 in NCCs driven by Wnt1-Cre leads to shortened OFTs and
disruption to PAA development (Li et al., 2013). These tissue-specific roles are discussed in
more detail in Section 4.5.1. Allelic balance between Brg1 and the transcription factor genes
Tbx5, Tbx20 and Nkx2.5 is also crucial for heart development, with cardiac malformations seen
when these sensitive interdependent relationships are disrupted in compound heterozygous
mutant embryos (Takeuchi et al., 2011).
Many other BAF complex subunits also have distinct roles during cardiogenesis, including
Baf60c, Baf180 and Baf45c. Baf60c is required for heart morphogenesis and the differentiation
of cardiomyocytes, with the ectopic expression of Baf60c, Tbx5 and Gata4 in non-cardiogenic
mesodermal cells sufficient to induce differentiation into contracting cardiomyocytes (Lickert
et al., 2004; Takeuchi and Bruneau, 2009). The early embryonic lethality resulting from small
interfering RNA knockdown of Baf60c in mice is accompanied by hypoplastic ventricles with
reduced trabeculation and shortened OFT, with downregulation of a number of cardiac genes,
including Hand2, Bmp10 and Irx3 (Lickert et al., 2004). Baf180 is required for the regulation of
a subset of retinoic acid pathway genes, such as RARβ2 and CRABPII, during cardiac chamber 
formation, as well as the expression of angiogenic, vasculogenic and EMT genes in the
epicardium for coronary vessel development (Huang et al., 2008; Wang et al., 2004b). Studies
in zebrafish show that morpholino knockdown of Baf45c leads to abnormal heart looping and
reduced contractility, although no significant developmental defects are seen in Baf45c-null
mice, so there may be redundancy in higher vertebrates (Lange et al., 2008; Mertsalov et al.,
2008).
The INO80 chromatin remodelling complexes contain the DNA helicase subunits Pontin and
Reptin, whose activity is essential for the chromatin remodelling function of the INO80
complexes (Gallant, 2007). Whilst these subunits have not been studied in mice, work in
zebrafish has indicated they have an antagonistic role in the regulation of myocardial growth,
through  their  opposing  effects  on  β-catenin  signalling:  morpholino  knockdown  of  pontin
causes cardiac hyperplasia, whilst over-activation of Reptin ATPase activity through an
insertional mutation also stimulates cardiomyocyte proliferation (Rottbauer et al., 2002).
These roles of Pontin and Reptin in the regulation of cardiac muscle growth strongly suggest
that INO80 complexes are also involved in cardiovascular development.39
Histone modifiers and chromatin remodellers often interact with regulatory enhancer
sequences at their target genes. Whilst a large number of cardiac transcriptional enhancer
sequences have been identified, these sequences appear to be weakly conserved between
vertebrates. A ChIP-seq study on E11.5 heart tissue using the enhancer-associated protein
p300 identified over 3000 candidate heart enhancers with good functional reproducibility,
although compared to other tissues studied at the same time point these sequences were less
deeply conserved between vertebrates (Blow et al., 2010). A further 1375 heart-specific
enhancers were predicted through genome-wide binding of multiple cardiac transcription
factors, including GATA4, Nkx2-5, Tbx5, SRF and Mef2A (He et al., 2011), whilst over 6200
candidate enhancer sequences were identified from fetal and adult human heart tissue (May
et al., 2012). Recently, distinct chromatin signatures of histone modifications have also been
identified through studying either human or mouse embryonic stem cells (ESCs) at distinct
stages during differentiation into cardiomyocytes, which can be correlated with cardiac-
specific gene expression (Paige et al., 2012; Wamstad et al., 2012). These findings again
highlight the importance of transitions in chromatin state during heart development, so
improving our understanding of it can provide further insights into cardiovascular
development and disease.40
1.4 CHD7 biological function
1.4.1 The CHD protein family
There are nine known mammalian chromodomain-helicase-DNA-binding (CHD) proteins, which
utilise ATP hydrolysis to alter the structure of nucleosomes, thereby regulating the accessibility
of DNA sequences (Becker and Horz, 2002; Lusser and Kadonaga, 2003; Woodage et al., 1997).
A conserved feature of the CHD proteins is the presence of a centrally-located helicase region,
which contains an SNF2 and DNA helicase domain (Figure 1-10). In addition, all CHD proteins
contain two adjacent chromodomains, which cooperate to interact with one methylated
histone tail (Flanagan et al., 2005). CHD7, as a member of the class III sub-family of CHD
proteins, also contains a SANT domain, believed to be involved in binding histone tails (Boyer
et al., 2004); two BRK domains, the function of which appears to be restricted to higher
eukaryotes and may be involved in the reorganisation of chromatin structure (Daubresse et al.,
1999; Doerks et al., 2002); and several nuclear localisation sequences.
Whilst sequence homology with other CHD proteins predicted CHD7 to have chromatin
remodelling activity, it has only recently been confirmed by biochemical studies, as functional
analysis is made difficult by its large size (336kDa). However, Bouazoune and Kingston recently
utilised a dual-tag system to purify recombinant histidine- and FLAG-tagged CHD7 protein,
which they used to demonstrate, through a restriction enzyme accessibility assay, that CHD7
has ATP-dependent nucleosome remodelling activity. Furthermore, through testing
remodelling of nucleosome constructs with varying lengths of DNA overhang, CHD7 activity
was found to be distinct to SWI/SNF-type remodellers. Instead, the remodelling reaction was
more similar to that seen for ISWI enzymes and yeast Chd1, which require longer extra-
nucleosomal DNA for nucleosome sliding activity (Bouazoune and Kingston, 2012; Gangaraju
and Bartholomew, 2007; McKnight et al., 2011).
Chd7 is ubiquitously expressed in early development, with expression patterns later becoming
more restricted to CHARGE-related tissues such as the developing ear, eye, and olfactory
system (Bosman et al., 2005; Hurd et al., 2007; Sanlaville et al., 2006). Its widespread
expression during development, combined with the range of congenital symptoms seen in
CHARGE, implies that CHD7 has multiple important tissue-specific roles during development.41
Figure 1-10: Conserved structural domains of the CHD protein family
The central helicase-like region, containing SNF2_N and Helicase_C domains, and two chromodomains
are conserved in all CHD proteins from yeast to humans. Distinct additional domains are used to divide
the CHD proteins into three subfamilies: the Chd1 subfamily (Class I in mammals), the Mi-2 subfamily
(Class II), and the Chd7 subfamily (Class III). CHD proteins are clustered based on structure and
functional conservation, with proteins from Saccharomyces cerevisiae (Sc), Drosophila (d), humans (h),
Arabidopsis (CHR4, CHR5, CHR6 and CHR7) and rice (CHR702, CHR703, CHR705 and CHR729). Human
CHD1-CHD9 are underlined in red.
Figure adapted from Hu et al. (2014).
1.4.2 CHD7 isoforms
Three splice isoforms have been reported for mammalian CHD7: full-length CHD7L, CHD7S and
CRA_E (Colin et al., 2010; Kita et al., 2012). CRA_E is formed by joining exons 3 and 36 of the
human Chd7 gene, and lacks most of the functional domains of the canonical CHD7L transcript.
CHD7S is generated by alternative splicing of exon 6 and lacks the DNA-binding domain, the
helicase/ATPase domain, the BRK domains and one of the two chromodomains that make up
the full-length CHD7L protein. The CHDL and CHD7S isoforms are predicted to function
differently: CHD7S localises specifically to the nucleolus whereas CHDL localises to both the42
nucleus and the nucleolus, and depletion of both CHD7L and CHD7S inhibits cell proliferation
and production of 45S precursor ribosomal RNA to a greater extent than depletion of CHD7L
alone. Furthermore, whilst both isoforms interact with Sox2, overexpression of CHD7L
increases Sox2-mediated transcription whereas overexpression of CHD7S represses it (Kita et
al., 2012). CHD7S therefore appears to have both antagonistic and agonistic roles in relation
with full-length CHD7 protein function.
1.4.3 The Drosophila Chd7 orthologue Kismet
CHD7 activity has been studied in numerous model organisms. The Drosophila gene Kismet
(kis) is the closest homologue to the mammalian Chd7 (Srinivasan et al., 2008), and KIS-L - one
of two major protein isoforms encoded by kis - contains a BRK domain, an ATPase domain and
two chromodomains (Srinivasan et al., 2005). KIS-L is a member of the trithorax group of
proteins. During Drosophila development, spatial information within the embryo initially
establishes expression patterns of the key Hox transcription factors, and these patterns are
then maintained by the ubiquitously-expressed trithorax group of activators and the Polycomb
group of repressors (Ringrose and Paro, 2004; Schuettengruber et al., 2007; Schwartz and
Pirrotta, 2007). These proteins therefore play a vital role in the regulation of cellular
pluripotency and differentiation. KIS-L appears to facilitate an early step in transcriptional
elongation by RNA Polymerase II (Srinivasan et al., 2005), acting downstream of P-TEFb
recruitment, and co-localising with the histone methyltransferases ASH1 and TRX on polytene
chromosomes in larvae (Srinivasan et al., 2008). Loss of kis activity results in an increase in
histone 3 lysine 27 (H3K27) methylation, a key marker for repression of Polycomb activity, and
a reduction in the recruitment of ASH1 and TRX to chromatin (Srinivasan et al., 2008).
Due to its key role in cell fate determination, null mutations of kis are embryonic lethal
(Daubresse et al., 1999), but studies utilising the GAL4/UAS system have further helped to
establish Drosophila as a model organism in which to study CHARGE. It has been shown that
adult flies with knockdown of kis show defects in motor coordination, learning and memory,
similar to symptoms observed in some CHARGE patients, which may be linked to its
developmental role in axonal pruning, guidance and extension (Melicharek et al., 2010).
However, to date a role for kis in cardiac development in Drosophila has not been reported.43
1.4.4 CHD7 co-localises with enhancer and promoter sites
Genome-wide studies of CHD7 distribution on chromatin were first carried out on human
colorectal carcinoma cells, human neuroblastoma cells and mouse ESCs cells before and after
differentiation into neural precursors (Schnetz et al., 2009). This work, using chromatin
immunoprecipitation followed by genomic tiling microarray hybridisation (ChIP-chip),
indicated that the binding pattern of CHD7 is cell-type specific, although in each cell type it
correlated with H3K4 methylation. These binding sites were most often contained within
DNase hypersensitive sites, at highly conserved sites distal to transcriptional start sites, and
often near genes expressed at relatively high levels, indicating it acts in enhancer-mediated
transcription (Schnetz et al., 2009).
ChIP followed by massively parallel DNA sequencing (ChIP-seq) identified over 10,000 discrete
CHD7-binding chromatin sites in mouse ESCs, many of which are predicted enhancer
sequences and, less frequently, promoter sequences (Schnetz et al., 2010). CHD7 co-localises
at many sites with potentially unique combinations of DNA-binding proteins, including the
known enhancer-binding protein p300 and the ESC ‘master regulators’ OCT4, SOX2 and
NANOG. The transcription factors SMAD1 and STAT3 were also found to co-localise with CHD7
at multiple sites, as well as the chromatin remodelling protein BRG1, although the overlap in
binding with BRG1 was not as extensive (Schnetz et al., 2010).
CHD7 binding sites were mostly located distal to transcriptional start sites, and comparison of
global gene expression profiles of ES cells with different doses of Chd7 indicated that CHD7 can
modulate gene expression in either a positive or negative direction, although there was some
bias towards the repression of gene expression (Schnetz et al., 2010). It has therefore been
proposed that CHD7 plays a role in enhancer-mediated regulation of gene expression,
although it is not clear whether this is through mediation of long-range communication
between enhancers and promoters via chromosome looping, or whether CHD7 acts locally to
open up the DNA structure for access by transcriptional activators. CHD7 has also been
proposed to function as a positive regulator of ribosomal RNA biogenesis in the nucleolus, with
ChIP assays on human DLD1 cells and mouse ESCs showing a physical association between
CHD7 and hypomethylated, active ribosomal DNA (Zentner et al., 2010a). Consistent with this
observation, knockdown or over-expression of CHD7 resulted in decreased or increased 45S
pre-rRNA levels, respectively, and altered the methylation state of the rRNA promoter.
Therefore, CHD7 appears to function both in the nucleoplasm and nucleolus for the regulation
of mRNA and rRNA expression.44
1.4.5 CHD7-protein interactions
Chromatin remodelling enzymes are often found in large, multi-protein complexes (Vignali et
al., 2000), the components of which are likely to be tissue- and/or temporally-specific and play
a role in the regulation of binding to specific DNA loci. A number of cofactor interactions have
been reported for CHD7: during osteoblast formation CHD7 forms a complex with SETDB1, NLK
and PPAR-γ as part of the non-canonical Wnt pathway (Takada et al., 2007), whilst in vitro
studies show CHD7 interacts with CHD8 both directly and indirectly through FAM124B,
suggesting a putative CHD7-CHD8 complex (Batsukh et al., 2010; Batsukh et al., 2012).
In neural stem cells (NSCs) CHD7 has been shown to physically interact with Sox2 and to have
overlapping binding sites: 43% of genes misregulated in NSCs with knockdown of Sox2 were
also misregulated in Chd7-knockdown cells, often in the same direction (Engelen et al., 2011).
Loss-of-function mutations in SOX2 in humans results in a characteristic developmental
disorder known as SOX2 Anophthalmia, or Anophthalmia-Esophageal-Genital (AEG), syndrome
(Ragge et al., 2005; Williamson et al., 2006a), and as previously mentioned there is
considerable overlap in the symptoms of AEG and CHARGE syndromes. Furthermore, Sox2 and
CHD7 have been shown to regulate a common set of target genes, including the Jag1, Gli3 and
Mycn genes that are associated with the human disorders Alagille, Pallister-Hall and Feingold
syndromes respectively (Kang et al., 1997; Okuno et al., 1990; van Bokhoven et al., 2005). It is
unsurprising therefore that these syndromes also show overlapping malformations with AEG
and CHARGE syndromes.
CHD7 has been shown by co-immunoprecipitation in human neural crest-like cells (NCLCs) to
also interact with a number of components of the SWI/SNF chromatin remodelling complexes
BAF and PBAF, including BRG1, BAF170, BAF155, BAF57, PB1, ARID2, and BRD7 (Bajpai et al.,
2010). Interaction between BRG1 and CHD7 was also seen in murine cardiac neural crest
tissue, where they co-occupy the PlexinA2 promoter region to activate its expression (Li et al.,
2013).
These interaction studies add to the information gained from ChIP-based studies that have
identified DNA-binding sites for CHD7 at enhancers, and proteins with overlapping DNA-
binding profiles. However, the complexes that CHD7 is found in at different binding sites, in
different tissue-types and in different stages in development may vary a great deal in order to
regulate its activity, so it is a challenge both to identify further interacting proteins and to
elucidate the contexts in which they may be found in complexes together.45
1.4.6 CHD7 and cardiovascular development
Whilst there is clearly an association between CHD7 mutations and congenital cardiovascular
defects (as described in Section 1.4), our understanding of the functional role of CHD7 during
heart development remains fairly limited. Currently, just one study has been published
investigating the role of CHD7 during early cardiogenesis (Liu et al., 2014). Hearts were
examined in Chd7-null mice at E9.5 and E10.5, which displayed hypocellular myocardial walls
and AV cushions, with embryonic lethality occuring soon after E10.5. Consistent with this
phenotype, increased cell death and reduced cell proliferation was seen at E10.0 in the
myocardium, alongside impaired BMP-dependent formation of the cushion mesenchyme.
Expression of a subset of BMP-dependent cardiogenic genes, including Nkx2.5, Gata4 and
Tbx20, was reduced in Chd7-null sections through the heart, whilst the presence of active
chromatin marks H3K4me2 and H3K4me3 at Nkx2.5 enhancers and its transcription start site
was significantly reduced. Furthermore, in vitro studies showed CHD7 is an interaction partner
of the BMP-activated SMAD1 transcription factor, and it binds Nkx2.5 enhancer regions in a
BMP-dependent manner. Overall, this work indicates that CHD7 interacts with BMP-activated
SMAD1/5/8 to regulate the chromatin landscape and thus expression of BMP cardiogenic
target genes such as Nkx2.5 during early cardiogenesis and chamber formation (Liu et al.,
2014).
Given the high incidence of interrupted aortic arch defects in CHARGE patients, great vessel
development has also been studied in heterozygous gene-trapped Chd7
xk/+ embryos, which
showed a high penetrance of 4
th PAA defects at E10.5 leading to great vessel malformations at
E14.5 (Randall et al., 2009). Interestingly, restoration of Chd7 expression specifically in the
pharyngeal surface ectoderm (PSE) rescued the PAA malformations, indicating a crucial role for
CHD7 in regulating the signalling from the PSE to migratory NCCs during PAA formation.
Furthermore, compound heterozygous mutation of Chd7 and Tbx1 increased the PAA
phenotype, indicating a dosage sensitive relationship between CHD7 and Tbx1 is important for
great vessel development. Therefore, whilst some insights have been gained into the role of
Chd7 in cardiovascular development, it is likely that further roles for such an important
chromatin remodelling protein remain to be discovered.
1.4.7 CHD7 activity in the neural crest
Several studies have addressed the role of CHD7 in NCCs, which have shown it is required for
both activation of the NCC transcriptional programme and for regulating NCC guidance signals.
This role is consistent with many of the congenital anomalies seen in CHARGE patients, which46
are associated with malformation of tissues derived from the neural crest (Siebert et al., 1985).
Having shown the interaction of CHD7 with multiple BAF and PBAF components, Bajpai and
colleagues demonstrated in Xenopus embryos an essential role of CHD7, in cooperation with
PBAF, for activation of the NCC transcriptional programme. Target genes included Sox9, Twist
and Slug, which are crucial for the epithelial-mesenchymal transition to migratory NCCs (Bajpai
et al., 2010). CHD7 has also been shown to bind directly at the PlexinA2 promoter in NCCs in
mouse embryos, which encodes a key cell surface receptor expressed in migratory NCCs and is
required for guidance of the cardiac NCCs during OFT development (Brown et al., 2001; Li et
al., 2013). CHD7 binds as part of a complex that also contains BRG1, with PlexinA2 promoter
activity activated in a dose-dependent manner by both CHD7 and BRG1 (Li et al., 2013).
Another study using whole-genome microarray analysis to compare the expression profiles of
E9.5 wild-type, Chd7
Whi/+ and Chd7
Whi/Whi female mouse embryos also identified disruption in
the expression of multiple genes involved in NCC migration and guidance (Schulz et al., 2014b).
Whilst this did not give any tissue-specific information on where these genes are being altered
by the loss of CHD7 activity, the misregulation of genes such as Sema3A, Sema3C and Sema3D
(encoding Semaphorin signalling molecules), and Epha3, Epha5 and Epha7 (encoding Ephrin
receptors) do support a role for CHD7 in the regulation of NCC migration.
Conditional deletion of Chd7 driven by Wnt1-Cre or Foxg1-Cre revealed CHD7 is important for
craniofacial and tracheal development (Sperry et al., 2014). NCC- specific deletion using Wnt1-
Cre produced hypoplastic maxillary shelves and mandible, abnormal frontal occipital bone
formation and cleft palate. The ectodermal and endodermal marker Foxg1-Cre ablated CHD7
activity in the developing eye, ear, nose, pharyngeal pouch, forebrain, and gut, which also
resulted in hypoplasia of the maxillary shelves and nasal epithelia, alongside abnormal
development of the eyes, concha and frontal bone, and reduced tracheal rings. Both
conditional lines resulted in postnatal respiratory distress and death. Whilst the molecular
basis for these defects caused by loss of CHD7 activity in the endoderm, ectoderm or NCCs is
not yet determined, comparison with the skeletal development of heterozygous Chd7
Gt/+ mice
revealed the role of Chd7 in craniofacial development is dosage-dependent (Sperry et al.,
2014).
An interesting link between CHD7 activity and p53 activation in NCCs has recently been
reported: loss of Chd7 in mouse NCCs or CHARGE syndrome patient samples resulted in
increased p53 activity (Van Nostrand et al., 2014). CHD7 was shown to bind at the p53
promoter site in NCCs, indicating it directly represses transcription of p53 to promote cell
survival. Strikingly, heterozygosity for p53 partially rescued the developmental delay seen in47
Chd7-null embryos, whilst a mouse model with hyper-activated p53 phenocopied many
CHARGE features, together indicating that inappropriate p53 activation in CHARGE patients
contributes to the disease phenotypes (Van Nostrand et al., 2014).
1.4.8 Other tissue-specific developmental roles of Chd7
Many studies have shown CHD7 functions in neural stem cell (NSC) populations and is
important for neurogenesis during different developmental processes, which again are
consistent with the range of symptoms seen in CHARGE patients. During inner ear
morphogenesis, CHD7 is required for the proliferation of inner ear neuroblasts, with targeted
Chd7 deletion in the otocyst driven by Foxg1-Cre leading to cochlear hypoplasia and absence
of the semicircular canals and cristae (Hurd et al., 2010). CHD7 also functions cooperatively
with retinoic acid signalling in the stem cell niche of the subventricular zone (SVZ) and inner
ear, which are important for olfactory bulb formation, hearing and balance (Micucci et al.,
2014). This role in the SVZ is maintained into adulthood, when the SVZ and subgranular zone
(SGZ) contain pools of multipotent NSCs for active neurogenesis (Gage, 2000). CHD7
expression is specifically enriched in active NSCs in the SVZ and SGZ, with deletion of Chd7
induced in adult mice resulting in a dramatic decrease in neurogenesis due to loss of Sox4 and
Sox11 expression ((Feng et al., 2013)). Interestingly, this phenotype could be rescued by
physical exercise, indicating that exercise-induced neurogenesis is independent of CHD7
activity.
Layman and colleagues also highlighted the importance of CHD7 for development of olfactory
tissue. High Chd7 expression was shown in basal olfactory epithelial NSCs, and Chd7
heterozygotes displayed smaller olfactory bulbs, reduced olfactory sensory neurons and
disorganisation of the epithelial structure due to loss of NSC proliferation. Consistent with
these observations, Chd7 deficient mice showed signs of loss of olfaction (Layman et al., 2009).
Furthermore, CHD7 has a critical role in the development and maintenance of gonadotropin-
releasing hormone (GnRH) neurons in the hypothalamus and embryonic nasal region, which
are important for reproduction (Layman et al., 2011).
The development of several brain structures are also found to be disrupted in Chd7 mutant
mice. For example, Chd7 haploinsufficiency results in a small cerebellar vermis, due to reduced
Fgf8 expression in the isthmus organiser (Yu et al., 2013). This cerebellar hypoplasia phenotype
was identified in 35% of a cohort of CHD7 mutation-positive CHARGE patients. Furthermore, a
synergistic relationship between Chd7 and Fgf8 loss-of-function alleles was shown,
demonstrating the importance of this genetic interaction (Yu et al., 2013). Development of the48
forebrain also relies on CHD7 activity: Chd7 heterozygotes show defects in the telencephalic
midline, including reduced cerebral cortex and dilated third and lateral ventricles (Jiang et al.,
2012). Apoptosis of cells in the telencephalic midline zone was impaired, along with disruption
to expression of Bmp4, a key factor in regulation of midline cell fate.
Finally, studies in zebrafish have identified CHD7 as the first chromatin remodeller to have a
role in somitogenesis (Jacobs-McDaniels and Albertson, 2011). Chd7 morpholino-knockdown
showed CHD7 functions in directing the bilaterally-symmetric expression of somitogenesis
genes in the pre-somitic mesoderm, including cdx1a, dlc, her7, mespa and ripply1, leading to
left-right asymmetry defects in zebrafish chd7-morphants. Overall, these studies clearly show
CHD7 has multiple crucial roles during development, regulating many key transcriptional
programmes in a tissue-specific manner.49
1.5 CHARGE syndrome
The human disorder CHARGE syndrome provides a key example of the severe congenital
anomalies that can arise when chromatin remodelling is disrupted during development,
including a range of cardiovascular malformations, which will be discussed in this section.
1.5.1 Clinical presentation
CHARGE syndrome (OMIM# 214800) is a developmental disorder with an estimated
prevalence of 1 in 15,000 to 1 in 17,000 live births (Janssen et al., 2012). It is characterised by a
specific pattern of anomalies, first described in 1979 (Hall, 1979). The acronym ‘CHARGE’ was
introduced two years later to summarise the major clinical features: ocular coloboma, heart
malformations, atresia of the choanae, retardation of growth or development, genital
hypoplasia and ear anomalies (Pagon et al., 1981). It was originally proposed that a clinical
diagnosis of CHARGE required 4/7 of these signs to be present (Oley et al., 1988), one of which
must be either choanal atresia or a coloboma (Pagon et al., 1981). Many other clinical findings
have since been frequently reported in CHARGE patients, including anomalies of the cranial
and CNS midline, brainstem dysfunctions, dysmorphic features, and hypoplasia of the
semicircular canals. Updates to the clinical criteria include these additional signs (Blake et al.,
1998; Verloes, 2005), with the most recent criteria summarised in Tables 1-2 and 1-3.
Table 1-2: Updated clinical criteria for CHARGE syndrome (Verloes, 2005)
Major Criteria Minor Criteria
1. Ocular coloboma
2. Choanal atresia
3. Hypoplastic semicircular canals
1. Rhombocephalic dysfunction (brainstem
and cranial nerve III to XII anomalies,
including sensorineural deafness)
2. Hypothalamo-hypophyseal dysfunction
3. Abnormal middle or external ear
4. Malformation of heart or oesophagus
5. Mental retardation
Table 1-3: Definition of Typical, Atypical, and Partial CHARGE syndrome (Verloes, 2005)
Typical Atypical Partial/Incomplete
3 major signs
2/3 major + 2/5 minor signs
2/3 major + 0/5 minor signs
1/3 major + 2/5 minor signs
2/3 major + 1/5 minor signs50
1.5.2 Genetic basis
CHARGE is an autosomal dominant disorder that usually occurs sporadically, although rarely it
has been transmitted from a mildly affected parent. It is caused by heterozygosity for loss-of-
function mutations of CHD7, the gene encoding the ATP-dependent chromatin remodelling
protein CHD7 (Vissers et al., 2004). CHD7 is located at chromosome 8q12 and consists of 38
exons. Estimates for the CHD7 mutation frequency in CHARGE patients vary depending on the
selection criteria, with recent studies giving a range of 58-71% of cases (Aramaki et al., 2006;
Lalani et al., 2006; Zentner et al., 2010b). This figure rises to over 90% if only patients meeting
the clinical diagnostic criteria of Blake and/or Verloes are included (Jongmans et al., 2006).
Mutations are found along the entire coding region and splice sites of the CHD7 gene (Figure
1-11) (Bartels et al., 2010; Lalani et al., 2006). Most reported mutations are unique for a
patient or family, although recurrent de novo mutations do occur rarely. The two most
frequently reported CHD7 mutations are the nonsense mutations C1480T and C7879T, which
both result in the introduction of a stop codon in the place of an arginine codon (Janssen et al.,
2012). Interestingly, a significant number of mutations reported in CHARGE patients involve
the substitution of the arginine CGA codon, which occurs 27 times in CHD7, for a TGA stop
codon (Bartels et al., 2010; Janssen et al., 2012). This is consistent with a previous report that
CG to TG mutations are highly frequent in the human genome (Antonarakis et al., 2000).
Nearly 80% of CHD7 mutations reported in CHARGE patients are predicted to be nonsense or
frameshift (Janssen et al., 2012). These mutations would likely result in nonsense-mediated
mRNA degradation (NMD), or else production of a truncated CHD7 protein. Investigation of
CHD7 protein deletion mutants in vitro indicates that the ATPase and nucleosome remodelling
activities of CHD7 are severely impaired or ablated following various truncations of the
protein, including truncation of the C-terminal domain or the chromodomains (Bouazoune and
Kingston, 2012). Therefore, the combination of degradation of mutant mRNA through the
NMD pathway and the loss of CHD7 activity caused by protein truncation indicates that the
pathogenic mechanism underlying the majority of CHARGE syndrome cases is
haploinsufficiency for CHD7.
Splice site (11%) and missense CHD7 mutations (8%) are found less commonly in CHARGE
patients (Janssen et al., 2012), and are thought to have variable effects on CHD7 remodelling
activity. Site-directed mutagenesis has been used to engineer in vitro a number of point
mutations reported in CHARGE patients at highly conserved residues in the CHD7 locus. K907T51
Figure 1-11: Distribution of mutations along the CHD7 locus and corresponding CHD7 protein domains
Coloured circles depict the loci of 200 CHARGE-causing mutations, as defined by the introduction of stop codons or frameshifts, or mutations of the canonical splice donor–
acceptor pair (GT-AG). Missense changes or other putative splice site changes were only considered disease-causing if the change was a de novo mutation not found in either
parent, or if it was reported in the literature as a de novo mutation. Overlapping circles indicate identical mutations. Protein domains are labeled and lines indicate where each
protein domain is encoded on the gene.
Diagram taken from Bartels et al. (2010).52
and T917M mutations, which affect the second chromodomain of CHD7, show a 3.5-fold and
1.5-fold reduction in ATPase activity respectively, whilst the S834F missense mutation found in
the first chromodomain completely abolishes both ATPase and nucleosome remodelling
activity (Bouazoune and Kingston, 2012). Again, these mutations appear to result in a non-
functional CHD7 protein, supporting the hypothesis that CHD7 haploinsufficiency causes
CHARGE syndrome.
The genetic basis of CHARGE remains unclear in approximately 10% of patients that fulfil the
clinical criteria for typical CHARGE, and many more patients with either the atypical or partial
CHARGE phenotype. The only other gene that has been implicated in CHARGE syndrome is
SEMA3E, which was mutated in one CHD7-negative CHARGE patient and disrupted in another
patient with a de novo chromosomal translocation between chromosomes 2 and 7 (Lalani et
al., 2004). Other candidate genes have been tested in CHARGE patients, including PITX2, PAX2
and CHD8, but none of these studies identified any pathogenic mutations (Batsukh et al., 2010;
Martin et al., 2002; Tellier et al., 2000). Undetectable disruption to the CHD7 locus, such as
intra-genic rearrangements, intronic mutations affecting unknown splice sites, or mutations in
regulatory regions could explain the presence of CHARGE in patients for which a pathogenic
mutation has not been identified.
1.5.3 Heart defects associated with CHD7 mutations
Whilst cardiac malformations are not considered a major criterion for the diagnosis of CHARGE
(see Table 1-2), there is a high incidence of congenital heart defects in CHARGE syndrome. A
review of 379 clinical cases of CHARGE found 77% of CHD7 mutation-positive patients had
cardiovascular defects (Zentner et al., 2010b), whilst a more recent study of 299 patients with
a pathogenic CHD7 mutation reported that 74% of the cohort had a congenital heart defect
(Corsten-Janssen et al., 2013a). A wide range of heart malformations are reported, including
Tetralogy of Fallot (characterised by ventricular septal defects, pulmonary stenosis, right
ventricular hypertrophy, and an overriding aorta), patent ductus arteriosus (PDA), septal
defects, aortic valve stenosis, and interrupted aortic arch (IAA) (Aramaki et al., 2006; Lalani et
al., 2006; Lin et al., 1987; Tellier et al., 1998; Wyse et al., 1993).
The most detailed study of the congenital heart defects found in patients with a pathogenic
CHD7 mutation was carried out by Corsten-Janssen and colleagues. They classified the heart
defects of 220 CHARGE patients and compared them to a cohort of 1,007 non-syndromic heart
defects. High variability in the types of congenital heart defects was observed, with
conotruncal defects, septal defects and atrioventricular septal defects (AVSDs) most commonly53
seen, either in isolation or in combination with other defects. Comparing the distribution of
cardiac defects between the CHARGE patients cohort and the non-syndromic cohort identified
an over-representation of AVSDs and conotruncal defects in patients with a CHD7 mutation
(Figure 1-12) (Corsten-Janssen et al., 2013a). However, the same group also reported that
CHD7 mutations are not present in a group of patients with these heart defects plus one other
feature of CHARGE (Corsten-Janssen et al., 2014). This indicates that CHD7 mutations are
associated with heart defects predominantly in the context of CHARGE syndrome, so analysis
of the CHD7 gene is not recommended in patients presenting with an AVSD or conotruncal
defects, even when an additional feature of CHARGE is present.
Figure 1-12: Comparison of heart malformations associated with CHD7 mutations (A) and
non-syndromic heart defects (B)
Classification of 239 congenital hearts defects in a cohort of 202 patients with CHD7 mutations (A) is
compared to 1,007 patients with non-syndromic heart defects (B), showing over-representation of
AVSDs and conotruncal defects in CHD7-mutation patients.
Figure taken from Corsten-Janssen et al (2013a). AVSD is atrioventricular defects; LVOTO, left ventricular
outflow tract obstruction; RVOTO, right ventricular outflow tract obstruction; PDA, patent ductus
arteriosus.54
The incidence of heart defects is significantly higher in CHARGE patients with truncating
nonsense or frameshift deletions (80%) compared to those with missense or splice site
mutations (58%) (Corsten-Janssen et al., 2013a). This is consistent with biochemical studies
that found variable effects of missense mutations on the biological function of CHD7
(Bouazoune and Kingston, 2012). Of 139 patients for which information about cardiac surgery
was available, 12 patients died before surgery could be performed, whilst 88 patients had
undergone surgery and a further 3 were predicted to need surgery in the future (Corsten-
Janssen et al., 2013a). Therefore, nearly 75% of CHARGE patients required cardiac surgery,
showing that congenital heart malformations have a significant impact on the morbidity and
mortality associated with CHARGE syndrome. CHD7 has also been detected in a large-scale
study of de novo mutations in human sporadic congenital heart defects (Zaidi et al., 2013),
again indicating an important role for CHD7 in the development of the heart.
1.5.4 Overlap with other developmental disorders
Phenotypic overlap has been noted between CHARGE syndrome and a number of other
developmental disorders, such as DiGeorge syndrome, Anophthalmia-Esophageal-Genital
syndrome, Kabuki syndrome and Kallman syndrome. Understanding of the molecular and
genetic basis for these disorders can lead to the identification of overlapping tissue
requirements and roles for the genes involved, as well as being informative for the clinical
diagnosis and genetic counselling of patients.
DiGeorge syndrome (DGS, OMIM# 188400) - also known as 22q11.2 Deletion syndrome – is a
genetic disorder caused by a 1.5- to 3.0-Mb hemizygous interstitial deletion of chromosome
22q11.2. The anomalies are largely attributed to the loss of the TBX1 gene in this region,
leading to haploinsufficiency for the transcription factor TBX1 (Paylor et al., 2006; Yagi et al.,
2003). DGS commonly features heart defects, most often affecting the outflow tract and aortic
arch (Momma, 2010). Furthermore, craniofacial dysmorphia, cleft palate, aplasia/hypoplasia of
the thymus gland, and ear defects are all characteristics associated with both CHARGE and
DGS. During development, the tissues affected by these overlapping anomalies are all
associated with the pharyngeal apparatus, indicating overlapping roles for Chd7 and Tbx1 in
this region. Hypo/aplasia of the fourth pharyngeal arch artery (PAA) at E10.5 is seen in both
Tbx1 and Chd7 heterozygous mice (Randall et al., 2009). Furthermore, Tbx1 and Chd7 have
been shown to be in epistasis, with biallelic expression of both genes required in the
pharyngeal surface ectoderm for normal PAA morphogenesis (Randall et al., 2009). It is
therefore unsurprising that patients clinically diagnosed as having CHARGE syndrome have55
been found to have 22q11.2 deletions, whilst patients with the DGS phenotype have been
identified with truncating CHD7 mutations (Corsten-Janssen et al., 2013b).
Anophthalmia-Esophageal-Genital (AEG) syndrome (OMIM# 206900) is caused by
heterozygous mutations in SOX2, which encodes a SOX family transcription factor (Fantes et
al., 2003; Kelberman et al., 2006; Williamson et al., 2006b). Again, a number of the congenital
anomalies seen in AEG patients overlap with CHARGE patients, including atresia of the
oesophagus, pituitary and genital abnormalities, and neurocognitive delays. Engelen and
colleagues have identified a molecular basis for the phenotypic overlap resulting from
mutations of SOX2 and CHD7, showing that CHD7 and SOX2 proteins physically interact and
have overlapping genome-wide binding sites in neural stem cells. They act synergistically to
regulate a common set of target genes, of which MYCN, GLI3 and JAG1 are also associated with
human syndromes that overlap with AEG and CHARGE (Engelen et al., 2011).
Kabuki syndrome (OMIM# 147920) shares a number of features with CHARGE syndrome,
including cleft palate, congenital heart, ear and eye defects, genital hypoplasia and retardation
of growth and development (Schulz et al., 2014a). The major cause of Kabuki syndrome is
mutations in the KMT2D gene, which encodes a SET1 histone H3 lysine 4 (H3K4)
methyltransferase also known as MLL2 (Li et al., 2011; Ng et al., 2010). It is only functional as a
methyltransferase when in a multi-subunit complex, including a core complex comprised of
WDR5, ASH2L and RbBP5 (Ernst and Vakoc, 2012; Zhang et al., 2012). CHD7 has also been
shown to interact with these three proteins, suggesting a possible mechanistic link between
CHD7 and KMT2D during chromatin modification, which would explain the phenotypic overlap
between CHARGE and Kabuki syndrome (Schulz et al., 2014a).
The disorder Kallman syndrome (KS, OMIM# 308700) combines congenital hypogonadotropic
hypogonadism (CHH) and anosmia (Kallmann FJ, 1944), which are features also frequently seen
in CHARGE patients (Pinto et al., 2005). Mutations in a number of genes have been implicated
in KS, including KAL1, FGFR1, PROK2, PROKR2, and SEMA3A (Dode et al., 2003; Dode et al.,
2006; Hanchate et al., 2012; Legouis et al., 1991). CHH in KS is caused by incomplete
embryonic migration of gonadotropin-releasing hormone (GnRH) cells along the olfactory
nerve fibers from the olfactory epithelium to the forebrain, so it is proposed that the protein
products of the genes associated with KS are involved in this process (Kim et al., 2008b;
Oliveira et al., 2001). Mutations in CHD7 have also recently been reported in 5.4-8.3% of KS
patients (Bergman et al., 2012; Jongmans et al., 2009; Kim et al., 2008a). It is therefore
possible that CHD7 has a role in the regulation, through chromatin remodelling, of KAL1,
FGFR1, PROK2, PROKR2 and/or SEMA3A during GnRH cell migration. Interestingly, the56
prevalence of CHD7 missense versus truncating mutations is higher in KS patients compared to
typical CHARGE patients, indicating that the clinical spectrum associated with CHD7 mutations
may at least partly be explained by genotype/phenotype correlations (Marcos et al., 2014).57
1.6 Mouse models to investigate Chd7 activity
Both human and mouse CHD7/Chd7 genes comprise 38 exons with similar intron-exon
structures, which produce proteins with 94.7% sequence identity (Layman et al., 2010). Mouse
models have therefore been widely used to study the function of CHD7 and the etiology of
CHARGE syndrome. A large number of mutant Chd7 alleles have now been reported, which
have been generated through various methods, including ethylnitrosurea (ENU) mutagenesis,
gene trapping and gene targeting (see Table 1-4). This final section will give an overview of
these mutant lines.
Table 1-4: Published Chd7 mutant alleles
Allele: Derivation: Mutation: Effect: Reference:
Coa1 ENU c.2155A>T p.K719X (Jiang et al., 2012)
Cycn ENU c.4286T>A p.L1429X (Bosman et al., 2005)
Dz ENU c.5536G>T p.E1846X (Bosman et al., 2005)
Edy ENU c.3070C>T p.Q103X (Bosman et al., 2005)
Flo ENU IVS27+2T>C p.S1864X (Bosman et al., 2005)
Gt(RRR136)Byg Gene trap Insertion in
intron 4
Reporter fusion (Randall et al., 2009)
Gt(S20-7E1)Sor Gene trap Insertion in
exon 1
Reporter fusion (Hurd et al., 2007)
Gt(XK403)Byg Gene trap Insertion in
intron 36
Reporter fusion (Randall et al., 2009)
Lda ENU c.3195T>A p.Y1066X (Bosman et al., 2005)
Looper ENU c.5690C>A p.S1897X (Ogier et al., 2014)
Mt ENU IVS22-2A>G p.V1688X (Bosman et al., 2005)
Obt ENU c.3945T>A p.Y1315X (Bosman et al., 2005)
Ome Spontaneous Del. exons
2 & 3
No protein (Tian et al., 2012)
tm1.1Dmm Gene targeting Floxed exon 2 No effect (Hurd et al., 2010)
tm1.2Dmm Gene targeting Del. exon 2 No protein (Hurd et al., 2010)
tm2a-
(EUCOMM)Wtsi
Gene targeting Floxed exon 2 No protein (Feng et al., 2013)
Todo ENU IVS3+2T>C p.H539X (Bosman et al., 2005)
Vik ENU c.4377T>A p.Y1459X (Lenz, 2010)
Whi ENU c.2918G>A p.W973X (Bosman et al., 2005)58
1.6.1 Chd7 ENU mutants
The first reported heterozygous Chd7 mutant mice were generated through ENU mutagenesis
screens that selected for mice displaying hyperactivity, circling and headshaking phenotypes in
heterozygotes, which is characteristic of inner ear defects (Bosman et al., 2005). ENU
mutagenesis involves the injection of the alkylating agent N-Ethyl-N-nitrosourea into adult
males to induce single nucleotide substitutions into mouse spermatogonia DNA at a frequency
of approximately one new mutation per gene in 700 first-generation progeny (Hitotsumachi et
al., 1985). Progeny with the desired/interesting phenotypes can then be selected, and linkage
analysis using microsatellite markers to identify the chromosomal location of the mutation, to
enable a non-biased approach to identifying important developmental genes based on their
mutant phenotype (Liu and Eggenschwiler, 2014). 12 lines were identified with the inner ear
defect and a mutation mapping to the proximal region of chromosome 4, and exon re-
sequencing identified a single nonsense or splice-site mutation in the Chd7 locus in nine of
these lines, which were spread throughout the gene (Table 1-4) (Bosman et al., 2005). A range
of defects were seen that are reminiscent of the human CHARGE symptoms, including cleft
palate, choanal atresia, septal defects of the heart, vulva and clitoral defects.
The Whi line, which carries a nonsense mutation in exon 11, which is predicted to produce a
truncated protein missing most of the SNF2 helicase domain and all other more C-terminal
domains, was characterised further. Whi/+ embryos were examined during development at
E15.5, when 45% had either mild or severe oedema, 10% had haemorrhage and 3 out of 5
showed VSDs. Post-natally, approximately 50% of Whi/+ mice died before weaning, and in
those that survived to adulthood, all showed the inner ear defect behaviour (Bosman et al.,
2005).
Three further ENU-generated lines with mutations in Chd7 have been reported, all with similar
phenotypes. Both the Volchok (Vlk) and Coa1 lines were also originally selected based on their
circling and head bobbing behaviour. Similar structural inner ear defects were described in
Vlk/+ mice to those seen by Bosman and colleagues, which was accompanied by mild hearing
loss (Lenz, 2010). Developmental defects in the telencephalic midline were characterised in the
Coa1 line, identifying a role for CHD7 in the regulation of Bmp4 expression during
development of the forebrain (Jiang et al., 2012). The most recently-reported Chd7 ENU line,
Looper, was identified in a screen using acoustic startle response testing, so again have hearing
impairments as well as a range of CHARGE-associated phenotypes (Ogier et al., 2014).59
1.6.2 Chd7 gene-trap mice
Gene-trapping enables the generation of a well characterised insertional mutation into a
random intronic or coding region of genomic DNA, which is introduced by electroporation or
retroviral infection of a vector into ESCs (Figure 1-13) (Stanford et al., 2001). The trapped locus
is identified using primer sequences from the ends of the vector to sequence mRNA
surrounding the vector cassette, and the mutant ESCs can be injected into blastocysts to
generate chimeric mice, from which germline transmissions of the gene-trapped allele can be
obtained. Hurd and colleagues characterised a loss of function Chd7 mouse line (Chd7
Gt(S20-
7E1)Sor, or Chd7
Gt) generated from Chd7-deficient gene-trapped lacZ reporter ESCs, which were
produced by retroviral infection of the ROSAFARY viral vector (Chen et al., 2004). The vector
cassette was inserted between exons 1 and 2 at the Chd7 locus (Hurd et al., 2007).
Heterozygous Chd7
Gt/+ mice had phenotypes very similar to those seen in the ENU-mutated
mice, whilst complete knock-out in Chd7
Gt/Gt mice was embryonic lethal by E10.5 (Hurd et al.,
2007). Chd7
Gt/GT embryos exhibited delayed turning, and sectioning at E10.5 revealed
hypoplasia of a number of structures, including the neuroepithelium, optic eminence and
hindlimbs. The otocyst, which develops into the inner ear, was also thickened and reduced in
size in Chd7
Gt/Gt embryos (Hurd et al., 2007). Two further gene-trapped reporter lines have also
been generated, which showed similar embryonic lethality in homozygotes and great vessel
defects in heterozygotes (Randall et al., 2009).
Figure 1-13: Conventional gene-trap mutagenesis in ESCs
The pGT4.5 vector, containing a lacZ reporter gene and a neomycin resistance gene (neo) that is driven
by an autonomous hβ-actin promoter, is shown ‘trapping’ an endogenous gene ‘X’ by insertion in an 
intron. The presence of the splice acceptor site (SA) immediately upstream of the lacZ gene interrupts
normal splicing of the gene, leading to transcription of the vector cassette sequence downstream of the
gene X exon when gene X expression is activated. The polyadenylation site (pA) at the end of the lacZ
gene signals a stop in translation. This therefore results in a fusion protein of the truncated protein X
with C-terminal β-galactosidase (β-gal), which can be used as a reporter to show successful integration 
of the vector into an expressed gene. If it is inserted close enough to the 5’ end of the gene this should
lead to a null allele. Integration into the genome will also lead to neomycin resistance, which allows
selection of ESCs with inserted mutations.
Adapted from Stanford et al. (2001).60
1.6.3 Conditional Chd7
fl allele
Due to the embryonic lethality of ubiquitous homozygous Chd7 mutation, conditional floxed
Chd7 alleles (Chd7
fl) have also been generated, to study further the tissue-specific roles of
Chd7 (Feng et al., 2013; Hurd et al., 2010). Briefly, a neomycin/kanamycin (N/k) cassette was
introduced between exons 2 and 3 of the Chd7 gene using recombineering techniques, with
LoxP sites positioned upstream of exon 2 and downstream of the N/k cassette (‘Floxed allele’,
Figure 1-14). Breeding with FLPeR mice (MGI; Gt(ROSA)26Sor
tm1(FLP1)Dym, (Farley et al., 2000))
results in recombination at the frt sites to excise the N/k cassette, leaving a conditional Chd7
fl
allele with LoxP sites surrounding exon 2 (‘Flp-recombined allele). When this Flp-recombined
allele is crossed with a tissue-specific Cre recombinase mouse, the Chd7 exon 2 is excised due
to recombination at the LoxP sites, which is predicted to lead to nonsense-mediated decay of
Chd7 mRNA. This allows conditional ablation of Chd7 in specific tissues relevant for different
organs or systems, such as cardiovascular development.
Figure 1-14: Schematic showing the generation of the conditional Chd7 construct
Adapted from Hurd et al. (2010)61
1.7 Scope of the thesis
It is clear from the literature that chromatin remodelling by CHD7 is extremely important
during development in a range of different tissues. Whilst congenital heart defects are
commonly seen in CHARGE patients, the specific role of CHD7 during cardiogenesis is still
poorly understood. This is partly due to the early embryonic lethality of constitutive Chd7
-/-
embryos. The overall aim of this thesis was to investigate the role of Chd7 during heart
development, using a conditional floxed Chd7 allele to allow examination of hearts at later
stages in development. Specifically, three key questions will be addressed:
 When and where is CHD7 protein present in the developing heart?
 What is the cardiovascular phenotype when Chd7 is ablated in the cardiogenic
mesoderm, and subsets of this lineage?
 What are the downstream transcriptional effects of loss of CHD7 activity in the heart?
Immunohistochemistry and western blot analysis data will be presented, along with detailed
morphological analysis of conditional Chd7 mutant embryos, to determine the tissue-specific
requirements for Chd7 in the developing heart. Microarray experiments will also be presented,
which were used to identify genome-wide transcriptional changes underlying the cardiac
defects caused by Chd7 ablation, with selected genes validated further by in situ hybridisation
and by functional calcium imaging assays.62
CHAPTER TWO
EXPERIMENTAL PROCEDURES
2.1 Mouse lines and genotyping
2.1.1 Mouse lines
Animal maintenance, husbandry and procedures were carried out in accordance with British
Home Office regulations. All genetically-modified lines were maintained on a C57Bl/6J
background. The mouse lines used were:
Whirligig - MGI: 3588650, Chd7
Whi, (Bosman et al., 2005)
Conditional Chd7
fl – MGI: 4433295, Chd7
tm2a(EUCOMM)Wtsi (Feng et al., 2013)
Conditional Brg1
fl - MGI: 3605892, Smarca4
tm1Pcn (Indra et al., 2005)
Conditional Sema3C
fl - MGI: 5428549, Sema3c
tm1a(KOMP)Wtsi, Wellcome Trust Sanger Institute
Mesp1-Cre - MGI: 2176467, Mesp1
tm2(cre)Ysa,(Saga et al., 1999)
Nkx2.5-Cre - (MGI:2654594, Nkx2-5
tm1(cre)Rjs,(Moses et al., 2001)
Mef2c-Cre - (MGI: 3639735, Tg(Mef2c-cre)2Blk, (Verzi et al., 2005)
Tie2-Cre - (MGI: 2450311, Tg(Tek-cre)1Ywa, (Kisanuki et al., 2001)
R26RYFP - (MGI: 2449038, Gt(ROSA)26Sor
tm1(EYFP)Cos,(Srinivas et al., 2001).
CD1 mice were also used, for anti-CHD7 immunohistochemistry on cryosections.
2.1.2 Mouse breeding
Mice were determined to have reached sexual maturity at 6 weeks of age for females and 8
weeks for males. Breeding pairs were set up once mice were sexually mature, and resulting
pups were ear-clipped at ~10 days of age for genotyping and identification. Offspring were
weaned at 21 days of age.
2.1.3 Embryo collection
Timed-matings were set up overnight and female mice checked for vaginal plugs the following
morning. The date of observation of a vaginal plug was considered embryonic day E0.5.
Pregnant females were culled by cervical dislocation followed by decapitation, and embryos
harvested into phosphate buffered saline (PBS) on ice. For embryos at E10.5, E11.5, E12.5,
E13.5, E15.5 or E18.5, collection was mid-late afternoon, and for E15.0 embryos collection was63
early in the morning. Embryos were dissected from the uterus and yolk sacs and/or tail tips
collected for genotyping.
2.1.4 Genomic DNA extraction
Genomic DNA was extracted from yolk sacs, tail tips or ear clips by incubation in Tail Lysis
buffer (10mM Tris-HCl pH8.0, 100mM NaCl, 10mM EDTA pH 8.0, 10mM EDTA pH 8.0, 0.5%
SDS, 400µg ml
-1 Proteinase K (Sigma)) overnight at 56°C, followed by enzyme heat inactivation
for 5 minutes at 95-100°C. DNA was precipitated by addition of an equal volume of
isopropanol, separated by centrifugation, and the pellet washed in ice-cold 70% ethanol
(EtOH) before air drying and resuspension in 100-150µl distilled H2O.
2.1.5 Polymerase chain reaction
Illustra PuReTaq Ready-To-Go PCR Beads (GE Healthcare) were used for genotyping the
conditional Chd7
fl, Brg1
fl and Sema3C
fl alleles, the Chd7
Whi allele and the R26RYFP allele. Beads
were dissolved in reaction mixes to contain a final concentration of 0.8µM of each required
primer (Table 2-1) and 20-50ng genomic DNA in a total volume of 25µl. PCR reactions were
carried out in a Thermal Cycler PCR machine (PTC-225, MJ Research) and PCR products run on
a 2% or 3% agarose gel.
The Chd7
Whi genotyping required an additional MfeI digestion step after the PCR reaction, as
the wild-type Chd7 sequence contains an MfeI recognition site in exon 11 that is lost in the
ENU-generated Chd7
Whi mutant allele. Digestion of PCR products for 2-3 hours at 37°C with
MfeI (New England Biolabs) produced a band of 204bp for the wild-type allele and 233bp for
the mutant Chd7
Whi allele, which could be resolved on a 3% agarose gel.
BIOTAQ
TM DNA polymerase kits (Bioline) were used for genotyping the Cre alleles. Reaction
mixtures were prepared containing 1x NH4 Reaction Buffer (Bioline), 1.5mM MgCl2, 0.8mM
dNTP mix (Bioline), 0.4mM Cre primers, 0.04u µl
-1 Taq DNA Polymerase and 20-50ng genomic
DNA in a total volume of 25µl. PCR reactions were again carried out in the Thermo Cycler PCR
machine and the products run on a 2% agarose gel.64
Table 2-1: Genotyping primer sequences, annealing temperatures and PCR product sizes
Allele: Primer sequences (5’-3’):
Annealing
temp (°C):
Size of PCR
products (bp):
Chd7
fl F: TGCAGATGGGACGTTTTCAG
WT-R: CTGCAAGAACACAGGGCAAG
Mut-R: TCGTGGTATCGTTATGCGCC
58°C Chd7
WT: 610
Chd7
fl: 411
Brg1
fl F: GCCTTGTCTCAAACTGATAAG
R: GTCATACTTATGTCATAGCC
60°C Brg1
WT: 268
Brg1
fl: 387
Sema3C
fl F: GAATCTGGCAAAGGACGATG
R: GACCACTGGGCTTGAGAGAG
60°C Sema3C
WT: ~400
Sema3C
fl: ~350
Chd7
Whi F: ACTCAGGGAATACCAATTGGAG
R: CAAAGAAAAGTTCCCAGCAAAC
58°C Chd7
WT: 204
Chd7
Whi: 233
Cre F: TGGAAAATGCTTCTGTCCGTTTGC
R: AACGAACCTGGTCGAAATCAGTG
60°C WT: No product
Cre: 300
R26RYFP F: AAGTCGCTCTGAGTTGTTAT
WT-R: 3: GGAGCGGGAGAAATGGATATG
Mut-R: GCGAAGAGTTTGTCCTCAACC
55°C WT: 500
R26RYFP: 25065
2.2 Phenotyping of morphological defects
2.2.1 Haemotoxylin and Eosin staining
Dissected embryos were fixed overnight in 4% paraformaldehyde (PFA) in PBS and then
dehydrated through an EtOH series to 100% EtOH, cleared by washing in histoclear (National
Diagnostics), and embedded in paraffin after overnight washes at 60°C. A microtome was used
to section embryos to 12-15µm thickness and sections were transferred onto 3-
triethoxysilylpropylamine (TESPA)-coated SuperFrost® microscope slides (VWR) for overnight
drying. E10.5-E115 embryos were sectioned in a coronal plane, and E13.5-E18.5 embryos in a
transverse plane.
For morphological examination, sections were warmed to 60°C and rinsed in histoclear to de-
wax, then rehydrated through an EtOH series to H2O. Slides were stained using freshly-filtered
Mayer’s Hemotoxylin solution (Sigma-Aldrich) followed by aqueous Eosin solution (Sigma-
Aldrich) and rinsed further in H2O. Slides were mounted with glass coverslips using DPX
solution (Merck).
2.2.2 Intracardiac Ink Injection
Following overnight fixation of E10.5 embryos in 4% PFA/PBS at 4°C, outflow tracts were
injected with India ink (Pélican) using a pulled glass capillary to fill the 3
rd, 4
th and 6
th
pharyngeal arch arteries (PAAs, as previously described (Lindsay et al., 1999)). Aplasia of the 4
th
PAA was only recorded for embryos in which the 6
th PAA was present.
Fixed E15.5 embryos were opened to view the chest cavity and India ink injected into the
cardiac ventricles by the same method when insufficient blood remained in the great vessels
to view their structure.
2.2.3 Optical Projection Tomography
Embryos were fixed overnight in 4% PFA/PBS, rinsed in PBS then mounted in 1% low-melting
agarose (Life Technologies). Samples were then trimmed and washed in 100% methanol
(MeOH) followed by the organic clearing agent BABB (2 parts benzyl alcohol to 1 part benzyl
benzoate), with several changes of each wash. Optical projection tomography was run on a
Bioptonics OPT Scanner 3001M (MRC Technology, Edinburgh, UK), with NRecon software
(Skyscan NV) used for image reconstruction from projections using a back-projection
algorithm. Images were analysed and digitally re-sectioned using ImageJ.66
2.3 Immunostaining
2.3.1 Cryosection preparation
Following dissection, E10.5-13.5 CD1 embryos were fixed in 4% PFA/PBS at 4°C for 30-60
minutes, washed in PBS and then incubated overnight in 30% sucrose/PBS at 4°C. This was
followed by incubation in a 50/50 mixture of 30% sucrose/OCT embedding matrix (Fisher) until
the embryos sank, and then incubation in 100% OCT. Samples were mounted into moulds on
dry ice and stored at -80°C before crysectioning at 10µM thickness onto SuperFrost® Plus glass
slides (VWR). Sections were either used immediately for immunohistochemistry (IHC) or stored
at -80°C then brought to room temperature on the day of staining.
2.3.2 Immunohistochemistry on cryosections
Sections were rinsed twice in PBS and permeabilised with 0.5% Triton X-100 (Sigma-
Aldrich)/PBS for 10 minutes before further rinses in PBS. Sections were incubated in blocking
solution (1% bovine serum albumin (BSA, Sigma-Aldrich), 10% goat serum (Sigma-Aldrich),
0.1% Triton X-100, PBS) for 1 hour in a humidified chamber, then incubated overnight at 4°C in
anti-CHD7 antibody (NBP1-77393, Novus Biologicals) diluted 1:200 in the blocking solution.
Following washes in 0.1% Triton X-100/PBS and then PBS, slides were incubated in AlexaFluor®
594 goat anti-rabbit-IgG (Invitrogen) diluted 1:1000 in blocking solution, before finally washing
again and counter-staining with DAPI. Slides were mounted with glass coverslips using
VECTASHIELD® mounting medium
2.3.3 Immunostaining on paraffin sections
Tissue sections were prepared in the same way as for Haemotoxylin and Eosin staining (section
2.2.1). Slides were de-waxed by pre-warming at 60°C followed by two 10 minute washes in
histoclear, and rehydrated by 5 minute washes through an EtOH series down to 30% EtOH.
Antigen retrieval was then carried out by incubation in pre-warmed Target Retrieval Solution
(Dako) for 30 minutes at 94-96°C, 20 minutes at room temperature, and then 5 minutes under
running water.
For immunofluorescence staining for RosaYFP lineage tracing, sections were incubated for 1
hour at room temperature in blocking solution (1% BSA, 2% fetal bovine serum (FBS, Life
Technologies), PBS) followed by incubation overnight at 4°C in anti-GFP antibody (ab13970,
Abcam) diluted 1:500 in the blocking solution. Slides were then rinsed in PBS and incubated in67
AlexaFluor® 488 goat anti-chicken IgG (Invitrogen) diluted 1:500 in blocking solution for 1 hour
at room temperature. Finally, slides were rinsed further in PBS, stained with DAPI and then
mounted with glass coverslips using VECTASHIELD® mounting medium.
For immunohistochemical staining for Notch1, antigen retrieval was followed by quenching of
endogenous peroxidase activity by incubation for 30 minutes in 0.3% H2O2. Slides were then
washed in PBS for 5 minutes and incubated at room temperature for 30 minutes in the
Blocking Serum included in the VECTASTAIN® ABC Kit (Vector Laboratories). Slides were then
incubated for 30 minutes in anti-Notch1 rabbit monoclonal antibody (#3608, Cell Signaling
Technology) diluted 1:100 in the Blocking Serum. Following a further PBS wash, slides were
incubated in VECTASTAIN® biotinylated secondary anti-rabbit IgG antibody solution, followed
by incubation with VECTASTAIN® ABC reagent solution, which contains both Avidin DH and
biotinylated peroxidase H. Slides were then stained using the NovaRED™ Substrate Kit for
Peroxidase (Vector Laboratories), rinsed in H2O and again mounted using VECTASHIELD®
mounting medium.
2.3.4 Immunocytochemistry
Cultured embryonic cardiomyocytes grown on laminin-coated coverslips (see section 2.6.1)
were gently rinsed in PBS and fixed in 4% PFA/PBS for 10 minutes, followed by further PBS
washes. Cells were permeabilised in 0.1% Triton-X100/PBS for 5 minutes, rinsed in PBS and
then incubated for 1 hour in primary antibodies diluted in 10% goat serum/PBS (1:50 anti-
Nkx2-5 rabbit polyclonal antibody, ab35842 Abcam, and 1:100 anti-cardiac heavy chain Myosin
mouse monoclonal antibody, ab15 Abcam). After further PBS washes, cells were incubated for
30 minutes in 10% goat serum/PBS containing 1:1000 AlexaFluor® 594 goat anti-rabbit-IgG and
1:1000 AlexaFluor® 488 goat anti-mouse-IgG (Invitrogen). Cells were finally rinsed again in PBS,
stained with DAPI and mounted on SuperFrost® microscope slides using ProLong® Gold
antifade reagent (Life Technologies). All incubations were carried out in a humidified chamber
at room temperature.
2.3.5 Visualising Parasympathetic Innervation on Wholemount Hearts
E14.5-E15.0 hearts were dissected into PBS before fixation for 20-30 minutes in 4% PFA/PBS at
room temperature. Hearts were then permeabilised by incubation in 0.5% Triton-X/PBS for 5
minutes, washed in PBS and stored overnight at 4°C in blocking solution (1% BSA, 10% sheep
serum, 0.1% Triton-X, PBS). Hearts of the required genotype were incubated overnight at 4°C
with rotation in anti-Neurofilament-66 antibody (04-1032, Millipore) diluted 1:50 in blocking68
solution, washed in PBS at room temperature, incubated overnight at 4°C in AlexaFluor® 594
goat anti-rabbit-IgG (Invitrogen) diluted 1:1000 in blocking solution, and finally washed again
in PBS.
2.3.6 Visualising Coronary Veins on Wholemount Hearts
E15.5 hearts were dissected into PBS, fixed in 4% PFA/PBS for 40 minutes at room
temperature, washed in PBS and then dehydrated through a methanol (MeOH) series and
stored at -20°C in 100% MeOH until genotyped. After rehydration to PBS, hearts were
permeabilised by washing twice in 0.1% Tween-20/PBS (PBT) before blocking for 2 hours at
room temperature in 10% goat serum/PBT and then overnight incubation in anti-Endomucin
antibody (sc-65495, Santa Cruz) diluted 1:50 in the blocking solution. Samples were washed in
PBT at room temperature and then incubated overnight at 4°C in secondary Alexafluor-594-
conjugated anti-rat-IgG antibody (Invitrogen) diluted 1:1000 in blocking solution, before final
PBT washes.
2.3.7 Fluorescence microscopy
Immunofluorescently-stained cardiomyocytes or tissue sections were imaged using a Zeiss
AxioImager Z1 upright microscope equipped with an AxioCam MRm camera and UV lamp,
using either the Ec-Plan-Neofluar 5x/0.16, Achro-Plan 10x/0.25 or Ec-Plan-Neofluar 20x/0.5
objectives as needed. Wholemount hearts stained with anti-Neurofilament-66 or anti-
Endomucin antibodies were photographed using a Zeiss SteREO Lumar.V12 microscope with
attached AxioCam HRc camera and UV lamp.
All images were processed using ImageJ.69
2.4 Measurement of gene expression changes
2.4.1 RNA extraction
For qRT-PCR analysis of Chd7 expression, total RNA was isolated from E11.5 hearts using the
TRIzol reagent (Invitrogen). Briefly, hearts were dissected in RNase-free PBS, 350µl TRIzol
reagent was added per dissected heart and samples stored at -80°C. Samples of the required
genotypes were thawed and homogenised using a 25G 0.5x25mm needle and syringe before 5
minutes incubation at room temperature. 60µl chloroform was then added and tubes shaken
vigorously, followed by a further 5 minutes incubation and centrifugation for 15 minutes. The
upper aqueous layer was transferred to a fresh tube, 150µl isopropanol added and samples
left for 10 minutes before further centrifugation for 10 minutes. RNA pellets were washed in
70% EtOH, air dried and resuspended in 30µl RNase-free H2O. All incubations were at room
temperature and centrifugations were 10,00rpm at 4°C.
For microarray or TaqMan® Array Micro Fluidic Card experiments, E11.5 or E13.5 hearts were
dissected into RNase-free PBS and stored in 300µl Buffer RLT (Qiagen) containing 10µl ml
-1 β-
mercaptoethanol (Sigma-Aldrich) at -80°C until genotyped. Total RNA was isolated using
RNeasy Mini kits (Qiagen) according to manufacturer’s instructions, including the optional on-
column DNase digestion step, and eluted into 30µl RNase-free H2O.
2.4.2 Reverse transcription
For Chd7 qRT-PCRs, cDNA was generated from total RNA extracts using Superscript® II Reverse
Transcriptase kits from Invitrogen. Immediately before reverse-transcription, samples were
DNase-treated utilising the RQ1 RNase-Free DNase kit (Promega). Digestion reactions were set
up comprising 1µg RNA, 1µl 10x reaction buffer, 1 unit RQ1 RNase-Free DNase, and ddH2O to a
total volume of 10µl, and incubated at 37°C for 30 minutes. 1µl RQ1 DNase Stop Solution was
added to terminate the reaction, and samples incubated at 65°C for 10 minutes to deactivate
the DNase enzyme.
DNase-treated RNA was incubated with 300ng Oligo(dT) Random Primer mix (Invitrogen) and
ddH2O to a total volume of 37µl for 5 minutes at 65°C and then 10 minutes at room
temperature. 10µl 5x Superscript® buffer, 2µl 10mM dNTPs and 1µl Superscript® II Reverse
Transcriptase was then added to each sample, pipetted up and down to gently mix and
incubated for 1 hour at 37°C. The enzyme was then deactivated for 5 minutes at 95°C, and
samples cooled on ice before storage at -20°C.70
The High-Capacity Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems) was
used to make cDNA for loading on TaqMan® Array Micro Fluidic Cards, according to
manufacturer’s instructions.
2.4.3 Real-time PCR for Chd7 expression
TaqMan® gene expression assay probes Mm01219527_m1 and Mm99999915_g1 were used
for quantitative real-time-PCR (qRT-PCR) analysis of mouse Chd7 and Gapdh expression levels,
respectively. Reactions were carried out in 96-well plates, with each well containing 1µl cDNA,
12.5µl Taqman® Universal PCR Master Mix (Life Technologies), 1µl TaqMan® assay, and 10.5µl
ddH2O. Plates were set up with 3 replicates of each sample, and 2 samples per genotype
tested. qRT–PCR analysis was performed on a CFX96 Touch
TM Real-Time PCR Detection System
(Bio-Rad). Data were normalised to Gapdh expression and fold-changes in gene expression
determined by the 2
−ΔΔCTmethod (Livak and Schmittgen, 2001).
2.4.4 Real-time PCR using TaqMan® Array Micro Fluidic Cards
600ng cDNA per lane was loaded on custom-designed TaqMan® Array Micro Fluidic Cards,
according to manufacturer’s instructions. Cards were run on an Applied Biosystems 7900HT
Fast Real-Time PCR System using a TaqMan® Array Micro Fluidic Card Thermal Cycling Block
with SDS Software v2.1. The comparative 2
−ΔΔCT method was again used for determination of
gene expression changes, normalised to Gapdh expression, and p-values calculated using two-
tailed Student’s t-Test.
2.4.5 Affymetrix mouse gene microarrays
For each time point, cDNA from four individual Chd7
fl/fl;Mesp1-Cre hearts was compared to
cDNA from four Chd7
+/+;Mesp1-Cre hearts. Sense-strand cDNA was generated from total RNA
using the Ambion® WT Expression Kit (Affymetrix), which was then processed for hybridisation
onto the Affymetrix Mouse Gene 1.0 ST Array according to manufacturer’s protocols. Scanning
was performed on an Affymetrix GeneChip Scanner. The array QC was performed using
Expression Console first and then Bioconductor. This work was performed by the UCL
Genomics facility. The data was normalised with the RMA normalisation algorithm using the
Affy R package (Gautier et al., 2004) provided as part of the Bioconductor libraries (Gentleman
et al., 2004) and analysed for differential expression using LIMMA (Smyth, 2004). Clustering
was performed using the Heatmap.2 package, with gene ontology (GO) annotation on71
representative clusters computed using DAVID (Huang da et al., 2009). Data has been
submitted to the Gene Accession Omnibus (accession number GSE59963).
2.5 RNA in situ hybridisation
2.5.1 RNA plasmid sources
Plasmids for synthesizing antisense RNA probes were kindly donated from the following
sources: Sox10, Sema3A and Sema3C from Christiana Ruhrberg; Robo1 and Robo2 from Gail
Martin; Slit2 from Bill Andrews (original clone from David Ornitz’s lab); PlexinA2 from Addgene
(plasmid 16423), deposited by Jonathan A. Raper ((Brown et al., 2001)); Wnt2 from Kathleen
M. Stewart; and Tgfbr2 from Elazar Zelzer. The Chd7 probe was generated using TOPO® TA
Cloning®  Kits  (Life  Technologies)  with  previously  reported  primers  (F:  5′-
CTATGCACCCTTCACAGCCTCAGGG-3′;  R:  5′-GGGACACATCCAGTGAGTTCCTGCG-3′)  (Bosman  et 
al., 2005).
Table 2-2: Restriction enzyme and RNA Polymerase combinations used for generation of
anti-sense and sense RNA probes
Probe:
Anti-sense
RNA probe:
Sense
RNA probe:
Length:
Chd7 SpeI, T7 NotI, T3 764bp
PlexinA2 BamHI, T3 XhoI, T7 2200bp
Robo1 EcoRI, T7 XhoI, T3 1000bp
Robo2 NotI, T7 XhoI, T3 1700bp
Slit2 NcoI, SP6 SpeI, T7 1300bp
Sema3A BamHI, T7 EcoRI, T3 1200bp
Sema3C NotI, T3 XhoI, T7 2500bp
Sox10 NcoI, T7 Unknown Unknown
Tgfbr2 BamHI, T7 SmaI, SP6 350bp
Wnt2 BamHI, T7 NotI, M13 500bp72
2.5.2 RNA Probe Preparation
Plasmids were linearised overnight using the appropriate restriction enzymes for generating
antisense probes (see Table 2-2), and extracted from a 1% agarose gel using the QIAquick Gel
Extraction Kit (Qiagen). In vitro transcription of probes was carried out by incubating 1µg of
linearised plasmid for 2 hours with 1x DIG RNA Labelling Mix (Roche), 1x Transcription
Optimised Buffer (Promega), 24u RNasin® Plus RNase Inhibitor(Promega), 10mM DTT
(Promega) and 20-40u RNA polymerase (T3, T7 or SP6). Incubations were at 37°C for T3 or T7
RNA Polymerases and 40°C for SP6 RNA Polymerase. Probes were precipitated by addition of
2µl 0.5M EDTA (pH 8), 5µl 4M LiCl and 150µl EtOH to the reaction, incubation on ice for 1 hour,
and extraction by centrifugation. Probes were resuspended in diethyl pyrocarbonate (DEPC)-
treated water.
2.5.3 In Situ Hybridisation on Paraffin Sections
Paraffin sections were prepared as previously described (section 2.2.1). Slides were rehydrated
then incubated in 20µg ml
-1 Proteinase K (Sigma-Aldrich) for 8 min, washed in 2mg ml
-1 glycine
then PBS, and fixed in 4% PFA/PBS for 20 minutes. Following further PBS washes they were
incubated for 1 hour at 70°C in a humidified chamber in hybridisation buffer (50% formamide
(Promega), 5xSSC pH 4.5, 50µg ml
-1 yeast RNA (Sigma-Aldrich), 50µg ml
-1 heparin (Sigma-
Aldrich), 1% SDS) followed by overnight incubation in hybridisation buffer containing 1µg ml
-1
antisense RNA probe. Slides were then rinsed twice in 2x SSC buffer pH4.5, followed by three
washes in Solution I (50% formamide, 5x SSC pH4.5, 1% SDS) at 65°C, two washes in Solution II
(50% formamide, 2x SSC pH4.5) and finally two washes at room temperature in MABT (0.1M
maleic acid, 0.15M NaCl, 0.01% Tween-20, 2mM Levamisole hydrochloride (Sigma-Aldrich),
pH7.5).
Slides were then incubated in blocking buffer (2% Boehringer Blocking Reagent (Roche), 10%
sheep serum, MABT) for 1 hour followed by overnight incubation at 4°C with an alkaline-
phosphatase (AP) conjugated anti-DIG antibody (Roche) diluted 1:2000 in blocking buffer.
Following further washes in MABT and then AP buffer (100mM Tris, pH 9.5, 50mM MgCl2,
100mM NaCl, 0.1% Tween-20, 2mM Levamisol in DEPC-treated water), AP activity was
detected using BM Purple (Roche). Once stain had developed sufficiently, slides were rinsed in
PBST and H2O, dried and mounted using DPX solution. Sections were pictured using an
Axiophoto2 microscope.73
2.5.4 Wholemount in situ hybridisation
Embryos were dissected in PBS and fixed overnight in 4% PFA/PBS, before dehydration
through a MeOH series to 100% MeOH and storage at -20°C until ready to use. For mutant vs
control wholemount in situ hybridisation, embryos were processed in the same well, with
removal of tails used for identification, and all washes/incubations were carried out with
rotation.
Embryos were rehydrated through a successive series of MeOH/PBT solutions and then
bleached for 1 hour in 6% H2O2 solution (Sigma-Aldrich) at room temperature. After several
PBT washes, E9.5 embryos were incubated for 7 minutes and E10.5 embryos for 9 minutes in
10mg ml
-1 Proteinase K, followed by further PBT washes and then fixation for 20 minutes in
fixing solution (4% PFA, 0.2% glutaraldehyde (Sigma-Aldrich), PBS). Pre-hybridisation was
carried out at 70°C in pre-warmed hybridisation solution (50% formamide, 5xSSC pH 4.5, 50µg
ml
-1 yeast RNA, 50µg ml
-1 heparin, 0.1% SDS) followed by overnight hybridisation at 70°C with
100ng ml
-1 anti-sense RNA probe.
Following a 5-minute rinse in the hybridisation buffer, embryos were washed three times at
70°C in Solution I (50% formamide, 5x SSC pH4.5, 1% SDS) and then three times at 65°C in
Solution II (50% formamide, 2x SSC pH4.5, 0.2% SDS, 0.1% Tween-20). Embryos were cooled,
washed three times in MABT and incubated for 2-3 hours in blocking buffer (2% Boehringer
Blocking Reagent, 10% sheep serum, MABT). During this time, the anti-DIG antibody (Roche)
was pre-absorbed with embryo powder (see next section) in antibody solution (2% BBR, 1%
sheep serum, MABT) at 4°C with rotation for 1.5 hours, before centrifugation to remove the
embryo powder. Embryos were incubated in the antibody solution containing 1:2000 pre-
absorbed anti-DIG antibody overnight at 4°C, 6-8 MABT washes throughout the following 24
hours, and then three 10-minute washes in AP buffer (100mM Tris, pH 9.5, 50mM MgCl2,
100mM NaCl, 0.1% Tween-20, 2mM Levamisol in DEPC-treated water). AP activity was again
detected using BM Purple, and the staining reaction stopped by incubation in 2mM EDTA/PBT,
followed by final PBT washes.
2.5.5 Preparation of embryo powder
E13.5 embryos were dissected in ice-cold PBS and the heads discarded. They were
homogenised thoroughly with 3ml PBS in a glass homogeniser. 12ml ice cold acetone was then
added and mixed in well, followed by incubation on ice for 30 minutes, with frequent mixing.
The mixture was then centrifuged at 10,000rpm at 4°C for 10 minutes and the supernatant74
discarded. The pellet was resuspended in ice-cold acetone, mixed and incubated on ice for 10
minutes, followed by another 10-minute centrifugation. The pellet was then transferred to
clean filter paper (Whatman), spread thinly and air-dried overnight in a fume hood. Once
dried, the pellet was spread and dispersed with a spatula multiple times to form a fine powder,
which was stored at 4°C until needed.
2.6 Investigating calcium handling function
2.6.1 Culture of Embryonic Cardiomyocytes
Individual E13.5 embryonic hearts were dissected in PBS on ice, then incubated at 37°C for 45
minutes in 200µl 0.05% Trypsin-EDTA (Life Technologies) containing 10µg ml
-1 DNase I (Sigma),
with pipetting every 5-10 minutes. 500µl DMEM (Life Technologies) containing 10% FBS was
then added to block the Trypsin activity, and samples fed through a 23G needle three times to
further aid dissociation. Cells were spun at 1500 rpm for 5 minutes and resuspended in 1ml
culture medium (10% FCS, 1x PenStrep, 1x Non-essential amino acids (Gibco) in DMEM) before
plating in a 24-well dish for 1.5 hours to allow adherence of fibroblasts. The supernatant
enriched for cardiomyocytes was then plated onto laminin-coated (Sigma) coverslip dishes
(PAA200350X), and cells cultured at 37°C, 5% CO2 for 36 hours, with culture medium replaced
when needed.
2.6.2 Measurement of Ca
2+ Transients
Cells were first washed in imaging buffer (156mM NaCl, 3mM KCl, 2mM MgSO4.7H20, 1.25mM
K2HPO4, 2mM CaCl2, 10mM HEPES, 10mM D-Glucose, pH7.4). They were then incubated at
37°C for 10 minutes in 500µl of imaging buffer / Opti-MEM® (50/50, Life Technologies)
containing 5µM Cal-520
TM (Stratech). Rapid line scan analysis (400Hz) of Ca
2+ transients in
individual cells was carried out on a Leica SP5 confocal inverted microscope using the 488nm
line of an argon laser set at 0.1% power, and by collecting emitted light between 500-600nm.
Cells producing Ca
2+ transients were chosen randomly and were electrically paced by field
stimulation at 1Hz using platinum electrodes. Data was collected and analysed by averaging
values across the line, over time, using Leica LAS AF software. “Paced” cells were classified as
those in which Ca
2+ transients were observed every 1Hz over a 40 s interval, whereas in “non-
paced”, Ca
2+ transients were absent or unsynchronised. P-values were calculated using the
two-tailed Fisher’s exact test.75
CHAPTER THREE
CHD7 IS EXPRESSED IN THE DEVELOPING HEART AND IS
REQUIRED IN THE CARDIAC MESODERM
To begin to address the role of CHD7 during cardiovascular development, it was important to
establish its spatial and temporal expression patterns. CHD7/Chd7 is ubiquitously expressed
early in development in both humans and mice, with expression later becoming restricted to
CHARGE-related tissues such as the ear, eye, and olfactory system (Randall et al., 2009;
Sanlaville et al., 2006). However, its expression specifically in the heart during development
has not been fully characterised. Immunohistochemistry (IHC) and western blotting on wild-
type CD1 hearts are presented here, which determine for the first time the developmental
window in which CHD7 protein is present in cardiac tissues.
The importance of CHD7 activity in neural crest cell (NCC) development has previously been
emphasised, such that CHARGE syndrome is often classified as a disease arising from
maldevelopment of the neural crest, known as a neurocristopathy (Etchevers et al., 2006).
CHARGE patients, however, present with a wide range of congenital heart defects, with an
overrepresentation of atrioventricular septal defects (AVSDs) and OFT defects (Corsten-
Janssen et al., 2013a). We therefore postulated that CHD7 function is required in the
cardiogenic mesoderm and its derivatives for the regulation of transcriptional programmes
during heart development. To investigate this, tissue-specific ablation of Chd7 was performed,
driven by a Mesp1-Cre allele, and the resulting cardiac defects are presented in this chapter.76
3.1 CHD7 expression in the developing heart until E13.5
3.1.1 Immunohistochemical detection of CHD7 protein expression in the heart
Randall and colleagues reported ubiquitous Chd7 expression in the embryonic region at E7.5
using LacZ reporter staining, and continued widespread expression throughout the embryo at
E8.5 and E9.5, although with weaker expression seen in the early heart tube. At E10.5
expression was seen in the OFT and presumptive ventricles of the heart, as well as the
pharyngeal arches, otic vesicle and developing forelimbs (Randall et al., 2009). To investigate
further the developmental window in which CHD7 protein is present in the heart, IHC using an
antibody raised against CHD7 was carried out on cryosections through the hearts of wild-type
CD1 embryos at E10.5, E11.5 and E13.5.
At E10.5 nuclear CHD7 protein was detected throughout the pharyngeal region, with high
magnification imaging showing it is present in the outer ectodermal, inner endodermal and
mesodermal tissue layers in each of the 3
rd, 4
th and 6
th pharyngeal arches (Figure 3-1, panel A).
It was also seen throughout the heart, with higher magnification confirming it is present in
both endocardial and myocardial cells (Figure 3-1, panel B). Similar nuclear expression was
seen at E11.5, with CHD7 present throughout the endocardial cushions and walls of the OFT
and again in the endocardium and myocardium (Figure 3-1, panels C and D). However, at E13.5
no CHD7 protein was detectable in the aorta, pulmonary trunk, atria or ventricles (Figure 3-1,
panels E and F).
3.1.2 Western blot analysis of CHD7 protein in the developing heart
To confirm the timing of CHD7 expression seen by IHC, western blot analysis was carried out
on total protein extracts from dissected CD1 hearts between stages E10.5 and E15.5 (Figure
3-2). CHD7 is reported as having a molecular weight of 336kDa. A clear band on the blots
above 300kDa in size can be seen, with little additional background staining and no equivalent
band in the HEK293T cell line negative control sample, so we can be confident this is CHD7
protein. Consistent with the IHC data, a steady decrease in the amount of CHD7 protein can be
seen as development progresses, with a band barely detectable by E13.5 and E15.5. Together,
these experiments indicate that CHD7 protein is present in the developing heart until E13.5.77
Figure 3-1: CHD7 protein levels during heart development
Immunohistochemistry on cryosections through wild-type CD1 hearts between developmental stages
E10.5 to E13.3.
(A, B) Ubiquitous CHD7 expression was seen at E10.5 in the pharyngeal region (A) and throughout the
heart (B), including the endocardial (blue arrows) and myocardial layers (yellow arrows). Higher
magnification imaging showed overlap with DAPI staining, confirming its nuclear localisation.
(C, D) Similar widespread CHD7 expression was seen in the endocardial cushions (green arrows) and
endothelial lining (white arrows) of the proximal outflow tract (C) and again in the myocardium and
endocardium of the ventricles (D).
(E, F) At E13.5 CHD7 protein could no longer be detected anywhere in the heart.
All scale bars represent 0.2mm. PAA indicates pharyngeal arch arteries; oft, outflow tract; a, atrium; rv,
right ventricle; lv, left ventricle; ao, aorta; pt, pulmonary trunk.78
Figure 3-2: Western blot analysis of whole heart protein extracts
Two replicates of western blots on heart total protein extracts are shown, analysing CHD7 protein levels
between E10.5 to E15.5. CHD7 protein levels are undetectable by E13.5. Positive controls (+) were
protein extracts from mouse embryonic stem cells, and negative controls (-) were from the human
embryonic kidney 293T (HEK293T) cell line. B-Actin or nuclear LaminB1 were used as protein loading
controls.
These blots were produced by Nelo Popal, and included with her permission.
3.2 Tissue-specific ablation of Chd7 in the cardiogenic mesoderm
3.2.1 Specificity of the Mesp1-Cre allele
Mesp1 is expressed transiently from E6.5, at the onset of gastrulation, in a heterogeneous
population of cells that ingress into and exit the primitive streak. These Mesp1-expressing cells
give rise to the cranial and cardiac mesoderm, including both the FHF and SHF of cardiac
progenitors (Saga et al., 1996). Genetic lineage tracing has been carried out using a knock-in
allele with Cre recombinase under the control of Mesp1 regulatory sequences (Mesp1-Cre)
crossed with a LacZ reporter, so that all Mesp1-expressing cells and their progeny can be
identified by β-galactosidase staining. These studies have shown β-galactosidase positive cells 
in all cardiac lineages, including the myocardium, endothelium, endocardium, epicardium and
conduction cells (Saga et al., 1999). Mesp1-derived cells also contribute to muscles and bones
of the face, the embryonic liver and to some fetal haematopoietic stem cells (Asahina et al.,
2009; McBratney-Owen et al., 2008; Yoshida et al., 2008).
The expression of Mesp1 in the earliest cardiac progenitors made Mesp1-Cre an ideal Cre allele
for studying the tissue-specific role of Chd7 in the developing heart. Previous work in the lab
confirmed mesodermal-specific LacZ expression driven by Mesp1-Cre at E10.5, with coronal
sections clearly showing β-galactosidase staining specifically in the mesoderm of the 3
rd and 4
th
pharyngeal arches and throughout the OFT and ventricles of the heart (Figure 3-3).79
To confirm its specificity at E13.5, Mesp1-Cre was crossed with a R26RYFP reporter allele.
Consistent with previous data, examination of YFP expression at E13.5 showed Mesp1-Cre is
active throughout the heart, as well as cells in the cranial and trunk mesoderm (Figure 3-4).
Immunostaining for YFP on sections through the heart at E13.5 showed the endothelial lining
of the aortic arch, aorta and pulmonary trunk, and most endocardial and myocardial cells were
YFP-positive (Figure 3-4, panels A-D). Some cells are seen around the OFT and top of the
interventricular septum that do not express YFP, which are most likely cells derived from the
neural crest. Furthermore, YFP expression driven by Mesp1-Cre was also examined on a
conditional floxed Chd7 background (Chd7
fl/fl), to ensure the conditional allele did not interfere
in any way with the Cre expression. Comparing Chd7
+/+;R26RYFP;Mesp1-Cre and
Chd7
fl/fl;R26RYFP;Mesp1-Cre embryos at E10.5 and E13.5 showed no difference in YFP
expression (Figure 3-4, panels E-H).
Figure 3-3: LacZ lineage trace of Mesp1-Cre activity at E10.5
(A) Wholemount images of an E10.5 R26RLacZ;Mesp1-Cre  embryo  after  β-galactosidase  staining, 
showing Cre activity in the cardiac, trunk and cranial mesoderm.
(B) Coronal sections through the 3
rd and 4
th  pharyngeal  arches  showed  β-galactosidase  staining 
specifically in the mesoderm of the arches.
(C) Section through the heart confirmed Mesp1-Cre activity throughout the left and right ventricles and
the outflow tract.
m indicates mesoderm; ect, ectoderm; endo, endoderm; oft, outflow tract; lv, left ventricle; rv, right
ventricle. Printed with permission of Karen McCue.80
Figure 3-4: YFP lineage trace of Mesp1-Cre activity
(A-D) Immunohistochemistry for YFP on transverse paraffin sections through the heart of an E13.5
Chd7
fl/fl;R26RYFP;Mesp1-Cre embryo marked Cre activity (white arrows) in endothelial cells of the aortic
arch (A), aorta and pulmonary trunk (B, C) and throughout the atria and ventricles (D). Yellow stars in B
and C highlight non-YFP expressing cells, presumably of neural crest origin.
(E-H) Wholemount images showed similar YFP expression in the heart, trunk and cardiac mesoderm on a
wild-type or conditional Chd7
fl/fl background at both E13.5 (E, F) and E10.5 (G, H).
Scale bars represent 0.2mm (A-D) or 2mm (E-H). aa indicates aortic arch; ao, aorta; pt, pulmonary trunk;
ra, right atrium; la, left atrium; rv, right ventricle; lv, left ventricle; h, heart.81
3.2.2 Validation of Chd7 ablation in the heart
The conditional floxed Chd7
fl allele described in section 1.6.3 was used in this project for
tissue-specific ablation of Chd7 expression. Chd7
fl/fl mice were crossed with Chd7
fl/+;Mesp1-Cre
mice in order to delete homozygously Chd7 expression in the cardiac and anterior mesoderm.
In situ hybridisation (ISH) confirmed loss of Chd7 mRNA throughout the heart at E11.5 in
Chd7
fl/fl;Mesp1-Cre embryos, whilst in other regions such as the neural tube the level of Chd7
expression remained unaffected (Figure 3-5, A and B).
Quantitative real-time PCR (qRT-PCR) using TaqMan® probes was also used to examine Chd7
mRNA levels in dissected E11.5 hearts after conditional Chd7 ablation. This analysis showed in
heterozygous Chd7
fl/+;Mesp1-Cre hearts Chd7 expression was reduced to ~75% of wild-type
levels, whilst in Chd7
fl/fl;Mesp1-Cre hearts it was reduced to ~45% (Figure 3-5, C). A number of
reasons could underlie the fact that complete ablation of Chd7 expression is not seen in
Chd7
fl/fl;Mesp1-Cre hearts. In the E11.5 embryonic hearts, there are likely to be some non-
Mesp1-derived cells, predominantly from the neural crest lineage, in which Chd7 expression
would be normal. The efficacy of recombination by the Cre-LoxP system using this combination
of floxed allele and tissue-specific Cre line may also be limiting the level of Chd7 deletion.
Figure 3-5: Chd7 ablation in E11.5 Chd7
fl/fl;Mesp1-Cre embryos
(A, B) Chd7 in situ hybridisation on E11.5 Chd7
fl/fl coronal sections showed Chd7 expression throughout
the heart, which was lost in the Chd7
fl/fl;Mesp1-Cre hearts. Inserts show sections through the neural
tube, showing Chd7 ablation was tissue-specific.
(C) Taqman RT-PCR for Chd7 on cDNA from dissected E11.5 hearts, showing Chd7 expression was
unaffected in Chd7
fl/fl hearts, but reduced after heterozygous and homozygous ablation driven by
Mesp1-Cre.
Scale bars represent 0.2mm. oft indicates outflow tract; avc, atrioventricular canal; (l/r)v, (left/right)
ventricle.82
3.3 The cardiovascular phenotype of Chd7
fl/fl;Mesp1-Cre embryos
3.3.1 The Chd7
fl/fl;Mesp1-Cre genotype is embryonic lethal
To examine the survival of Chd7
fl/fl;Mesp1-Cre mice, timed matings were set up to cross
Chd7
fl/fl with Chd7
fl/+;Mesp1-Cre mice. The probability of each of the four possible genotypes
from this breeding pair – Chd7
fl/+, Chd7
fl/fl, Chd7
fl/+;Mesp1-Cre and Chd7
fl/fl;Mesp1-Cre - was
25%, based on Mendelian inheritance (Table 3-1).
The observed and expected numbers of each genotype were compared at different
developmental stages. Table 3-2 shows that at E10.5 and E13.5, there was no significant
difference between the observed and expected numbers of Chd7
fl/fl;Mesp1-Cre embryos, and
no necrotic embryos were collected at these stages. However, at E15.5 noticeably fewer than
expected Chd7
fl/fl;Mesp1-Cre embryos were seen, and a significant number of necrotic
embryos of this genotype were also collected. By the end of gestation, at E18.5, there was a
significant loss of Chd7
fl/fl;Mesp1-Cre embryos, with only 2 Chd7
fl/fl;Mesp1-Cre embryos found
in a total of 41 embryos collected. Pups were ear-clipped for genotyping at postnatal day
(P)10, and no Chd7
fl/fl;Mesp1-Cre pups survived to this stage. Therefore, homozygous ablation
of Chd7 in the cardiac mesoderm is embryonic lethal, with embryos mostly dying around
E15.5, although a small number survive to the end of gestation but are not viable postnatally.
Table 3-1: Punnett Square to show the possible outcomes of the Chd7
fl/fl x Chd7
fl/+;Mesp1-Cre
cross
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Table 3-2: Embryonic lethality of the Chd7
fl/fl;Mesp1-Cre genotype
Developmental
Stage:
Genotype: Observed: Expected: Necrotic:
E10.5 Chd7
fl/+ 22 18 0
Chd7
fl/fl 19 18 0
Chd7
fl/+;Mesp1-Cre 15 18 0
Chd7
fl/fl;Mesp1-Cre 15 18 0
E13.5 Chd7
fl/+ 17 14 0
Chd7
fl/fl 18 14 0
Chd7
fl/+;Mesp1-Cre 8 14 0
Chd7
fl/fl;Mesp1-Cre 13 14 0
E15.5 Chd7
fl/+ 36 36 0
Chd7
fl/fl 43 36 1
Chd7
fl/+;Mesp1-Cre 36 36 1
Chd7
fl/fl;Mesp1-Cre 27 36 7**
E18.5 Chd7
fl/+ 13 10 0
Chd7
fl/fl 13 10 0
Chd7
fl/+;Mesp1-Cre 13 10 0
Chd7
fl/fl;Mesp1-Cre 2* 10 1
P10 Chd7
fl/+ 12 9 -
Chd7
fl/fl 8 9 -
Chd7
fl/+;Mesp1-Cre 15 9 -
Chd7
fl/fl;Mesp1-Cre 0** 9 -
Expected numbers are based on Mendelian ratios, rounded to the nearest whole number.
* p <0.05, ** p<0.01, based on Chi squared analysis.84
3.3.2 Chd7
fl/fl;Mesp-1Cre embryos exhibit oedema and haemorrhaging
Chd7
fl/fl;Mesp1-Cre embryos collected at E10.5 did not show any obvious external phenotype
when compared to littermates. However, at E13.5 around two-thirds of Chd7
fl/fl;Mesp1-Cre
embryos (n=15) had oedema, which was often severe, and approximately one-third also had
some signs of haemorrhaging (Figure 3-6, Table 3-3). By E15.5, oedema and/or haemorrhaging
was seen in over 90% (n=22) of Chd7
fl/fl;Mesp1-Cre embryos, and the haemorrhaging was
usually more widespread than at E13.5 (Figure 3-7, A-C). Necrotic embryos collected at this
stage also showed signs of previous haemorrhaging (Figure 3-7, D). These results suggest the
haemorrhagic phenotype occurs slightly later than oedema during development, and may be
contributing to the embryonic lethality. Consistent with this, the two Chd7
fl/fl;Mesp1-Cre
embryos that were collected at E18.5 did not show any evidence of oedema or haemorrhaging.
However, these two embryos still exhibited severe cardiovascular defects so would have been
highly unlikely to survive postnatally. The lack of developmental delay in the Chd7
fl/fl;Mesp1-
Cre embryos indicates bypass of the p53-dependent pathway actively regulated by CHD7
during early embryogenesis (Van Nostrand et al., 2014), allowing examination of the role of
Chd7 later in cardiogenesis than can be achieved in constitutively-null embryos.
Table 3-3: External phenotypes observed at E13.5 and E15.5
Genotype:
E13.5 E15.5
n: Oedema: Haemorrhage: n: Oedema: Haemorrhage:
Chd7
fl/+ 19 0% 11% 23 4% 4%
Chd7
fl/fl 20 0% 10% 33 12% 6%
Chd7
fl/+;Mesp1-Cre 9 11% 0% 22 9% 0%
Chd7
fl/fl;Mesp1-Cre 15 67% 33% 22 68% 64%85
Figure 3-6: External phenotypes seen with E13.5 Chd7
fl/fl;Mesp1-Cre embryos
(A-C) Embryos collected at E13.5, Chd7
fl/fl;Mesp1-Cre embryos predominantly exhibited oedema, often severe, as can be seen in B and C (white arrows). Some haemorrhagic
patches were also seen (C).
Scale bars represent 2mm.86
Figure 3-7: Oedema, haemorrhaging and necrotic Chd7
fl/fl;Mesp1-Cre embryos at E15.5
(A) At E15.5 control Chd7
fl/fl embryos again appeared normal, whilst Chd7
fl/fl;Mesp1-Cre embryos showed oedema (white arrows, B and C) and often severe haemorrhaging (C).
Necrotic embryos collected at the stage also usually showed previous signs of haemorrhaging (D).
Scale bars represent 2mm.87
3.3.3 Chd7
fl/fl;Mesp1-Cre embryos have great vessel remodelling defects
Great vessel defects have been reported with partial penetrance in heterozygous gene-
trapped Chd7
+/- embryos, including interrupted aortic arch type B (IAA-B) and absence of the
right subclavian artery (Randall et al., 2009). Chd7
fl/fl;Mesp1-Cre embryos were therefore
examined at E15.5 for similar defects. This revealed that 21% (n=14) of Chd7
fl/fl;Mesp1-Cre
embryos at E15.5 had IAA-B (Figure 3-8, A’, and Table 3-4). One embryo examined had a
vascular ring: this phenotype will be addressed further in Chapter 4. The great vessels of the
E18.5 Chd7
fl/fl;Mesp1-Cre embryos were also found to have structural defects: one had a right-
sided aortic arch (Figure 3-8, B’), and the other had aberrant posterior branching of the right
subclavian from the right common carotid (Figure 3-8, B’’).
Structural defects of the great vessels are often associated with earlier defects in the
symmetrical formation of the pharyngeal arch arteries (PAAs) around E10.5, which then
undergo a complex process of programmed asymmetrical expansion, regression and spatial
rearrangements of the vessels to form the final aortic arch structure. Specifically, hypo/aplasia
of the 4
th PAA leads to defects such as IAA-B (Lindsay et al., 1999), although recovery from
earlier PAA defects can occur (Lindsay and Baldini, 2001). The reported great vessel defects in
Chd7
+/- heterozygotes were attributed to PAA defects at E10.5, which predominantly affected
the 4
th PAA (Randall et al., 2009). However, examination of the PAAs at E10.5 in revealed no
defects in Chd7
fl/fl;Mesp1-Cre embryos (Figure 3-8, panel C, and Table 3-4), indicating that the
great vessel defects observed are likely due to a later remodelling defect.
Table 3-4: Frequency of PAA defects at E10.5 and IAA-B at E15.5
Genotype: n: 4
th PAA defects: n: IAA-B:
Chd7
fl/+ 16 6% 11 0%
Chd7
fl/fl 18 0% 16 6%
Chd7
fl/+;Mesp1-Cre 15 7% 9 11%
Chd7
fl/fl;Mesp1-Cre 14 0% 14 21%88
Figure 3-8: Great vessel defects in Chd7
fl/fl;Mesp1-Cre embryos
(A) The great vessels at E15.5. In Chd7
fl/fl embryos the normal arrangement was seen (A), whilst 21% of
Chd7
fl/fl;Mesp1-Cre embryos had interrupted aortic arch type B, where the aortic arch is disrupted
between the left common carotid and left subclavian arteries (star, A’).
(B) The heart and great vessels at E18.5. In one Chd7
fl/fl;Mesp1-Cre embryo right-sided aortic arch was
seen (arrow, B’), whilst in the other the branching of the right subclavian artery was dorsal to the right
common carotid (B’’).
(C) Ink injection of the pharyngeal arch arteries (PAAs) at E10.5 showed normal formation of the 3
rd, 4
th
and 6
th PAAs bilaterally in both Chd7
fl/fl (C) and Chd7
fl/fl;Mesp1-Cre (C’) embryos.
Scale bars represent 0.5mm. aa indicates aortic arch; rsc, right subclavian artery; rcc, right common
carotid artery; lcc, left common carotid artery; lsc, left subclavian artery; ra, right atrium; la, left atrium;
rv, right ventricle; lv, left ventricle; oft, outflow tract.89
3.3.4 Further arterial pole defects in Chd7
fl/fl;Mesp1-Cre hearts
Haematoxylin and eosin (H&E) staining of transverse sections showed major structural defects
in Chd7
fl/fl;Mesp1-Cre hearts. 60% of hearts examined at E15.5 (n=10) had double outlet arising
from the right ventricle (DORV, Figure 3-9). This occurs when the OFT is not aligned correctly,
so rather than the aorta arising exclusively from the left ventricle and the pulmonary trunk
arising exclusively from the right ventricle, both the aorta and pulmonary trunk arise from the
right ventricle. This is a serious structural defect as it means the pulmonary and systemic
circulations are not separated.
Common arterial trunk (CAT, also known as persistent truncus arteriosus) occurs when the OFT
fails to septate properly, and so a connection between the aorta and pulmonary trunk
remains. This was seen in an E13.5 Chd7
fl/fl;Mesp1-Cre embryo (Figure 3-10, A’), although not
in any of the E15.5 Chd7
fl/fl;Mesp1-Cre hearts examined, so the penetrance is low. Therefore,
to increase the efficiency of Chd7 deletion and further impact downstream CHD7 targets, the
Chd7 ENU mutant Whirligig mouse (Chd7
Whi) (Bosman et al., 2005) was used for mesodermal
Chd7 ablation on a constitutively heterozygous background (Chd7
Whi/fl;Mesp1-Cre). Optical
projection tomography (OPT) imaging at E13.5 showed CAT arising from the right ventricle in
50% (n=4) of Chd7
Whi/fl;Mesp1-Cre embryos and DORV in the other 50%, along with IAA-B and
DILV (see Figure 3-10, B’ and B’’, and Movies 1 and 2).90
Figure 3-9: Double outlet right ventricle in Chd7
fl/fl;Mesp1-Cre hearts
Transverse sections at E15.5 showed DORV in 60% of Chd7
fl/fl;Mesp1-Cre hearts (A’), whereas in all
Chd7
fl/fl controls the aorta arises as normal from the left ventricle (A). In the mutant sections, both the
pulmonary trunk and then the base of the aorta (arrow) can be seen opening from the right ventricle.
Scale bars represent 0.5mm. rv indicates right ventricle; lv, left ventricle; ra, right atrium; la, left atrium;
ao, aorta; pt, pulmonary trunk.
Figure 3-10: Common arterial trunk in Chd7
fl/fl;Mesp1-Cre and Chd7
Whi/fl;Mesp1-Cre hearts
(A) CAT was seen in a Chd7
fl/fl;Mesp1-Cre embryo at E13.5 (star, A’), compared to normal OFT septation
in Chd7
fl/fl controls (A).
(B) OPT imaging at E13.5 also showed 50% of Chd7
Whi/fl;Mesp1-Cre embryos also had CAT (red stars, B’
and B’’), whereas the OFT was fully septated in Chd7
Whi/fl controls (white arrow, B).
Scale bars represent 0.2mm. ao, indicates aorta; pt/p, pulmonary trunk.91
3.3.5 Mesp1-Cre driven ablation of Chd7 provides a model for the “Holmes Heart”
All hearts examined at E15.5 had double inlet left ventricle (DILV), whereby both atria were
connected through a common atrioventricular (AV) valve to a dominant left ventricle, with no
access from the AV junction to the incomplete right ventricle (Figure 3-11, panel A). The
venous valves were absent or poorly formed and an inter-ventricular communication was
observed in all hearts. Furthermore, the ventricular mural myocardium was often poorly
compacted (Figure 3-11, panel B).
The rare combination of DILV with concordant ventriculo-arterial connections is known in
humans as the “Holmes heart” (Dobell and Van Praagh, 1996). The arrangement seen in the
Chd7
fl/fl;Mesp1-Cre hearts with DILV and spiralling arterial trunks is therefore analogous to the
situation found in the Holmes heart.
Table 3-5 and Figure 3-12 summarise the major structural cardiovascular defects seen in the
E15.5 embryos collected from the Chd7
fl/fl x Chd7
fl/+;Mesp1-Cre. Whilst severe defects were
seen with high frequency in the Chd7
fl/fl;Mesp1-Cre embryos, malformations were not seen
above background levels in the Chd7
fl/fl;Mesp1-Cre embryos. This lack of haploinsufficiency for
Chd7 in the mesoderm was unexpected, given the cardiac defects observed in both CHD7-
haploinsufficient CHARGE patients and constitutive Chd7
+/- mouse models, and is discussed
further in section 3.4.4.
Table 3-5: Major cardiac phenotypes observed at E15.5
Genotype: IAA-B: AVSD: DILV: DORV:
Myocardial non-
compaction:
Venous valve
defect:
Chd7
fl/+ 0/11 0/7 0/7 0/7 0/7 0/7
Chd7
fl/fl 1/16 0/5 0/5 0/5 0/5 0/5
Chd7
fl/+;Mesp1-Cre 1/9 0/4 0/4 0/4 0/4 0/4
Chd7
fl/fl;Mesp1-Cre 3/14 10/10 10/10 6/10 8/10 9/10
IAA-B indicates interrupted aortic arch type-B; AVSD, atrioventricular septal defect; DILV, double inlet left
ventricle; DORV, double outlet right ventricle.92
Figure 3-11: Double inlet left ventricle and thin myocardial walls in Chd7
fl/fl;Mesp1-Cre hearts
(A) H&E transverse heart sections at E15.5 showed normal morphology in Chd7
fl/fl embryos, whilst all
Chd7
fl/fl;Mesp1-Cre hearts had DILV, including inter-ventricular communication, common AV valves
(stars, A’) and poor formation of the venous valves (green arrows, A’).
(B) The compact layer of the ventricular myocardial wall should be well formed by E15.5, but was also
thin in 80% of Chd7
fl/fl;Mesp1-Cre hearts (B’).
Figure 3-12: Schematic to show the major structural defects seen in Chd7
fl/fl;Mesp1-Cre
hearts
The normal configuration of the heart in Chd7
fl/fl controls has complete separation of the pulmonary and
systemic circulatory systems, compared to major septation and alignment defects seen in
Chd7
fl/fl;Mesp1-Cre hearts. These included interrupted aortic arch type B (1), double outlet right
ventricle (DORV - 2) and double inlet left ventricle (DILV - 3).
Chd7
fl/fl Chd7
fl/fl;Mesp1-Cre93
3.3.6 Cardiac neural crest cell migration is abrogated in Chd7
fl/fl;Mesp1-Cre embryos
Although the expression of Chd7 in NCCs would not be cell-autonomously affected in
conditional Chd7
fl/fl;Mesp1-Cre embryos, NCC migration was investigated as aberrant NCC
behaviour could be contributing to the OFT defects observed. The cardiac neural crest plays a
crucial role in septation and alignment of the outflow tract and aortic arch artery
development, with classic studies in chick embryos demonstrating interrupted aortic arch,
common arterial trunk and DORV after disruption to neural crest migration (Kirby et al., 1983).
Wholemount ISH analysis of Sox10 expression, which marks migrating NCCs (Kuhlbrodt et al.,
1998), showed similar patterns of expression in Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre somite-
matched embryos at E10.5 (Figure 3-13, A and B). NCCs were seen beginning to enter the 4
th
PAA in both genotypes, although the post-otic stream appeared to be slightly shorter in
Chd7
fl/fl;Mesp1-Cre embryos.
PlexinA2 is expressed by NCCs that surround the aortic arches and migrate into the OFT in a
distal to proximal direction (Brown et al., 2001). Sequential coronal sections through the OFT
of Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre embryos were therefore also analysed at E11.5 for PlexinA2
expression (Figure 3-13, C-J). At the distal end of the OFT, similar PlexinA2 expression can be
seen in both genotypes, showing migratory NCCs are present. However, towards the proximal
end of the OFT the two characteristic clusters of NCCs in the endocardial cushions are not seen
in Chd7
fl/fl;Mesp1-Cre embryos (Figure 3-13, H’-J’). Together, these results indicate that NCCs
migrate normally through the pharyngeal region at E10.5, but as they are populating the OFT
at E11.5 their migration is abrogated following mesodermal ablation of Chd7.94
Figure 3-13: Neural crest cell migration in Chd7
fl/fl;Mesp1-Cre embryos
(A, B) Sox10 ISH on E10.5 Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre embryos (both 27 somites) showed post-otic
streams of neural crest cells migrating through the pharyngeal arches (red arrows, A and A’). Higher
magnification images showed neural crest cells beginning to branch off to the 4
th PAA in both genotypes
(white arrows, B and B’).
(C-J) Comparison of PlexinA2 ISH on coronal E11.5 sections through the outflow tract in a Chd7
fl/fl (C-J)
and Chd7
fl/fl;Mesp1-Cre (C’-J’) embryo. Sections were arranged sequentially in a distal to proximal
direction through the outflow tract, with equivalent sections (C and C’, D and D’ etc.) matched as closely
as possible. PlexinA2-expressing cardiac neural crest cells were seen migrating through to the most
proximal section in the Chd7
fl/fl control (blue arrows, J), whilst neural crest cell migration was abrogated
in the Chd7
fl/fl;Mesp1-Cre (red arrows, H’-J’).
Scale bars represent 2mm (A-B) or 0.2mm (C-J).95
3.3.7 Malformation of the vestibular spine and AV cushions at E11.5
The presence of a common AV valve and lack of venous valves is indicative of a failure of the
vestibular spine (also referred to as the dorsal mesenchymal protrusion) to form at the venous
pole. The vestibular spine is a mesenchymal structure, derived from the dorsal mesocardium,
that drives the separation of the AV canal into its left and right components and carries
forward the inferior ends of the venous valves (Anderson et al., 2003a). To investigate its
formation in Chd7
fl/fl;Mesp1-Cre embryos, OPT was used to image hearts at E11.5. The
vestibular spine was found to be absent or reduced in size in Chd7
fl/fl;Mesp1-Cre hearts (Figure
3-14, Movies 3 and 4).
The OPT imaging also showed grossly abnormal positioning of the AV endocardial cushions,
which were markedly rotated within the AV canal compared to the control heart (Figure 3-14,
C). As these endocardial cushions are also crucial for AV canal septation, their misalignment
could therefore also be contributing to the AVSDs observed at later stages.
Figure 3-14: OPT imaging of hearts at E11.5
(A, B) Transverse images through a Chd7
fl/fl heart showed formation of the primary atrial septum (green
arrow, A), and the vestibular spine (red arrow, B). The endocardial superior and inferior AV cushions
were seen sequentially in A and B (yellow stars). In the Chd7
fl/fl;Mesp1-Cre heart the atrial septum
formed as expected (green arrow, A’), but the vestibular spine was completely absent (red star, B’). The
arrangement of the cushions was also grossly abnormal, with both seen adjacently in the same plane
(yellow stars, A’).
(C, C’) Digital re-slicing was used to produce coronal sections of the same hearts, which highlighted the
abnormal positioning of the endocardial cushions (yellow stars).
Scale bars represent 0.2mm. oft indicates outflow tract; rv, right ventricle; lv, left ventricle; a, atrium; v,
ventricle.96
3.3.8 Disruption to Cardiac Innervation and Coronary Vein Development
To characterise further the cardiac phenotype following mesodermal Chd7 ablation, the
innervation and vascularisation of Chd7
fl/fl;Mesp1-Cre hearts was also investigated.
Immunostaining using an antibody against Neurofilament-66 at E15.0 showed major disruption
to the innervation of Chd7
fl/fl;Mesp1-Cre hearts (Figure 3-15, panel A). The neuronal axons
extending down from the cardiac plexus to the ventricles were extremely truncated in all the
Chd7
fl/fl;Mesp1-Cre hearts examined (n=4), and did not branch out through the ventricles at all.
Furthermore, anti-Endomucin immunostaining revealed severe disruption to the coronary
veins on the surface of the heart at E15.5 in Chd7
fl/fl;Mesp1-Cre hearts, with either truncation
of vessels or ectopic formation of multiple under-developed veins (Figure 3-15, panel B).
However, coronary plexus formation looked relatively normal at E13.5, as determined by
expression of the arterial marker Notch1 (Figure 3-15, panel D).
Interestingly, the coronary veins developed normally following endothelial-specific Chd7
ablation using Tie2-Cre (Figure 3-15, C). CHD7 activity within the myocardium therefore
appears to have a non-cell-autonomous effect on the migratory endothelial cells required for
the development of the coronary veins.97
Figure 3-15: Innervation and vascularisation of Chd7
fl/fl;Mesp1-Cre hearts
(A) Wholemount immunostaining at E15.0 for Neurofilament-66 allowed visualisation of the
parasympathetic and sympathetic axons descending from the cardiac plexus and branching into the
ventricles (white arrows, A). Severe truncation of axons was seen in Chd7
fl/fl;Mesp1-Cre hearts (stars, A’
and A’’).
(B) Dorsal view of E15.5 hearts immunostained with anti-Endomucin antibody showed formation of
three main coronary veins (white arrows, B). In Chd7
fl/fl;Mesp1-Cre hearts patterning of the veins was
disrupted, with either extra, smaller vessels (stars, B’) or truncated vessels (star, B’’).
(C) Coronary vein development was normal in Chd7
fl/fl;Tie2-Cre hearts (arrows, C).
(D) Despite morphological differences, Notch1 staining on E13.5 transverse sections showed similar
establishment of the vascular plexus (arrows) in both Chd7
fl/fl (D) and Chd7
fl/fl;Mesp1-Cre (D’) hearts.
Scale bars represent 0.2mm. cp indicates cardiac plexus.98
3.4 Discussion
This chapter has demonstrated a novel role for Chd7 in mesodermal cardiac progenitors. CHD7
protein was shown to be present in the developing heart until E13.5, including within the walls
and cushions of the OFT, and in the endocardial and myocardial layers of the atria and
ventricles. To investigate the role of Chd7 specifically in the mesoderm, a conditional floxed
Chd7 allele was crossed with the Mesp1-Cre allele, and analysis of Chd7 mRNA levels in the
heart confirmed that Chd7 expression was reduced. Homozygous ablation of Chd7 in the
mesoderm was embryonic lethal, with embryos showing severe oedema and haemorrhaging,
and major structural cardiovascular defects. Double inlet left ventricle (DILV) with concordant
ventriculo-arterial connections was fully penetrant, making this an excellent model for the rare
human condition known as the “Holmes heart” (Dobell and Van Praagh, 1996). Furthermore,
many Chd7
fl/fl;Mesp1-Cre hearts also had double outlet from the right ventricle (DORV), poor
compaction of the myocardium, and great vessel defects. Disruption of NCC migration towards
the proximal end of the OFT, failure of formation of the vestibular spine, and misalignment of
the atrioventricular (AV) endocardial cushions all likely underlie the defects observed by E15.5.
This requirement for Chd7 in mesodermal cardiac progenitors suggests the current hypothesis
that CHARGE syndrome is a neurocristopathy may be an over-simplification, at least regarding
the cardiac malformations associated with this syndrome.
3.4.1 CHD7 expression
Following early ubiquitous expression of Chd7, from around E10.5 its expression pattern
becomes more restricted and tissue-specific (Bosman et al., 2005; Randall et al., 2009). CHD7
protein was present throughout the heart until E13.5. This temporal cardiac expression pattern
of CHD7 is reminiscent of BRG1, the ATPase subunit of the SWI/SNF chromatin remodelling
complex BRG1/BRM-associated factor (BAF) (Wang et al., 1996). BRG1 is similarly highly
expressed during development (Stankunas et al., 2008) but repressed in the adult heart (Hang
et al., 2010). Brg1 is reactivated by cardiac stresses, inducing a pathological shift from the
adult myosin heavy chain isotope α-MHC to the fetal β-MHC. Preventing Brg1 re-expression
reduces cardiac hypertrophy, thereby identifying it as a therapeutic target (Hang et al., 2010).
Given their similarities in expression and chromatin remodelling activity, it would be
interesting to see if a similar pathological reactivation of Chd7 occurs in the context of cardiac
failure.99
Whilst this work provides new insights into the timing of CHD7 protein expression in the
developing heart, the mechanisms involved in the regulation of its expression remain
unknown. The loss of CHD7 protein by E13.5 could be resulting from downregulation or
inhibition of transcription factors and other regulatory proteins that are required at the Chd7
locus. Transcriptional repression could also be initiated at the epigenetic level through post-
translational modifications to the histone tails, chromatin remodelling to a heterochromatic
state, or DNA methylation. However, no studies have been carried out into the mechanism(s)
of regulation of Chd7 expression during development, to the author’s knowledge. Given the
variation in Chd7 expression in different tissue types and organs during development, it would
be useful to understand more about its cell-specific regulation. Functional splice variants of
CHD7 have also been reported (Aramaki et al., 2006; Colin et al., 2010), but again there is no
information on the mechanisms that may be regulating the splicing of the different CHD7
isoforms.
3.4.2 Structural cardiovascular defects in Chd7
fl/fl;Mesp1-Cre embryos
Chd7
-/- mouse mutants are embryonic lethal at E10.5 due to growth failure (Alavizadeh et al.,
2001), making it difficult to study the role of Chd7 in the heart beyond this stage. Although it
has recently been shown that heterozygosity for p53 can partially rescue the Chd7
-/- phenotype
(Van Nostrand et al., 2014), at least in terms of embryonic growth, conditional mutagenesis is
required to bypass the early lethality and allow a proper assessment of heart development.
Chd7
fl/fl;Mesp1-Cre embryos survived until E15.5, when the heart is fully septated and the
vessels are in their proper configuration. At this stage, Chd7
fl/fl;Mesp1-Cre embryos exhibited
severe oedema and haemorrhaging along with major structural cardiovascular defects.
Oedema is the accumulation of fluid within body tissues, and is a classic sign of poor cardiac
function resulting from underlying cardiovascular defects (Conway et al., 2003). It can also be
caused by defective development of the lymphatic vasculature, for example when Prox1 is
knocked out during development (Wigle and Oliver, 1999). The lymphatic system was
examined in two Chd7
fl/fl;Mesp1-Cre embryos and loss of expression of lymphatic markers was
seen in one embryo, but this was not confirmed in the other mutant. The first embryo was
determined to be likely dead in utero or compromised in some way, which would explain the
aberrant gene expression, but these investigations were not taken any further (personal
communication, Elizabeth Illingworth). Given the severe cardiovascular malformations found in
the Chd7
fl/fl;Mesp1-Cre embryos, poor cardiac function is the most likely underlying cause of
the oedema. The haemorrhagic phenotype indicates poor vessel integrity in these embryos,
although this was not investigated further. Mild or more severe haemorrhaging was also seen100
in heterozygous ENU mutant Whirligig embryos (Chd7
Whi/+), supporting a role for Chd7 in blood
vessel development.
Great vessel defects were found with partial penetrance in Chd7
fl/fl;Mesp1-Cre embryos. At
E15.5, interrupted aortic arch type-B (IAA-B) was seen in 21% of these embryos, compared to
just 4% of heterozygous gene-trapped Chd7
xk/+ embryos (Randall et al., 2009). Interestingly, in
the Chd7
xk/+ embryos the great vessel defects were attributed to a high penetrance of
pharyngeal arch artery (PAA) malformations at E10.5, particularly affecting the 4
th PAA, but no
PAA defects were observed in E10.5 Chd7
fl/fl;Mesp1-Cre embryos. Randall and colleagues
showed that in their haploinsufficient model, restoration of Chd7 expression in the pharyngeal
surface ectoderm (PSE) rescued the PAA malformations, indicating a vital role for Chd7 in the
regulation of signalling from the ectoderm to the mesenchymal NCCs populating the PAAs.
However, restoration of Chd7 driven by Mesp1-Cre did not rescue the early phenotype.
Together, these findings suggest that biallelic expression of Chd7 in the PSE, but not in
mesodermal cardiac progenitors, is required for PAA morphogenesis (Randall et al., 2009).
The lack of PAA defects in Chd7
fl/fl;Mesp1-Cre embryos indicates that even with further levels
of Chd7 ablation in the cardiac mesoderm the PAAs form normally, confirming CHD7 activity in
these cells is not required for early PAA development. Instead, it seems to be required later in
mesodermal derivatives, most likely the SHF, for remodelling of the OFT and PAAs to form the
mature configuration of the aortic arch and great vessels. It is relatively unusual to find great
vessel defects without earlier underlying disruption to the PAAs, but examples have been
reported following targeted mutagenesis of Sema3C (Feiner et al., 2001), endothelial-specific
conditional double-knockout of α5 and αv integrins (van der Flier et al., 2010) and neural crest-
specific ablation of Alk5 (Wang et al., 2006).
Mesodermal Mesp1-Cre-driven ablation of Chd7 produced serious structural defects affecting
both the inflow and outflow tracts. Correct alignment and septation of the developing cardiac
components ensures the complete separation of the pulmonary and systemic circulations,
which is vital for effective cardiovascular function. An overrepresentation of conotruncal
defects and common arterial trunk (CAT, also known as persistent truncus arteriosus) was seen
in a cohort of patients with CHD7 mutations compared to a control group of non-syndromic
heart defects (Corsten-Janssen et al., 2013a). Consistent with this, CAT was present in one
Chd7
fl/fl;Mesp1-Cre embryo as well as in Chd7
Whi/fl;Mesp1-Cre embryos, and conotruncal
defects such as DORV and great vessel defects were frequently seen.101
Defects affecting the arterial pole of the heart are often attributed to disruption to the
migration or differentiation of the cardiac NCCs. This transient cell population migrates from
the neural tube through the pharyngeal arches towards the proximal OFT, contributing in
complex tissue interactions that are vital for formation and remodelling of the PAAs and for
septation of the OFT (Hutson and Kirby, 2007). The abrogation of the cardiac neural crest in
the OFT seen in E11.5 Chd7
fl/fl;Mesp1-Cre embryos could therefore be contributing to the
DORV and IAA-B defects that develop subsequently. This indicates that Chd7 expression in the
Mesp1-derived tissue in the walls of the OFT has a cell non-autonomous effect on the cardiac
neural crest, presumably through extracellular guidance signalling. This would support the
hypothesis that the neural crest is involved in the pathogenesis of the heart defects associated
with CHARGE syndrome (Siebert et al., 1985), but loss of Chd7 expression in the OFT
myocardium and endocardium is sufficient to disrupt cardiac neural crest migration and lead
to the OFT defects described.
The presence of DILV with spiralling arterial trunks in all Chd7
fl/fl;Mesp-1Cre hearts was
analogous to the “Holmes heart” seen in humans. The original formalin-fixed specimen
described by Holmes in 1823, which is still on display at McGill University, had absence of the
inflow tract of the right ventricle and thus a single morphologically left ventricle with DILV, and
normally-related great arteries (Dobell and Van Praagh, 1996). DILV is predicted to make up
1% of congenital heart malformations (Franklin et al., 1991). In a study of 60 cases of human
single-ventricle hearts, 15% were found to have this “Holmes heart” configuration with
normally related arteries (also known as type I), 42% had the aorta positioned anterior and
rightward (type II), and 43% had an anterior and leftward-transposed aorta (type III)
(Vanpraagh et al., 1964).
Although DILV is not reported in CHARGE patients, atrioventricular septal defects (AVSDs) were
also significantly overrepresented in patients with CHD7 mutations (Corsten-Janssen et al.,
2013a). DILV represents one of the two extreme ends of the spectrum of ventricular imbalance
that can be seen with AVSDs (see Figure 3-16). This increase in severity of the alignment and
septation defects affecting the AV canal in the Chd7
fl/fl;Mesp1-Cre embryos compared to the
human CHARGE phenotype reflects the importance of Chd7 dosage: CHARGE patients are
haploinsufficient for CHD7, whilst in this mouse model the cells in the cardiogenic mesoderm
undergo homozygous ablation of Chd7 driven by Mesp1-Cre, thereby producing a more severe
defect.102
Figure 3-16: Spectrum of ventricular balance in atrioventricular septal defects
Abnormal hearts with a common AV junction can range in the severity of the structural misalignment
from the most extreme double inlet left ventricle through a common AV valve with an incomplete right
ventricle (asterisk, upper left panel) through to double inlet right ventricle with an incomplete left
ventricle (asterisk, lower right panel).
The common AV junction and AV valves in the Chd7
fl/fl;Mesp1-Cre embryos was likely caused
by failure of the formation of the vestibular spine and disorganisation of the AV endocardial
cushions, as seen at E11.5. Septation of the AV canal involves multiple developmental
structures (Figure 3-17). The muscular primary atrial septum descends from the roof of the
primary atrial component of the heart tube, extending into the atrial cavity between the
openings of the pulmonary and systemic veins, and carrying a prominent mesenchymal cap on
the extending edge. Concurrently, a further mass of mesenchyme known as the vestibular
spine extends inferiorly into the heart from the mediastinum (Webb et al., 1998). The
mesenchymal masses capping the primary atrial septum and the vestibular spine first merge
and fuse, followed by fusion with the inferior endocardial cushion in the AV canal, which
subsequently fuses with the superior endocardial cushion. The fusion of these primordial
mesenchymal structures therefore closes the gap below the primary atrial septum (the
primary atrial foramen) and divides the common AV junction into its right and left components
(Anderson et al., 2003a). Given the crucial roles of both the vestibular spine and the
endocardical cushion in the septation and alignment of the AV canal, it is clear how their
absence or abnormal positioning can result in the lack of fusion of the central mesenchymal
mass, and thus in AVSDs and DILVs (Figure 3-17). The venous valve defects recorded in almost
all Chd7
fl/fl;Mesp1-Cre are also characteristic of malformation of the vestibular spine, as it
should normally drive forward the inferior ends of the venous valves as it extends into the
heart (Anderson et al., 2003a).103
Figure 3-17: Schematic diagram showing the developmental primordia that form the central
mesenchymal mass
Normal fusion occurs between the mesenchymal caps of the vestibular spine and primary atrial septum,
followed by fusion with the endocardial cushions. In the Chd7
fl/fl;Mesp1-Cre hearts, the vestibular spine
is absent or reduced in size and the endocardial cushions are abnormally arranged in the AV canal,
resulting in loss of fusion of the mesenchymal structures and subsequent AVSD and DILV.
Adapted from Webb et al. (1998). On the directional arrows, S indicates superior; I, inferior; R, right; and
L left.
It is interesting to note that the combination of DILV and DORV in Chd7
fl/fl;Mesp1-Cre hearts is
reminiscent of the earliest formation of the heart tube following looping and chamber
myocardial ballooning, prior to growth of the primary atrial septum. At this stage, around
E10.5, the AV canal opens to the developing left ventricle, whilst the OFT is supported above
the developing right ventricle (Anderson et al., 2003a), i.e. DILV and DORV (see Figure 1-2, C).
This can be considered the “default option” of the heart. During normal development this
arrangement is soon remodelled as the right ventricle expands, with concomitant remodelling
of the inner heart curvature, to allow formation of the right AV orifice, and the AV canal is
septated through fusion of the mesenchymal components described above. However, in the
Chd7
fl/fl;Mesp1-Cre embryos this default configuration still persists at E15.5, leading to cardiac
failure and embryonic lethality.104
3.4.3 Disruption to cardiac innervation and vascularisation
In Chd7
fl/fl;Mesp1-Cre embryos, loss of Chd7 expression in the ventricular myocardium also
appeared to have a non-cell autonomous effect on the development of the coronary veins and
the innervation of the heart, as shown by wholemount immunostaining. Strikingly, the
coronary veins formed normally when Chd7 was ablated specifically in endothelial cells using
Tie2-Cre. This indicates that it is extracellular guidance signalling from the myocardium to the
venous endothelial cells that is disrupted in Chd7
fl/fl;Mesp1-Cre hearts, leading to aberrant
coronary vein formation. Large diameter coronary veins develop in the subepicardium from an
existing primary capillary plexus through angiogenesis, a remodelling process in which
endothelial cells re-organise into a network of branching vessels (Lavine and Ornitz, 2009). Key
developmental signalling pathways, such as FGF and Hedgehog signalling, operate between
the myocardium, endocardium and developing vasculature to control pro-angiogenic factor
expression and coronary vessel development. Disruption to this signalling in the myocardium
in Chd7
fl/fl;Mesp1-Cre hearts could therefore be disrupting the reorganisation of endothelial
cells into the coronary veins. Unfortunately the embryos did not survive long enough through
gestation to also examine the formation of the coronary arteries by staining for smooth muscle
markers.
Severe truncation of the neuronal axons and branching into the ventricles was also seen on
Chd7
fl/fl;Mesp1-Cre hearts. Both sympathetic and parasympathetic neuronal axons can be seen
on the dorsal surface of the heart at E15.0, although they are predominantly sympathetic
(Nam et al., 2013). They are derived from NCCs, which migrate to the dorsal aorta,
differentiate into neurons and extend axonal projections into the cardiac tissue (Hasan, 2013).
As Chd7 expression would not have been be ablated in NCCs in Chd7
fl/fl;Mesp1-Cre embryos,
this may again be indicative of a non-cell autonomous effect of mesodermal Chd7 knockdown
on the NCCs or neurons that contribute to cardiac innervation. Alternatively, this innervation
defect may be secondary to the disruption to the coronary veins: sympathetic axons have been
demonstrated to extend along the developing large coronary veins in the dorsal subepicardium
of the ventricles, with mutant analysis indicating that this association is important for proper
cardiac innervation, but not for coronary vascular patterning (Nam et al., 2013). This close link
between nerve and blood vessel patterning is well established throughout the developing
embryo (Carmeliet and Tessier-Lavigne, 2005).105
3.4.4 The conditional Chd7
fl allele is slightly hypomorphic
A small proportion of Chd7
fl/+ and Chd7
fl/fl embryos presented with a phenotype, despite the
absence of a Cre allele, as seen in Tables 3-3, 3-4 and 3-5. This ranged from mild defects such
as slight oedema or developmental delay, to occasionally more severe problems including
haemorrhage or great vessel malformations. This indicates that the floxed Chd7
fl allele is
slightly hypomorphic, possibly resulting in a reduction in Chd7 expression levels compared to a
wild-type allele, even without Cre-driven recombination. This may be due to the remaining frt
site or the loxP sites present either side of exon 2 in the Flp-recombined Chd7
fl allele after
Flipase-recombination for removal of the N/k cassette (see ‘Flp-recombined Chd7
fl allele’,
Figure 1-14). These sites should not affect Chd7 expression, but may be increasing the
probability for spontaneous recombination events to occur at the Chd7 locus, or it is possible
that they are disrupting a transcriptional regulatory element or an intronic splice acceptor or
repressor. In a small proportion of embryos this disruption to the Chd7 locus has resulted in a
sufficient reduction in CHD7 levels for an observable phenotype.
The Chd7 expression levels in wild-type and Chd7
fl/fl E11.5 embryos did not appear to be
different in the qRT-PCR data shown in Figure 3-5. However, to further investigate this
hypomorphic behaviour, further expression analysis was carried out on total RNA from E10.5
embryos, comparing Chd7 mRNA expression levels in higher numbers of Chd7
+/+, Chd7
fl/+ and
Chd7
fl/fl embryos. It was apparent from this data that some embryos carrying the Chd7
fl allele
had some reduction in Chd7 mRNA. This reduction was generally greater in Chd7
fl/fl embryos
compared to Chd7
fl/+, although there was also a noticeable level of biological variation seen
between all embryos, even those with the same genotype and collected from the same litter
(Karen McCue and Nelo Popal, personal communication). Whilst this hypomorphic behaviour
must be kept in consideration, the affect is still relatively mild and infrequent, and the severe
cardiac structural defects seen in Chd7
fl/fl;Mesp1-Cre embryos remain very distinctive for this
genotype.
3.4.5 Relevance to CHARGE syndrome
In contrast with human CHARGE and constitutive heterozygous Chd7
+/- mouse models, cardiac
defects were not observed in Chd7
fl/+;Mesp1-Cre embryos above background levels.
Haploinsufficiency in non-mesodermal tissues is known to contribute to the syndromic
phenotype, for example, biallelic expression of Chd7 in the PSE is required for great vessel
development. Therefore, hemizygosity for CHD7 protein in multiple tissue types may be
required for the disease phenotype to become manifest. This is consistent with the drastically106
increased frequency of CAT in Chd7
Whi/fl;Mesp1-Cre hearts compared with Chd7
fl/fl;Mesp1-Cre
hearts. Furthermore, Chd7
Whi/fl;Mesp1-Cre hearts were embryonic lethal approximately 2 days
earlier than Chd7
fl/fl;Mesp1-Cre embryos, with none surviving to E15.5 (data not shown). The
background of constitutive Chd7 heterozygous mutation in non-mesodermal tissue is likely to
be contributing to the more severe OFT defects and earlier cardiac failure.
The efficacy of Cre-driven recombination at the LoxP sites in the Chd7
fl allele is also an
important consideration, as less than 100% recombination efficiency and selection for dizygous
cells could result in a lack of haploinsufficiency in the mesodermal conditional mutants. A
recent study has shown non-parallel recombination of different Cre reporter alleles in
otherwise genetically identical cell types, with high variation in recombination efficacy (Liu et
al., 2013). Differences can be attributed to the chromosomal location of LoxP sites (Vooijs et
al., 2001) and to the distances between the LoxP sites (Collins et al., 2000; Koike et al., 2002),
with sensitivity to recombination inversely correlated with this distance (Liu et al., 2013). The
sequences around the LoxP sites can also affect Cre efficacy, as epigenetic mechanisms such as
methylation of the promoter sequence may induce a heterochromatic state and therefore
inhibit the Cre enzyme activity (Long and Rossi, 2009). Therefore, although Chd7 mRNA levels
were reduced in Chd7
fl/+;Mesp1-Cre and Chd7
fl/fl;Mesp1-Cre embryos, as shown by RT-PCR and
ISH, this was not sufficient to produce the characteristic heart malformations seen with CHD7
haploinsufficiency in other mouse models. Chd7 expression is also not ablated until the Cre
recombinase is expressed, at around E6.5 (Saga et al., 1999), unlike in CHARGE patients or
gene-trap and ENU-generated mouse models. This delay in Chd7 ablation could allow very
early CHD7 activity to reduce the severity of phenotype seen in heterozygous Chd7
fl/+;Mesp1-
Cre embryos.
Despite the requirement for homozygous ablation of Chd7 in the cardiogenic mesoderm, this
conditional deletion does provide a useful model for studying the role of Chd7 during
cardiovascular development. The defects produced are similar to those seen in CHARGE
patients, and importantly, the early lethality seen in homozygous Chd7
-/- mutants is bypassed,
allowing for detailed phenotyping of the cardiac defects.107
Overall, this chapter has shown that CHD7 is present throughout the developing heart until
E13.5, and has demonstrated a crucial role for this protein in the anterior mesoderm for
cardiogenesis. Conditional ablation of Chd7 expression in the early cardiogenic mesoderm
resulted in major structural cardiac defects affecting both the venous and arterial poles of the
heart, as well as disruption to cardiac innervation and vascularisation, leading to embryonic
lethality. This requirement for Chd7 in the cardiogenic mesoderm alters our perspective on the
hypothesis that the cardiac malformations seen in CHARGE arise due to it being a
neurocristopathy.108
CHAPTER FOUR
CARDIOVASCULAR DEFECTS FOLLOWING
CARDIOMYOCYTE-, SECOND HEART FIELD- AND
ENDOTHELIAL-SPECIFIC ABLATION OF CHD7
The results in Chapter Three indicate that Chd7 plays a vital role in the cardiogenic mesoderm.
To delineate further the tissue-specific requirements of Chd7 within this cell population, the
Chd7
fl allele was also crossed with Nkx2.5-Cre, Mef2c-Cre and Tie2-Cre mice. These Cre lines
are all expressed in distinct subsets of cells derived from Mesp1-expressing progenitors, and
the resulting range of cardiovascular defects are presented.
This chapter also includes the results of an investigation into possible epistatic interactions
between Chd7 and Brg1 during heart development. An essential allelic balance between Brg1
and the haploinsufficiency genes Tbx5 and Nkx2.5 has previously been demonstrated
(Takeuchi et al., 2011). Brg1 has a similar temporal expression pattern to Chd7 in the heart,
and has well-established roles in a number of processes during heart development (Chang and
Bruneau, 2012). Furthermore, CHD7 and Brg1 proteins have also been shown to interact in
murine neural crest cells in vivo (Li et al., 2013) and in human neural crest-like cells in vitro
(Bajpai et al., 2010). We therefore hypothesised that interaction between these proteins may
also be important for heart development, so compound conditional heterozygotes for Chd7
and Brg1 driven by Mesp1-Cre were generated.109
4.1 Nkx2.5-Cre driven ablation of Chd7 expression
4.1.1 Nkx2.5-Cre expression in cardiomyocytes
The transcription factor Nkx2-5 is one of the earliest markers of cardiac-specific fate in
vertebrates (Lints et al., 1993; Moses et al., 2001). Nkx2.5 is a predicted homologue of the
Drosophila gene tinman, which is required for specification of the heart and visceral muscles
(Azpiazu and Frasch, 1993; Bodmer, 1993). Murine Nkx2.5 is expressed from E7.5, when it is
seen in the early cardiac crescent, and its expression continues throughout the myocardium of
the heart tube as it undergoes looping (Moses et al., 2001). At E11.5, it is seen throughout the
myocardium, but not in the endocardial cushions. It is also expressed in the pharyngeal
ectoderm and endoderm (Lints et al., 1993; Moses et al., 2001). More recently, the
endothelium of the pharyngeal arch arteries (PAAs) has also been shown to be derived from
Nkx2.5
+ progenitors within the lateral plate mesoderm, which were previously thought to
contribute solely to the heart (Paffett-Lugassy et al., 2013).
This section addresses the cardiac phenotype resulting from conditional Chd7 ablation driven
by a knock-in Nkx2.5-Cre allele, which has the Cre recombinase gene introduced into exon 2 of
the Nkx2.5 locus (Moses et al., 2001). This allowed for investigation into the role of Chd7
specifically in the myocardium, without affecting expression in the endocardial cushions. It
would also indicate whether disruption to CHD7 activity in the endothelium of the PAAs is
contributing to the great vessel defects observed in Chd7
fl/fl;Mesp- embryos.
4.1.2 The Chd7
fl/fl;Nkx2.5-Cre genotype is embryonic lethal
Chd7
fl/fl mice were mated with Chd7
fl/+;Nkx2.5-Cre mice in order to generate Chd7
fl/fl;Nkx2.5-
Cre offspring. Embryos were collected at E15.5, or pups genotyped at postnatal day (P)10, in
order to examine whether the Chd7
fl/fl;Nkx2.5-Cre genotype was observed in the expected
Mendelian ratios. Table 4-1 shows that the expected number of Chd7
fl/fl;Nkx2.5-Cre embryos
was seen at E15.5, and no necrotic embryos were recorded at this stage for any genotype.
However, no Chd7
fl/fl;Nkx2.5-Cre pups survived to P10, indicating that this genotype is not
viable. Unfortunately none of the litters were seen straight after birth, but it is likely the
Chd7
fl/fl;Nkx2.5-Cre pups died neonatally and were cannibalised, as no trace of them was
found.110
Table 4-1: Survival of embryos from the Chd7
fl/fl x Chd7
fl/+;Nkx2.5-Cre cross
Developmental
Stage:
Genotype: Observed: Expected:
E15.5 Chd7
fl/+ 17 17
Chd7
fl/fl 16 17
Chd7
fl/+;Nkx2.5-Cre 19 17
Chd7
fl/fl;Nkx2.5-Cre 16 17
P10 Chd7
fl/+ 8 8
Chd7
fl/fl 8 8
Chd7
fl/+;Nkx2.5-Cre 18 8
Chd7
fl/fl;Nkx2.5-Cre 0** 8
** p<0.01, based on Chi squared analysis111
4.1.3 E15.5 Chd7
fl/fl;Nkx2.5-Cre embryos show no external phenotype or great vessel
defects
All of the embryos collected at E15.5 were examined upon dissection for external phenotypes
such as oedema or haemorrhaging, which were seen with high frequency in the
Chd7
fl/fl;Mesp1-Cre embryos. However, none of the Chd7
fl/fl;Nkx2.5-Cre embryos (n=16)
exhibited any abnormal phenotype, and could not be distinguished from their littermates
(Figure 4-1, A and B) . Similarly, the great vessels were formed normally in all these embryos,
with no examples of interrupted aortic arch or right-sided arch (Figure 4-1, C and D), indicating
that Chd7 ablation in the Nkx2.5-expressing myocardial lineage is not sufficient to reproduce
the great vessel defects seen in Chd7
fl/fl;Mesp1-Cre embryos. Given the normal configuration of
the vessels at E15.5, the PAAs were not examined at E10.5 for this cross.
Figure 4-1: Normal external appearance and great vessel development in E15.5
Chd7
fl/fl;Nkx2.5-Cre embryos
(A, B) Two examples of embryos at E15.5 are shown, with no evidence of the external phenotypes of
haemorrhaging or oedema seen in Chd7
fl/fl;Mesp1-Cre embryos.
(C, D) Great vessel development was also normal in all Chd7
fl/fl;Nkx2.5-Cre embryos examined (n=16).
Scale bars represent 2mm (A, B) or 0.5mm (C, D). rsc indicates right subclavian artery; rcc, right common
carotid; lsc, left subclavian; lcc, left common carotid; aa, aortic arch.112
4.1.4 Chd7
fl/fl;Nkx2.5-Cre hearts have atrioventricular septal defects
Whilst no external or great vessel defects were seen in the Chd7
fl/fl;Nkx2.5-Cre embryos, 90%
of hearts examined (n=10) had either a VSD or an AVSD (see Table 4-5). Two examples of these
are shown in Figure 4-2. The first heart had an AVSD with common atrioventricular (AV) valve
and left ventricular dominance (Figure 4-2, A’’). The right component of the common valve
opened into a sequestrated inlet component of the right ventricle, with myocardium
supporting the bridging part of the superior leaflet, and blood was able to enter the right
ventricle beneath the superior bridging leaflets via the common AV junction. Minimal
formation of the venous valves was also seen. Together, these defects indicate a failure of the
vestibular spine to form, as seen in Chd7
fl/fl;Mesp1-Cre hearts. There was also poor compaction
of the myocardium, which was seen in 60% of Chd7
fl/fl;Nkx2.5-Cre hearts.
The second example of an Chd7
fl/fl;Nkx2.5-Cre heart had separate AV junctions, but the
tricuspid valve that connects the right atrium and ventricle was grossly hypoplastic and
dysplastic (Figure 4-2, B’’). The apical component of the right ventricle was fed through a VSD,
which opened beneath the aortic root (Figure 4-2, B’). Fusion of the atrial septum to separate
the AV junctions was seen, but there was minimal formation of the vestibular spine-derived
buttress that supports the septum, and poorly-formed venous valves. Therefore, the septation
defects seen in Chd7
fl/fl;Nkx2.5-Cre hearts appear to be caused by disruption to the vestibular
spine. The most severe examples that showed common AV valves and left ventricular
dominance were again analogous to the Holmes heart. Unlike the Chd7
fl/fl;Mesp1-Cre hearts,
however, the arterial pole of all the Chd7
fl/fl;Nkx2.5-Cre hearts was formed normally, with no
alignment or septation defects (Figure 4-2, A and B).113
Figure 4-2: Atrioventricular septal defects in Chd7
fl/fl;Nkx2.5-Cre hearts
Transverse H&E sections through two examples of Chd7
fl/fl;Nkx2.5-Cre hearts. The OFT region of all
Chd7
fl/fl;Nkx2.5-Cre hearts were normally septated and aligned (A and B), whilst inter-ventricular
communication was highly penetrant (stars, A’ and B’). Further towards the apex of the heart, example
A shows an AVSD with common AV valves and dominant left ventricle, as seen in 30% of Chd7
fl/fl;Nkx2.5-
Cre hearts (star, A’’). Example B shows a grossly hypoplastic and dysplastic tricuspid valve opening into a
sequestrated inlet component of the right ventricle (star, B’’).
Scale bars represent 0.5mm. ao indicates aorta; p, pulmonary trunk; ra, right atrium; la, left atrium; rv,
right ventricle; lv, left ventricle.
Heterozygous Chd7
fl/+;Nkx2.5-Cre embryos did not show any similar septation defects (n=3,
data not shown). Similar to the Chd7
fl/+;Mesp1-Cre embryos, this indicates that either the Cre-
driven ablation was not efficient enough to reduce Chd7 levels sufficiently in the
cardiomyocytes, or that heterozygosity in multiple tissue types is required for the CHD7
haploinsufficient cardiac phenotype. The lack of cardiac phenotype in these hearts also
provided a control for possible effects of the Nkx2.5-Cre allele, as this is a knock-in construct so
could be affecting the levels of Nkx2.5 expression. Haploinsufficiency for Nkx2.5 causes
disruption to cardiovascular development (Jay et al., 2004; Jay et al., 2005), whilst complex
dosage interactions between Nkx2.5 and the chromatin remodeller Brg1 also affect
cardiogenesis (Takeuchi et al., 2011). Therefore, it was important to confirm that the
phenotype seen in Chd7
fl/fl;Nkx2.5-Cre hearts is due to the specific ablation of Chd7 in
cardiomyocytes, rather than the Nkx2.5-Cre allele itself.114
4.2 Mef2c-Cre driven ablation of Chd7
4.2.1 Mef2c-Cre expression in the second heart field
Mef2c is expressed around E7.5, shortly after Nkx2.5 expression, in a subset of cardiac
progenitors known as the anterior or second heart field (SHF) (Dodou et al., 2004; Edmondson
et al., 1994). The SHF cells reside in the splanchic and pharyngeal mesoderm, lying medially to
the cardiac crescent of the FHF. They are seen to be progressively added to the arterial and
venous poles of the heart around the time of cardiac looping (Kelly et al., 2001; Mjaatvedt et
al., 2001; Waldo et al., 2001). The primary heart tube of FHF-myocardial cells provides a
scaffold onto which the SHF cells can migrate in order to extend the heart tube (Kodo and
Yamagishi, 2011), where they contribute to the right ventricle, OFT and atrial myocardium
(Buckingham et al., 2005; Meilhac et al., 2004).
Figure 4-3 highlights the heterogeneity of cells within the SHF, which is now considered to
have a number of subdomains distinguished by their gene expression patterns and
contribution to the different parts of the heart. Mef2c is expressed in the anterior region of the
SHF. Two linked enhancer elements have been identified that drive Mef2c expression in the
SHF, one of which is activated by Gata4 and Isl1 (Dodou et al., 2004), and the other by Fox1h
and Nkx2-5 (von Both et al., 2004). Mef2c expression in the SHF has been traced using both
transgenic mice expressing lacZ under control of a Mef2c transcriptional enhancer, and by a
Mef2c-Cre allele crossed to Cre-dependent lacZ reporter mice. The first study confirmed the
Mef2c enhancer begins to function at E7.5 in the pre-cardiac SHF mesoderm, and traces its
derivatives to the OFT and right ventricle (Dodou et al., 2004). Further detailed study using the
Mef2c-Cre allele traced both endothelial and myocardial components of the OFT, right
ventricle and ventricular septum as derivatives of Mef2c-expressing cells, whilst excluding the
atria, epicardium, coronary vessels and the majority of OFT smooth muscle (Verzi et al., 2005).
The Mef2c-Cre construct generated by Verzi and colleagues is used in this section to drive
conditional Chd7 ablation in the anterior SHF. This again should provide valuable information
on how much of the Chd7
fl/fl;Mesp1-Cre phenotype can be attributed to Chd7 activity in this
smaller population of cardiac progenitors.115
Figure 4-3: Subdomains within the second heart field
Schematic of the SHF in an E8.0 embryo. The SHF is characterised by expression of Nkx2-5 and Islet1.
The anterior region (yellow) also expresses Mef2c, along with Tbx1, Fgf8 and Fgf10, whilst in the
posterior region (green) Wnt2 is additionally expressed. The most posterior region is distinguished by
expression of Tbx18 (red), which contains the progenitors for the sinus horn. Pitx2c is expressed
throughout the left side of the SHF only (striped).
Adapted from Vincent (2010).
4.2.2 Chd7
fl/fl;Mef2c-Cre mice are viable
Chd7
fl/+;Mef2c-Cre mice were crossed to mice homozygous for the conditional Chd7
fl allele. As
can be seen in Table 4-2, at E15.5 Chd7
fl/fl;Mef2c-Cre embryos were collected in their expected
Mendelian ratios. A number of Chd7
fl/fl;Mef2c-Cre mice were also seen at P10, unlike the
Chd7
fl/fl;Mesp1-Cre or Chd7
fl/fl;Nkx2.5-Cre genotypes. These mice were able to survive to
adulthood and could be used for breeding. There were fewer than expected Chd7
fl/fl;Mef2c-Cre
pups compared to the other genotypes in the litter, but Chi squared analysis did not indicate
this was a significant reduction in numbers.
Table 4-2: Survival of embryos from the Chd7
fl/fl x Chd7
fl/+;Mef2c-Cre cross
Developmental
Stage:
Genotype: Observed: Expected:
E15.5 Chd7
fl/+ 12 20
Chd7
fl/fl 19 20
Chd7
fl/+;Mef2c-Cre 29 20
Chd7
fl/fl;Mef2c-Cre 20 20
P10 Chd7
fl/+ 13 9
Chd7
fl/fl 8 9
Chd7
fl/+;Mef2c-Cre 9 9
Chd7
fl/fl;Mef2c-Cre 5 9116
4.2.3 Great vessel defects are present after ablation of Chd7 in the second heart field
At E15.5, just one of the Chd7
fl/fl;Mef2c-Cre embryos collected (n=20) exhibited some external
oedema (Figure 4-4, A), whilst the remainder showed no external difference to control
littermates (Figure 4-4, B). Examination of the great arteries, however, showed that 25% of
Chd7
fl/fl;Mef2c-Cre embryos had IAA-B – that is, disruption of the aortic arch between the left
common carotid and left subclavian arteries (Figure 4-4, C and D). This was very similar to the
penetrance of the same defect in Chd7
fl/fl;Mesp1-Cre embryos.
When the pharyngeal arch arteries (PAAs) were examined in E10.5 Chd7
fl/fl;Mef2c-Cre
embryos, the left 4
th PAA was absent in 20% of embryos (Figure 4-4, E and F). This was
unexpected, as early PAA defects were not seen in Chd7
fl/fl;Mesp1-Cre embryos. It indicates
that the IAA-B seen following second heart field-specific ablation of Chd7 is due to early
disruption to the formation of the PAAs, unlike in the Chd7
fl/fl;Mesp1-Cre embryos, which
appeared to be caused by later remodelling defects.
Table 4-3: Frequency of PAA defects at E10.5 and IAA-B at E15.5 in embryos from the Chd7
fl/fl
x Chd7
fl/+;Mef2c-Cre cross
Genotype: n: 4
th PAA defects: n: IAA-B:
Chd7
fl/+ 5 0% 12 0%
Chd7
fl/fl 14 0% 19 0%
Chd7
fl/+;Mef2c-Cre 4 0% 29 0%
Chd7
fl/fl;Mef2c-Cre 10 20% 20 25%117
Figure 4-4: External appearance and great vessel development in Chd7
fl/fl;Mef2c-Cre embryos
(A and B) External examination of Chd7
fl/fl;Mef2c-Cre embryos at E15.5 found only one embryo with
mild oedema (arrows, A), whilst most Chd7
fl/fl;Mef2c-Cre embryos were indistinguishable from their
control littermates (B).
(C and D) Two examples of interrupted aortic arch type B (IAA-B) in Chd7
fl/fl;Mef2c-Cre embryos. The
white stars highlight the interruption between the left common carotid and left subclavian arteries.
(E and F) Ink injection of the pharyngeal arch arteries (PAAs) at E10.5 shows normal bilateral formation
of the 3
rd, 4
th and 6
th PAAs in a control Chd7
fl/fl embryo (E), whilst in the Chd7
fl/fl;Mef2c-Cre embryo the
left 4
th PAA is absent (star, F).
Scale bars represent 2mm (A and B), 0.5mm (C and D) or 0.2mm (E and F). rsc indicates right subclavian;
rcc, right common carotid; lcc, left common carotid.118
4.2.4 Low frequency of cardiovascular septation defects in Chd7
fl/fl;Mef2c-Cre hearts
The most notable defects seen on H&E sections through Chd7
fl/fl;Mef2c-Cre hearts were
vascular rings, which were present in 3 out of 8 hearts examined. This was a higher frequency
than was noted in Chd7
fl/fl;Mesp1-Cre hearts, in which just 10% of hearts exhibited this defect
(Table 4-5). Vascular rings can be formed by a number of different abnormal combinations of
derivatives of the aortic arch system, which encircle the trachea and oesophagus (Hernanz-
Schulman, 2005). Two examples of these are shown in Figure 4-5. The first had a vascular ring
produced by a right aortic arch and a ductal arch, with the dorsal part of the left 4
th PAA
running retro-oesophageally to supply the left subclavian and common carotid arteries (Figure
4-5, A). The second example shows another variant of vascular ring more commonly seen in
humans, where again the aorta was right-sided, but in this case gave rise to the left common
carotid artery as its first branch. It then continued as a right aortic arch, giving rise to the right
common carotid and subclavian arteries, before running retro-oesophageally to give rise to the
left subclavian artery (Figure 4-5, B). The ring was completed by the left-sided arterial duct,
which was widely patent. These slightly differing configurations were distinguished by studying
serial sections through the great vessels (full series not shown). Reconstructions of the
vascular rings are shown in Figure 4-10, and the developmental processes underlying these
structural defects are addressed in the discussion section of this chapter.
Despite the occurrence of great artery defects, the proximal OFT region of all the
Chd7
fl/fl;Mef2c-Cre hearts examined were normally septated and aligned. Fewer AV septation
defects were also observed following SHF-specific Chd7 ablation. Only one heart (12.5%) had
an AVSD, which still showed separate left and right AV orifices within the common AV junction
(Figure 4-5, A’’). Therefore, the left ventricular dominance observed in Chd7
fl/fl;Mesp1-Cre and
some Chd7
fl/fl;Nkx2.5-Cre hearts was not recapitulated. Furthermore, just one heart had a VSD,
meaning that the majority of Chd7
fl/fl;Mef2c-Cre hearts were normally septated.
Non-compaction of the myocardium of the right ventricle could be seen in 37.5% of
Chd7
fl/fl;Mef2c-Cre hearts. This is consistent with the specificity of the Cre line, as the left
ventricular walls - which are not derived from Mef2c-expressing cells - formed normally (Figure
4-5, B’ and B’’). Overall, SHF-driven ablation of Chd7 predominantly resulted in great vessel
defects, along with some septation and myocardial compaction defects, which are consistent
with the known contribution of this cell population to the developing heart. However, the
cardiovascular defects were not severe enough to induce embryonic or post-natal lethality.119
Figure 4-5: Vascular rings and septation defects in Chd7
fl/fl;Mef2c-Cre hearts
Transverse H&E sections through two examples of E15.5 Chd7
fl/fl;Mef2c-Cre hearts. The proximal OFT
region was normal in all Chd7
fl/fl;Mef2c-Cre hearts, although vascular rings were observed in 30% of
hearts (the retro-oesophageal components of the vascular rings are starred in A and B). Example A has
inter-ventricular communication (star, A’) and AVSD (star, A’’), although there are separate right and left
AV orifices. Other than the vascular ring, heart B was anatomically normal, although non-compaction of
the right ventricle can be seen in B’’.
Scale bars represent 0.5mm. ao indicates aorta; p, pulmonary trunk; ra, right atrium; la, left atrium; rv,
right ventricle; lv, left ventricle.120
4.3 Tie2-Cre driven deletion of Chd7
4.3.1 Tie2-Cre expression in endothelial cells
Tie2 promoter and enhancer regions drive expression in a pan-endothelial-specific manner in
both embryonic and adult mice (Schlaeger et al., 1997). Tie2 expression is seen in the embryo
from E8.0 as the first endothelial cells arise, as well as in a subset of extraembryonic
mesodermal cells from E7.5 (Kisanuki et al., 2001; Sato et al., 1993). Tie2-lacZ transgenic mice
were first generated using the promoter and an enhancer region located in the first intron of
the Tie2 gene, that could drive universal endothelial-specific lacZ staining (Schlaeger et al.,
1997), and the same promoter/enhancer region was then used to generate a transgenic Tie2-
Cre line (Kisanuki et al., 2001).
Lineage tracing of Tie2-expressing cells and their derivatives using this Tie2-Cre allele showed
that at E8.5 only a subset of the endocardium and endothelial cells in the aorta expressed lacZ.
It was only from E9.5 that lacZ expression was seen in the majority of endocardial and
endothelial cells, as well as in the first mesenchymal cells that appear in the cushions of the AV
canal and proximal OFT (but not the distal OFT). This is consistent with cells in the cushions
being derived from Tie2-expressing endocardial cells that have undergone endocardial-
mesenchymal transitions to form the endocardial cushions (Kisanuki et al., 2001).
This Tie2-Cre allele was used to drive Chd7 ablation, firstly to examine whether the oedema
and haemorrhaging seen in Chd7
fl/fl;Mesp1-Cre embryos could be attributed to a cell
autonomous role for CHD7 activity in vessel development and integrity. It would also elucidate
whether loss of Chd7 expression specifically in the endocardium and endocardial cushions
would be sufficient to recapitulate the alignment and septation defects seen in Chd7
fl/fl;Mesp1-
Cre embryos, as the endocardial cushions were malformed in these hearts.121
4.3.2 Chd7
fl/fl;Tie2-Cre mice are viable
Endothelial-specific ablation of Chd7 was not embryonic lethal, with the expected numbers of
Chd7
fl/fl;Tie2-Cre embryos collected at E15.5 (Table 4-4). Similar to the SHF-specific ablation,
these offspring were also viable, with pups genotyped at P10 and surviving to adulthood,
although Chd7
fl/fl;Tie2-Cre mice were seen at slightly lower numbers than their expected
Mendelian ratios. Again, Chi squared analysis indicated this was not a significant loss of the
Chd7
fl/fl;Tie2-Cre genotype, so this may be a result of normal biological variability.
Table 4-4: Viability of offspring from the Chd7
fl/fl x Chd7
fl/+;Tie2-Cre cross
Developmental
Stage:
Genotype: Observed: Expected:
E15.5 Chd7
fl/+ 9 11.5
Chd7
fl/fl 9 11.5
Chd7
fl/+;Tie2-Cre 16 11.5
Chd7
fl/fl;Tie2-Cre 12 11.5
P10 Chd7
fl/+ 9 8
Chd7
fl/fl 6 8
Chd7
fl/+;Tie2-Cre 13 8
Chd7
fl/fl;Tie2-Cre 5 8122
4.3.3 Chd7
fl/fl;Tie2-Cre embryos exhibit some cardiovascular septation defects
Mild oedema was only seen in two Chd7
fl/fl;Tie2-Cre embryos (n=11), and no embryos exhibited
signs of haemorrhaging (Figure 4-6, A and B). This indicates the main underlying cause of these
phenotypes in Chd7
fl/fl;Mesp1-Cre embryos was poor cardiac function, rather than a
requirement for CHD7 activity in endothelial cells during vessel formation. Furthermore,
coronary vein formation was normal in Chd7
fl/fl;Tie2-Cre hearts, as previously discussed (see
Figure 3-15), again indicating that vascular defects were not due to a cell autonomous effect of
Chd7 ablation in the endothelial lineage.
Whilst Tie2-Cre is expressed in the endothelial lining of the aorta and PAAs, IAA-B was
observed in just one Chd7
fl/fl;Tie2-Cre embryo at E15.5 (n=8, Figure 4-6, C). 87.5% of the
embryos had a normal configuration of the great vessels, suggesting that CHD7 activity in the
Tie2-expressing lineage is not playing a significant role in great vessel formation (Figure 4-6, D).
Figure 4-6: Chd7
fl/fl;Tie2-Cre embryos show a low penetrance of oedema and IAA-B
(A and B) A small number of Chd7
fl/fl;Tie2-Cre embryos showed some oedema (arrows, A), but none as
severe as the Chd7
fl/fl;Mesp1-Cre phenotype. Most Chd7
fl/fl;Tie2-Cre embryos looked normal at E15.5 (B).
(C and D) The great vessels were examined at E15.5. Just one embryo (n=8) had an interrupted aortic
arch type B (star, C), but again the majority had normally-developed great vessels (D).
Scale bars represent 2mm (A and B) or 0.5mm (C and D). rsc indicates right subclavian artery; rcc, right
common carotid; lcc, left common carotid; lsc, left subclavian; aa, aortic arch.123
Similar frequencies of septation defects were seen in Chd7
fl/fl;Tie2-Cre hearts compared to
Chd7
fl/fl;Mef2c-Cre embryos (see Table 4-5). Again, the OFT tracts in all Chd7
fl/fl;Tie2-Cre hearts
were normally aligned and septated (Figure 4-7, A and B), and the overall ventricular balance
was normal. The first example of a Chd7
fl/fl;Tie2-Cre heart in Figure 4-7 shows the only AVSD
seen for this cross, which had a ventricular connection seen below the aortic opening (A’) and
separate right and left AV junctions, although the mitral and tricuspid AV valves were slightly
dysplastic (A’’). Interestingly, the venous valves do not appear as under-developed as in
previous AVSDs, possibly indicating that the primary cause of this malformation is disruption to
the endocardial cushion formation rather than the vestibular spine. The second example
shows one of two VSDs seen in Chd7
fl/fl;Tie2-Cre hearts, with the rest of the heart looking
anatomically normal. Unlike Chd7
fl/fl;Mef2c-Cre embryos, no vascular rings were observed on
the H&E sections through Chd7
fl/fl;Tie2-Cre hearts, again suggesting CHD7 activity in vessel
endothelium is not crucial for great vessel formation.
Figure 4-7: Septation defects in Chd7
fl/fl;Tie2-Cre embryos
Transverse H&E sections through two examples of E15.5 Chd7
fl/fl;Tie2-Cre hearts. Endothelial-ablation of
Chd7 also did not produce any OFT defects (A and B), although some septation defects were again
present. One AVSD with separate right and left AV valves was observed (stars, A’ and A’’), whilst 25% of
Chd7
fl/fl;Tie2-Cre hearts had a VSD (star in B’) but the AV junction was normally septated (B’’).
Scale bars represent 0.5mm. ao indicates aorta; p, pulmonary trunk; ra, right atrium; la, left atrium; rv,
right ventricle; lv, left ventricle.124
4.4 Overview of lineage-specific Chd7 ablation
Table 4-5 summarises the major cardiovascular phenotypes seen in all of the conditional Chd7
mutants described so far. External signs of oedema or haemorrhaging at E15.5 were highly
penetrant in Chd7
fl/fl;Mesp1-Cre embryos, but absent or much lower penetrance and severity
in Chd7
fl/fl;Nkx2.5-Cre, Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Tie2-Cre embryos. IAA-B was found in
comparable proportions of Chd7
fl/fl;Mesp1-Cre and Chd7
fl/fl;Mef2c-Cre embryos, and in one
Chd7
fl/fl;Tie2-Cre embryo. However, no great vessel defects were identified in Chd7
fl/fl;Nkx2.5-
Cre embryos, which was surprising given its overlapping expression with Mef2c.
The most severe structural cardiac defects were seen in Chd7
fl/fl;Mesp1-Cre hearts: CAT, DORV
and DILV were only seen with this genotype. A high penetrance of septation defects was also
seen in Chd7
fl/fl;Nkx2.5-Cre embryos, along with myocardial non-compaction and venous valve
defects. Some septation defects were also present in Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Tie2-Cre
hearts. The lower penetrance and less severe cardiac phenotype of these two genotypes is
reflected in the fact that only these mice were viable.
Table 4-5: Comparison of cardiovascular defects seen at E15.5 and viability following
homozygous Chd7 ablation using different Cre lines
Mesp1-Cre: Nkx2.5-Cre: Mef2c-Cre: Tie2-Cre:
Oedema 68% 0% 5% 18%
Haemorrhage 64% 0% 0% 0%
IAA-B 21% 0% 25% 12.5%
Vascular ring 10% 0% 37.5% 0%
AVSD 100% 30% 12.5% 12.5%
VSD only N/A 60% 12.5% 25%
ASD only N/A 0% 0% 12.5%
DILV 100% 0% 0% 0%
DORV 60% 0% 0% 0%
Myocardial non-compaction 80% 60% 37.5% 37.5%
Venous valve defects 90% 50% 0% 0%
Viable? No - 0/9 No - 0/8 Yes - 5/9 Yes - 5/8
Genotypes were recorded as viable if live pups were found at P10, the numbers indicate the number of
observed pups compared to the expected number based on Mendelian ratios.
IAA-B indicates interrupted aortic arch type-B; AVSD, atrioventricular septal defect; VSD, ventricular
septal defect; ASD, atrial septal defect; DILV, double inlet left ventricle; DORV, double outlet right
ventricle.125
4.5 Investigating a possible epistatic interaction between Chd7 and Brg1 during
heart development
4.5.1 The role of Brg1 in heart development
The SWI/SNF chromatin remodelling complex BRG1/BRM-associated factor (BAF) is composed
of at least 11 subunits, with the incorporation of different subunit isoforms allowing it to
perform distinct functions during development (Bruneau, 2010). The ATPase subunit of the
complex is encoded by one of two homologous genes, Brm or Brg1 (Chiba et al., 1994). Whilst
Brm is dispensable during mammalian development, Brg1-null mutant embryos die in the peri-
implantation stage before E6.5 (Bultman et al., 2000). Heterozygous Brg1 mice show 50%
lethality before 3 weeks of age, with congenital heart defects such as dilated hearts, muscular
VSDs and patent foramen ovale, suggesting haploinsufficiency of Brg1 during heart
development (Takeuchi et al., 2011). Tissue-specific ablation of Brg1 expression in different
lineages has identified multiple roles during heart development.
Brg1 is required in the endocardium for the dynamic regulation of the expression of the
secreted matrix metalloproteinase Adamts1 (Stankunas et al., 2008). Brg1 represses Adamts1
expression between E9.5 to E11.5, in order to allow establishment of the cardiac jelly and
promote myocardial trabeculation, before de-repression between E12.5 to E14.5 for
degradation of the cardiac jelly and termination of trabeculation. Endocardial ablation of Brg1
driven by Tie2-Cre resulted in hypotrabeculation of the myocardium and absence of the
cardiac jelly, leading to embryonic lethality around E10.5-E11.5 (Stankunas et al., 2008).
In the myocardium Brg1 also plays an important role in the transcriptional regulation of
cardiac growth and differentiation (Hang et al., 2010; Takeuchi et al., 2011). Myocardial
ablation of Brg1 results in embryonic lethality at E11.5, with thin myocardium and absence of
the interventricular septum. Brg1 promotes cardiomyocyte proliferation through maintenance
of Bmp10 expression and suppression of the cyclin-dependent kinase inhibitor p57kip2, which
prevents cell cycle progression (Hang et al., 2010). Furthermore, Brg1 ablation in the SHF using
Mef2c-Cre resulted in a hypoplastic OFT and right ventricle, phenocopying the Bmp10
downregulation, ectopic p57kip2 expression and reduced proliferation, whilst the Brg1
+/+ left
ventricle developed normally (Hang et al., 2010).
Additional roles for Brg1 have been identified for development of the OFT and great vessels.
Loss of Brg1 expression in smooth muscle cells results in patent ductus arteriosus (PDA) in
approximately one-third of mice, leading to cyanosis and dilated cardiac chambers by P3126
(Zhang et al., 2011). Closure of the ductus arteriosus is mediated by contraction of smooth
muscle cells during the neonatal period, in order to switch from fetal to adult circulation, and
in cultured cells Brg1 promotes expression of smooth muscle contractile genes. Furthermore,
embryos lacking Brg1 in NCCs have aberrant PAA development and shortened OFTs, and
embryonic lethality occurs between E11.5-E12.5 (Li et al., 2013). This was attributed to a role
for Brg1 in maintaining a multipotent NCC reservoir through repressing the apoptotic factor
Ask1 and the cell cycle inhibitor p21cip1. It is also located at the PlexinA2 promoter in NCCs to
directly promote the expression of this semaphorin receptor (Li et al., 2013), which has a role
in guidance of cardiac NCCs within the OFT (Brown et al., 2001). Overall, it is clear Brg1 is
required in multiple lineages for a diverse range of processes during heart development.
4.5.2 Interaction between Brg1 and Chd7
CHD7 and the polybromo- and BRG1-associated factor (PBAF) complex have been reported to
interact in human neural crest-like cells (hNCLCs), with multiple components of PBAF identified
by mass spectrometry analysis of CHD7-associated proteins and confirmed by reciprocal co-
immunoprecipitations (Bajpai et al., 2010). Similar phenotypes were seen following Chd7 or
Brg1 morpholino (MO) injection into eight-cell-stage Xenopus embryos, including eye
coloboma and craniofacial malformations. Downregulation of the NCC-specific transcription
factors Twist and Slug genes was also seen following both MO knockdowns, with a dosage-
dependent synergistic effect observed following co-injection of Chd7 and Brg1 MOs.
Furthermore, comparison of genome-wide CHD7 and Brg1 occupancy datasets showed 81% of
Brg1 regions were bound by CHD7, whilst 34% of CHD7 sites were co-occupied by Brg1.
Chromatin immunoprecipitation (ChIP) analyses from hNCLCs showed both chromatin
remodellers occupy a NCC-specific distal SOX9 enhancer and a conserved upstream region of
TWIST1, indicating that CHD7 and BRG1 together directly regulate expression of the critical
NCC transcriptional circuitry (Bajpai et al., 2010).
Li and colleagues also demonstrated an interaction between Brg1 and Chd7 whilst studying the
role of Brg1 in NCCs. ChIP analysis on dissected neural crest tissues from the rhombomere 6-8
region using an anti-CHD7 antibody showed enrichment for CHD7 within 9 conserved regions
of the PlexinA2 promoter, which was also enriched for Brg1 in a similar ChIP-qPCR experiment.
This indicated Brg1 and CHD7 were in close proximity, and a physical interaction between
them was confirmed by co-immunoprecipitation, again on dissected neural crest tissue.
Furthermore, reporter assays on the PlexinA2 promoter showed an approximately two-fold
synergistic effect of co-expression of Brg1 and Chd7 on promoter activation (Li et al., 2013).127
4.5.3 Lack of epistasis following Chd7 and Brg1 ablation in the cardiac mesoderm
Given the roles for Brg1 in many cardiogenic lineages during development, including the
Mesp1-derived myocardium and endocardium, and the formation of functional complexes
containing both CHD7 and Brg1 at genomic regulatory elements, we postulated that similar
interactions may be important in the cardiogenic mesoderm and its derivatives. Chd7
fl/fl mice
were therefore crossed with Brg1
fl/+;Mesp1-Cre mice, in order to generate mesodermal
conditional compound heterozygous Chd7
fl/+;Brg1
fl/+;Mesp1-Cre offspring. Table 4-6 shows the
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre genotype was seen in Mendelian ratios at E15.5 and P10, indicating
it does not cause embryonic or postnatal lethality.
Table 4-6: Offspring generated from the Chd7
fl/fl x Brg1
fl/+;Mesp1-Cre cross
Developmental
Stage:
Genotype: Observed: Expected:
E15.5 Chd7
fl/+ 6 7
Chd7
fl/+;Brg1
fl/+ 8 7
Chd7
fl/+;Mesp1-Cre 8 7
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre 7 7
P10 Chd7
fl/+ 6 5
Chd7
fl/+;Brg1
fl/+ 7 5
Chd7
fl/+;Mesp1-Cre 2 5
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre 4 5
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre embryos (n=7) were examined at E15.5 for cardiovascular defects.
None of the embryos showed any abnormal external phenotypes (data not shown), and the
great vessels all formed the correct mature configuration (Figure 4-8, A-C). Furthermore, H&E
sectioning to investigate the cardiac morphology of these embryos did not reveal any obvious
structural defects: the hearts were all fully septated and the alignment appeared normal
(Figure 4-8, D-G). Consistent with this lack of embryonic cardiovascular phenotype, the four
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre pups that were seen at P10 survived to adulthood and had no
obvious defects. Together, this data suggests that a synergistic relationship does not occur
between Brg1 and Chd7 in the cardiogenic mesoderm, and so this hypothesis was not pursued
any further.128
Figure 4-8: No cardiovascular phenotype in Chd7
fl/+;Brg1
fl/+;Mesp1-Cre embryos
(A-C) dissection of E15.5 control Chd7
fl/+;Brg1
fl/+ embryos (A) and Chd7
fl/+;Brg1
fl/+;Mesp1-Cre embryos (B
and C) revealed there were no great vessel defects in the compound heterozygotes.
(D-F) Transverse H&E sections also revealed no apparent cardiac defects in any Chd7
fl/+;Brg1
fl/+ (D) or
Chd7
fl/+;Brg1
fl/+;Mesp1-Cre hearts (E and F)
Scale bars represent 0.5mm. rsc indicates right subclavian; rcc, right common carotid; lcc, left common
carotid; lsc, left subclavian; aa, aortic arch; ao, aorta; p, pulmonary trunk; ra, right atrium; la, left
atrium; rv, right ventricle; lv, left ventricle.129
4.6 Discussion
This chapter has presented cardiovascular phenotypes resulting from Chd7 ablation driven by
Nkx2.5-Cre, Mef2c-Cre and Tie2-Cre. These lineages are all derived from Mesp1-expressing
progenitors, but none of the crosses completely reproduced the Chd7
fl/fl;Mesp1-Cre
phenotype. Instead, each cross resulted in a milder subset of the cardiac defects observed
after mesodermal ablation, indicating a continued requirement for Chd7 in multiple lineages
within the cardiogenic mesoderm. This spectrum of defects will be discussed further, to
attempt to attribute different aspects of the Chd7
fl/fl;Mesp1-Cre phenotype to CHD7 activity in
different cardiogenic lineages.
Compound conditional heterozygotes for Chd7 and Brg1 were also generated to investigate
whether these genes interact epistatically in the cardiogenic mesoderm. However, no cardiac
phenotype was identified, suggesting independent roles for these genes in the development of
cardiac structures derived from the mesoderm.
4.6.1 Perinatal lethality and external phenotypes
Chd7 ablation driven by Nkx2.5-Cre was the only cross that was not viable, other than Mesp1-
Cre, although at E15.5 Chd7
fl/fl;Nkx2.5-Cre embryos were collected in Mendelian ratios and no
necrotic embryos were observed. It is therefore likely these pups were dying in the perinatal
period. Given the high penetrance of cardiac septation defects seen in the Chd7
fl/fl;Nkx2.5-Cre
embryos at E15.5, but otherwise morphologically normal appearance, cardiac failure is the
most likely cause. The initiation of breathing at birth is associated with significant changes in
the circulatory system, as it switches from fetal to respiratory circulation (Turgeon and
Meloche, 2009). Correct septation is required to keep the oxygenated and deoxygenated blood
of the systemic and pulmonary systems separated, and the heart must also be strong enough
to produce increased blood flow to the lungs. Cardiac abnormalities such as VSDs and AVSDs,
which alone may not be sufficient to cause embryonic lethality, are therefore associated with
neonatal death through poor blood oxygenation, congenital cyanosis and respiratory distress
(Turgeon and Meloche, 2009).
It is likely that some of the more severely affected Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Tie2-Cre
pups also died perinatally and were cannibalised, as the numbers of each of these genotypes
seen at P10 were slightly lower than their expected Mendelian numbers. However, the
penetrance of the septation defects seen in these genotypes was much lower than for
Chd7
fl/fl;Nkx2.5-Cre, which is reflected in a number of them surviving to full maturity.130
Whilst severe oedema and haemorrhaging was seen in E15.5 Chd7
fl/fl;Mesp1-Cre embryos, only
a small proportion of Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Tie2-Cre embryos exhibited much milder
oedema. This indicates that the structural heart defects found in Chd7
fl/fl;Nkx2.5-Cre,
Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Tie2-Cre embryos did not cause major loss of fetal cardiac
function, and were not severe enough to recapitulate the major external phenotype of the
Chd7
fl/fl;Mesp1-Cre embryos. Furthermore, the lack of external phenotype in Chd7
fl/fl;Tie2-Cre
embryos indicates that loss of CHD7 activity in the endothelial cells of blood vessels is not
sufficient to produce severe oedema or haemorrhaging. Instead, given the most severe
structural heart malformations were seen in Chd7
fl/fl;Mesp1-Cre embryos (Table 4-5), it seems
likely their external phenotypes were primarily due to cardiac failure rather than primary
disruption to vessel integrity.
4.6.2 Great vessel defects following second heart field-specific ablation
The presence of great vessel defects predominantly in Chd7
fl/fl;Mef2c-Cre embryos indicates
that the IAA-B and other aortic arch defects observed in Chd7
fl/fl;Mesp1-Cre embryos were
predominantly due to a requirement for CHD7 activity in the anterior SHF. This was
unsurprising given the well-established importance of signalling between the migratory cardiac
neural crest and SHF derivatives during great vessel development (Dyer and Kirby, 2009).
Consistent with this, a number of other transcriptional regulators expressed in the SHF, such as
Tbx1 and Pitx2c, have roles in the development of the PAAs and great vessels (Liu et al., 2002;
Vitelli et al., 2002). It is unclear why atresia of the 4
th PAA was only seen in E10.5
Chd7
fl/fl;Mef2c-Cre embryos, but not in Chd7
fl/fl;Mesp1-Cre embryos. This observation suggests
that different mechanisms underlie the IAA-B observed in both genotypes: in Chd7
fl/fl;Mef2c-
Cre embryos early PAA formation appears to be disrupted, whilst in Chd7
fl/fl;Mesp1-Cre
embryos later remodelling defects appear to be the more likely mechanism. It is possible,
however, that examination of a greater number of E10.5 Chd7
fl/fl;Mesp1-Cre embryos might
reveal that 4
th PAA aplasia is found in Chd7
fl/fl;Mesp1-Cre embryos, but due to biological
variability the sample size of 14 embryos was not high enough to detect this phenotype.
The much lower frequency of IAA-B in Chd7
fl/fl;Tie2-Cre embryos indicates that it is
predominantly the SHF-derived myocardium at the arterial pole in which CHD7 is important,
rather than in the endothelial lining of the vessels. It was, however, surprising not to see any
great vessel defects in Chd7
fl/fl;Nxk2.5-Cre embryos, given that Mef2c-Cre should be expressed
in a subset of Nkx2.5-expressing cells in the anterior SHF. The most likely explanation is that
there was a difference in the levels of Cre-driven Chd7 ablation in the SHF in Chd7
fl/fl;Mef2c-Cre
and Chd7
fl/fl;Nxk2.5-Cre embryos, with a greater impact on CHD7 activity in Chd7
fl/fl;Mef2c-Cre131
embryos. Consistent with this hypothesis, the levels of NKX2-5 protein have been shown to be
five-fold lower in the anterior SHF than in the myocardium of the primary heart tube at E9.0
(Prall et al., 2007). Unlike Nkx2.5, Mef2c is also expressed in arch mesoderm, which is
contiguous with the anterior SHF, which could have both autonomous and non-cell
autonomous effects on great vessel development in Chd7
fl/fl;Mef2c-Cre embryos.
Investigating the relative levels of Chd7 mRNA in the SHF in Chd7
fl/fl;Mef2c-Cre and
Chd7
fl/fl;Nxk2.5-Cre embryos would have been beneficial to this study, although this presented
a number of technical difficulties. ISH could have been used to compare Chd7 mRNA
expression in the two genotypes, as was done on Chd7
fl/fl;Mesp1-Cre hearts in chapter 3, as
this would allow examination specifically of SHF-derived structures. However, this technique is
qualitative, so a large difference in Chd7 ablation in the SHF would be required to convincingly
show a difference in the Cre-driven recombination levels. qRT-PCR would be much more
sensitive for quantitatively identifying subtle changes in Chd7 dosage, but it would be difficult
to specifically isolate SHF-derived cells to carry out such analysis. Manual dissection of
predominantly SHF-derived structures would be difficult and likely to contain additional cell
types that would increase background in the analysis. Alternatively, the introduction of
reporter lines that could be used for FACS of SHF cells would require complex breeding
programmes and large numbers of litters in order to generate sufficient samples of the
required genotype.
The higher frequency of vascular rings seen in Chd7
fl/fl;Mef2c-Cre embryos compared to
Chd7
fl/fl;Mesp1-Cre embryos was also surprising, although again relatively low sample numbers
and biological variability could explain this apparent inconsistency. Vascular rings make up less
than 1% of cardiovascular congenital abnormalities in humans, and involve the encirclement of
the trachea and oesophagus by an abnormal combination of derivatives of the PAA system
(Park, 2008). They can be comprised of purely vascular components, or contain ligamentous
components to complete the ring, and either way result in obstruction to the trachea and
oesophagus with varying degrees of severity (Hernanz-Schulman, 2005). The best way to
understand the development of vascular rings is to use the hypothetical model of a double
aortic arch, introduced by Jesse E. Edwards to explain both normal and abnormal aortic arch
artery remodelling (Edwards, 1948). This hypothetical model represents a relatively late stage
of great vessel development, with the OFT fully septated and the descending aorta centrally
positioned (Figure 4-9 and Figure 4-10). Symmetrical aortic arches are seen either side of the
trachea and oesophagus to connect the ascending and descending aorta bilaterally, with a
common carotid and subclavian artery arising from each arch. Right-sided and left-sided
arterial ducts also connect the pulmonary arteries to the distal ends of each aortic arch, so in132
total the model contains two vascular rings around the trachea and oesophagus, formed of the
bilateral aortic arches and bilateral arterial ducts.
Figure 4-9 shows the normal development of the great vessels, in which the right-sided arterial
duct and the right aortic arch (distal to the right subclavian artery) regress, whilst the left
aortic arch and left-sided duct persist, to form the recognisable left aortic arch configuration.
The remaining proximal region of the right aortic arch persists as the brachiocephalic artery,
which connects the right subclavian and right common carotid arteries to the aortic arch
(Figure 4-9, middle panel). Further regression of the left arterial duct postnatally separates the
systemic and pulmonary circulations (Figure 4-9, right panel).
Figure 4-9: The Edwards Hypothetical Model of a Double Aortic Arch
The left panel shows the hypothetical double aortic arch formation proposed by Edwards in 1948, which
was used to predict vascular rings that were only later reported. The red lines highlight the normal
breakage points in the right aortic arch and right arterial duct, which lead to the normal left-sided aortic
arch seen in fetal circulation (middle panel). Oxygenated (red arrow) and deoxygenated (blue arrow)
blood, from the aorta and pulmonary trunk respectively, continue to mix in the descending aorta. Soon
after birth, the left arterial duct (also known as ductus arteriosus) regresses, so the pulmonary trunk no
longer connects to the dorsal aorta and the systemic and pulmonary circulations are separated (right
panel).
RAA indicates right aortic arch; LAA, left aortic arch; RSA, right subclavian artey; RCCA, right common
carotid artery; LSA, left subclavian artery; LCCA, left common carotid artery; RPA, right pulmonary artery;
LPA, left pulmonary artery; PT, pulmonary trunk; RBA, right brachiocephalic artery.
Figure from Shi-Joon Yoo (2009)133
In most cases, structural anomalies such as vascular rings can be explained by incorrect
persistence or regression of one or more components of this hypothetical double arch. These
alterations correspond to different ‘breakage points’ on the hypothetical arch (Figure 4-10, left
panel). Two subtly different vascular rings were seen in Chd7
fl/fl;Mef2c-Cre hearts, both of
which included a right-sided arch. The first (example A in Figure 4-5) is a variant rarely seen in
humans, involving abnormal regression of the left aortic arch proximal to the origin of the left
common carotid artery (i.e. breakage point 5, middle panel on Figure 4-10). The persisting
arterial duct was left-sided, as is most commonly seen, completing the vascular ring.
The second variant, seen in two Chd7
fl/fl;Mef2c-Cre hearts (including example B in Figure 4-5),
also had a right-sided arch, but with an aberrant left subclavian artery. In this case, regression
of the left aortic arch occurs in between the origins of the left common carotid and left
subclavian arteries (breakage point 3, right panel on Figure 4-10), so the distal remnant of the
left aortic arch and aberrant left subclavian artery form the retro-oesophageal component of
the ring. As with the first variant, the ring was again completed by persistence of the left
arterial duct, connecting the left aortic arch remnant and left pulmonary artery. The vascular
ring recorded in one Chd7
fl/fl;Mesp1-Cre embryo also had this configuration, consistent with its
higher incidence in humans.
Figure 4-10: Vascular rings seen in Chd7
fl/fl;Mef2c-Cre embryos
The Edwards hypothetical arch is shown again to indicate the possible regression, or breakage, points
around the double arch, labelled 1 to 5 (left panel). Breaks at 1 or 2 would lead to a left-sided arch,
whilst breaks at 3, 4 or 5 would lead to a right-sided arch.
The middle panel corresponds to the vascular ring seen in Figure 4-5 (A), due to breakage of the double
arch at position 5, and the right panel corresponds to the ring seen in Figure 4-5, (B) due to a breakage
at position 3. Both rings are completed by a left ductal ligament (arrows).
AA indicates ascending aorta; DA, descending aorta; PA, pulmonary artery; RPA, right pulmonary artery;
LPA, left pulmonary artery; RS, right subclavian; RC, right common carotid; LS, left subclavian; LC, left
common carotid; E, oesophagus.
Adapted from Hernanz-Schulman (2005).134
The Edwards Hypothetical Double Aortic Arch model therefore provides an excellent basis for
understanding the mechanisms underlying the formation of vascular rings, including those
seen in Chd7
fl/fl;Mef2c-Cre and Chd7
fl/fl;Mesp1-Cre embryos. Vascular rings have been reported
in CHARGE syndrome patients (Blake and Prasad, 2006; Turkoz et al., 2012), so these tissue-
specific Chd7 mutant models indicate that loss of CHD7 activity in the anterior SHF makes an
important contribution to the great vessel defects seen in CHARGE patients.
4.6.3 Spectrum of septation defects in Chd7
fl/fl;Nkx2.5-Cre, Chd7
fl/fl;Mef2c-Cre and
Chd7
fl/fl;Tie2-Cre embryos
The Chd7
fl/fl allele was crossed with the Nkx2.5-Cre, Mef2c-Cre and Tie2-Cre lines in order to try
to dissect further the tissue-specific roles of Chd7 within the cardiogenic mesoderm. We
postulated that if one of these crosses could completely recapitulate the severe cardiovascular
defects seen in Chd7
fl/fl;Mesp1-Cre embryos, this would narrow down the requirement for
Chd7 to a smaller sub-population of cardiac progenitors. Alternatively, if different aspects of
the Chd7
fl/fl;Mesp1-Cre phenotype were seen with each cross, this would be informative for
assigning specific defects to CHD7 activity in different lineages.
As discussed in the previous section, the great vessel defects seen in Chd7
fl/fl;Mesp1-Cre
embryos can be largely attributed to loss of CHD7 activity in the anterior, Mef2c-expressing
SHF. The Nkx2.5-Cre cross, meanwhile, showed the most similar cardiac septation phenotype
to the Chd7
fl/fl;Mesp1-Cre embryos: Chd7
fl/fl;Nkx2.5-Cre hearts had the highest penetrance of
severe septation defects, and these defects were characteristic of malformation of the
vestibular spine. This is consistent with the expression of Nkx2.5 in the posterior region of the
SHF (see Figure 4-3), which also expresses Islet1 and Wnt2 - but not Mef2c - from which the
vestibular spine is derived (Vincent, 2010). Just one AVSD, with no left ventricular dominance,
was seen in a Chd7
fl/fl;Tie2-Cre heart, indicating that loss of CHD7 activity in the vestibular
spine has a greater effect on AV canal septation than loss in the endocardial cushions.
However, ablation in both the vestibular spine and endocardial cushions is required to produce
the most severe DILV defect seen only in Chd7
fl/fl;Mesp1-Cre hearts. This is consistent with the
roles of both of these mesenchymal structures during development of the AV canal (see Figure
3-17), as well as the observed disruption to both vestibular spine and endocardial cushion
formation in Chd7
fl/fl;Mesp1-Cre hearts.
The DORV phenotype seen frequently in Chd7
fl/fl;Mesp1-Cre hearts was also not observed
following Chd7 ablation driven by any of the Cre lines investigated in this chapter. Nkx2.5-Cre
should be expressed in a large proportion of Mesp1-expressing cells throughout the FHF and135
SHF, whilst Tie2-Cre is expressed in the endocardium that contributes to the OFT cushions.
Therefore, loss of CHD7 activity in both myocardial and endocardial cells at the arterial pole
contribute to the OFT defects seen in Chd7
fl/fl;Mesp1-Cre hearts. The earlier expression of
Mesp1-Cre compared to Nkx2.5-Cre, Mef2c-Cre and Tie2-Cre, could also be contributing to the
increased severity of the cardiovascular phenotype seen in Chd7
fl/fl;Mesp1-Cre embryos.
Mesp1-Cre is activated at approximately E6.5, whereas the other Cre lines are activated from
E7.5, so this longer exposure to Cre expression would be expected to increase the efficiency of
recombination.
Overall, it appears that the activity of CHD7 within multiple lineages in the cardiogenic
mesoderm is required for cardiovascular development, and the most severe combination of
cardiovascular phenotypes is only seen when Chd7 is ablated in all of these lineages.
4.6.4 Independent roles for Chd7 and Brg1 during heart development
A number of previous reports suggested that Brg1 could be a candidate interaction partner of
CHD7 in the cardiogenic mesoderm. As discussed in sections 4.5.1 and 4.5.2, Brg1 plays
multiple roles in the transcriptional control of heart development in endocardial, myocardial,
smooth muscle and neural crest cells (Hang et al., 2010; Li et al., 2013; Stankunas et al., 2008;
Zhang et al., 2011). In particular, the thin ventricular walls seen following myocardial Brg1
ablation are reminiscent of the thin walls and poor compaction observed in some of the
conditional Chd7 mutants described here. CHD7 and Brg1 are also known to synergistically
interact in NCCs, where they have common binding sites and regulatory activity (Bajpai et al.,
2010; Li et al., 2013). Furthermore, Brg1 has been shown to interact with two other chromatin-
modifying enzymes, histone deacetylases (HDACs) and poly(ADP-ribose) polymerase (PARP), to
activate the embryonic β-MHC whilst repressing the adult α-MHC within cardiomyocytes.
Together, these three factors cooperate to regulate gene expression to maintain
cardiomyocytes in an embryonic state during cardiac growth, differentiation, and
pathologically during cardiac hypertrophy (Hang et al., 2010).
Synergistic interactions between Brg1 and other cardiac-related genes have also previously
been reported: disruption to the allelic balance between Brg1 and the crucial cardiac
transcription factors Tbx5, Tbx20 and Nkx2.5 has been shown to lead to severe cardiovascular
malformations (Takeuchi et al., 2011). Generation of compound heterozygous mice for Brg1
and each transcription factor resulted in significant increases in phenotype severity compared
with heterozygosity for each gene alone. For example, loss of endocardial cushion formation
was seen in Brg1
+/-;Tbx5
+/- and Brg1
+/-;Nkx2.5
+/- hearts, whilst thinned ventricular walls were136
seen in Brg1
+/-;Nkx2.5
+/- and Brg1
+/-;Tbx20
+/- hearts. None of the compound heterozygous mice
survived past E14.5, indicating complex dosage-sensitive interdependent relationships exist
between transcription factors and BAF complexes during heart development (Takeuchi et al.,
2011). Chd7 also shows dosage dependence with the transcription factor Tbx1 in the
pharyngeal surface ectoderm during great vessel development.
Despite the combination of coincidental evidence indicating that synergistic interplay between
Chd7 and Brg1 could be functioning in the cardiogenic mesoderm, the data collected here
using compound conditional Chd7 and Brg1 heterozygotes suggests that this is not the case.
Whilst it is possible that the recombination of the conditional floxed Brg1 allele, driven by
Mesp1-Cre, was insufficient to produce an epistatic effect with Chd7, this floxed allele has
been reported in a number of published articles with deletion driven by other Cre lines, so this
seems unlikely (Glaros et al., 2008; Griffin et al., 2008; Indra et al., 2005). Instead, it would
appear these chromatin remodellers have independent roles in mesodermal derivatives,
indicating that association between CHD7 and Brg1 is cell-type specific during development. It
is well established that the subunit composition of the BAF and PBAF complexes, in which Brg1
is found, varies between different cell types and contexts. These variations influence the
function of the complexes, presumably through interaction with different partner proteins (Ho
et al., 2009; Lessard et al., 2007; Lickert et al., 2004; Wu et al., 2007). It is therefore likely that
the composition of BAF and PBAF complexes in the cardiogenic mesoderm does not promote
interaction with CHD7.
In summary, this chapter has demonstrated a requirement for Chd7 activity in multiple
lineages within the cardiogenic mesoderm, consistent with the widespread expression of Chd7
throughout the developing heart until E13.5. Chd7 ablation in the posterior Mef2c-Cre-
expressing SHF was sufficient to reproduce the great vessel defects observed in
Chd7
fl/fl;Mesp1-Cre embryos, indicating a crucial role for Chd7 in this subpopulation during
aortic arch development. CHD7 activity is also very important in the vestibular spine for
septation of the AV canal, although it appears ablation in both endocardial and myocardial
precursors is required to produce the characteristic combination of DORV and DILV seen in
Chd7
fl/fl;Mesp1-Cre embryos. Consequently, external phenotypes and embryonic lethality
associated with cardiac failure were most severe in Chd7
fl/fl;Mesp1-Cre embryos. The
hypothesis that CHD7 and BRG1 act synergistically in the cardiogenic mesoderm has also been
tested, although the data presented indicates that this is not an important interaction during
cardiovascular development.137
CHAPTER FIVE
ANALYSIS OF DOWNSTREAM TRANSCRIPTIONAL
CHANGES FOLLOWING CHD7 ABLATION IN THE
CARDIOGENIC MESODERM
Ablation of Chd7 expression in the cardiogenic mesoderm results in severe cardiovascular
malformations. To investigate the transcriptional changes underlying these defects,
microarrays were performed to compare genome-wide expression in Chd7
fl/fl;Mesp1-Cre
versus Chd7
+/+;Mesp1-Cre hearts. Gene expression was examined at both E11.5 and E13.5, as
growth of the vestibular spine, development of the endocardial cushions, and septation occur
at these stages. The resulting lists of dysregulated genes were analysed for over-represented
gene ontology (GO) terms, to indicate processes or pathways that could be disrupted in
Chd7
fl/fl;Mesp1-Cre hearts.
Following qRT-PCR validation of the microarray datasets, several genes of interest were further
investigated, based on their known roles during heart development. In situ hybridisation
provided spatial information on the specific regions of downregulation to components of
Semaphorin and Slit-Robo signalling pathways in Chd7
fl/fl;Mesp1-Cre hearts. Functional studies
were also performed on Chd7
fl/fl;Mesp1-Cre cardiomyocytes to investigate the effect of Chd7
ablation on excitation-contraction coupling, as multiple genes associated with this process
were dysregulated in the microarray datasets.
This chapter presents the results of these studies, which identify genes affected by CHD7
activity during cardiovascular development and correlate their aberrant expression to the
phenotypes seen in Chd7
fl/fl;Mesp1-Cre hearts.138
5.1 Microarray datasets at E11.5 and E13.5
5.1.1 RNA collection and quality control
To perform genome-wide analysis of gene expression, total RNA was extracted from dissected
E11.5 and E13.5 hearts. At E11.5, the hearts have just undergone looping, the endocardial
cushions are forming, the primary atrial septum and vestibular spine are developing, and
robust levels of CHD7 protein are seen. By E13.5, the chambers should be well formed and
septation almost complete, and whilst CHD7 levels are reduced, transcriptional changes
identified at this stage should still reflect earlier activity due to the epigenetic nature of
chromatin remodelling. Furthermore, at these stages there were no gross structural changes,
and embryos were not yet becoming necrotic, which would confound interpretation of the
microarray data. Therefore, examining transcriptional changes at these time points in
Chd7
fl/fl;Mesp1-Cre hearts should be informative for understanding the cardiovascular defects
in these hearts. Microarray analysis at two different stages would also give an indication of
whether gene expression changes caused by loss of CHD7 activity are transient or maintained.
For each time point, gene expression was compared in four biological replicates of
Chd7
fl/fl;Mesp1-Cre and Chd7
+/+;Mesp1-Cre hearts, bled out as much as possible following
dissection, which would contain cells predominantly derived from the Mesp1-lineage. The
quality of the RNA template for each sample was important to ensure successful hybridisation
onto the microarrays, so each sample was analysed spectrophotometrically and on an Agilent
2100 Bioanalyzer. Tables 5-1 and 5-2 summarise this quality control for each of the samples.
The RNA Integrity Number (RIN) calculated by the Bioanalyzer apparatus gives an overall
measure of the quality of the RNA (Schroeder et al., 2006). A value above 8 is considered
suitable for microarray applications. All of the RNA samples used for the microarray
experiments fulfilled this requirement, and many had a value over 9. This is reflected in the
electrophoretic traces for each sample, which show distinct 18S and 28S rRNA peaks with very
little background contamination (Figure 5-1).
The 260nm/280nm ratio generated by spectrophotometric analysis gives an indication of the
presence of protein, phenol or other contaminants, which absorb strongly at or near 280nm. A
ratio of close to 2.0 is desirable, as this indicates a high ratio of RNA (which absorbs at 260nm)
compared to contaminants. The E11.5 RNA samples all had 260/280 values very close to 2.0,
indicating very little contamination. The E13.5 samples were slightly more variable, but as the
RIN values were very high it was decided they should still be suitable for microarray analysis.139
Figure 5-1: Bioanalyzer traces for Chd7
+/+;Mesp1-Cre and Chd7
fl/fl;Mesp1-Cre RNA samples collected for microarray analysis
E11.5 (top panel) and E13.5 (bottom panel) RNA samples were run on RNA 6000 Pico Chips using an Agilent 2100 Bioanalyzer, which showed two distinct peaks corresponding to
18S and 28S rRNA, with little background contamination. Control samples are Chd7
+/+;Mesp1-Cre and mutant samples are Chd7
fl/fl;Mesp1-Cre.140
Table 5-1: Quality control parameters for E11.5 RNA samples
Genotype: Sample: RIN: 260/280: Concentration (ng µl
-1):
Chd7
+/+;Mesp1-Cre 1 8.8 2.02 118.4
2 8.5 2.06 83.2
3 8.2 2.07 78.4
4 8.9 1.98 83.4
Chd7
fl/fl;Mesp1-Cre 1 9.3 2.03 85.1
2 8.4 1.93 79.5
3 9.0 2.05 134.3
4 8.5 1.94 48.8
RIN is the RNA Integrity Number, 260/280 indicates the A260/A280 absorption ratio detected by
spectrophotometric analysis
Table 5-2: Quality control parameters for E13.5 RNA samples
Genotype: Sample: RIN: 260/280: Concentration (ng µl
-1):
Chd7
+/+;Mesp1-Cre 1 9.1 1.76 198.99
2 9.4 1.84 159.94
3 9.4 2.04 160.51
4 9.0 2.13 210.95
Chd7
fl/fl;Mesp1-Cre 1 9.5 1.78 130.36
2 9.5 2.06 128.55
3 9.4 1.41 112.55
4 9.2 1.96 137.63
RIN is the RNA Integrity Number, 260/280 indicates the A260/A280 absorption ratio detected by
spectrophotometric analysis
5.1.2 Differential gene expression in E11.5 and E13.5 hearts following mesodermal
ablation of Chd7
The RNA samples collected at E11.5 and E13.5 were reverse-transcribed and processed for
hybridisation onto GeneChip® Mouse Gene 1.0 ST Arrays by the UCL Genomics Service. The
array data for both time points passed the quality control criteria using both Affymetrix
Expression Console and Bioconductor. Data was normalised using an RMA normalisation
algorithm (Gautier et al., 2004), and analysis of differential gene expression performed using
the R package LIMMA (Smyth, 2004).
The fold change values for differences in gene expression between the Chd7
fl/fl;Mesp1-Cre and
Chd7
+/+;Mesp1-Cre groups were calculated on a binary logarithmic scale (log2FC), and initial p-141
values of significance calculated using a Bayes moderated t-test. Taking parameters of log2FC >
0.5 and p < 0.05, 338 genes were significantly downregulated and 281 genes upregulated at
E11.5 in Chd7
fl/fl;Mesp1-Cre hearts compared to control Chd7
+/+;Mesp1-Cre hearts. Fewer
genes showed altered expression at E13.5, with 142 genes downregulated and 125 genes
upregulated, which likely reflects the lower levels of CHD7 protein at this later time point. Both
time points showed more genes downregulated than upregulated. Of the genes with
expression changes at E11.5, 15% (91 genes) were also altered at E13.5 (Figure 5-2, panel A).
Lists of these up- and downregulated genes at each time point can be found in Appendix B.
Differentially-expressed genes were clustered based on their similarity of expression changes
following Chd7 ablation at both E11.5 and E13.5 (Figure 5-2, panel B). Gene ontology (GO)
analysis performed on the three resultant clusters highlighted a number of processes relevant
for cardiac development and the defects observed in Chd7
fl/fl;Mesp1-Cre embryos, including
neuron projection development, regulation of neurotransmitter levels, blood vessel
development, and regulation of muscle contraction (Figure 5-2, panel B). GO analysis will be
discussed further in section 5.1.4.
Although a moderated t-test was used to calculate the p-values for the differences in
expression for each gene, accounting to some extent for large sample sizes, with over 21,000
genes tested in the microarray there will still be a high occurrence of false positive results. This
is because the p-values (i.e. the probability that any difference in expression level between the
mutant and control is due to chance alone) are calculated independently for each individual
gene. Therefore, whilst for an individual gene a p value of 0.05 means there is a probability of
just 5% that a change from the control expression value is due to chance alone, as the sample
size increases the probability of genes being called significant by random chance also
increases. In order to reduce this false discovery rate, multiple testing correction was carried
out to adjust the individual p-values. The Benjamini and Hochberg False Discovery Rate was
used to calculate adjusted p-values, as this method provides a good balance between limiting
false positive occurences whilst not being so stringent as to prevent discovery of statistically
significant genes (Benjamini, 1995).
Following multiple testing correction, a list of four genes were found to be downregulated and
one gene upregulated in both the E11.5 and E13.5 datasets (Table 5-3). The gene with the
largest decrease in expression was Chd7, which validates the knockdown model. At E11.5 a
further 20 genes were downregulated and 13 upregulated (Table 5-4), whilst at E13.5 one
further gene was downregulated and two were upregulated (Table 5-5).142
Figure 5-2: Microarray analysis of gene expression at E11.5 and E13.5
(A) Bar graph showing the number of genes up- and down-regulated at E11.5 compared to E13.5 (p <
0.05, log2FC > 0.5). Fewer genes showed altered expression at E13.5, with 91 genes common to both
time points.
(B) Heat map to show clustering of dysregulated genes (p < 0.05, log2FC > 0.5) based on gene expression
changes. Selected GO terms for the three main clusters are highlighted.143
Table 5-3: Genes with significantly altered expression at both E11.5 and E13.5 following multiple testing correction
Ensembl ID: Symbol: Chrom: Description:
E11.5
log2FC
E11.5
adj.P.Value
E13.5
log2FC
E13.5
adj.P.Value
ENSMUSG00000041235 Chd7 4 chromodomain helicase DNA binding protein 7 -1.6829 0.0002 -1.5832 0.0005
ENSMUSG00000069171 Nr2f1 13 nuclear receptor subfamily 2, group F, member 1 -1.2412 0.0277 -1.4321 0.0366
ENSMUSG00000023964 Calcr 6 calcitonin receptor -1.0667 0.0548 -1.3886 0.0403
ENSMUSG00000028883 Sema3a 5
sema domain, immunoglobulin domain (Ig), short
basic domain, secreted, (semaphorin) 3A
-0.8941 0.0026 -0.7043 0.0437
ENSMUSG00000025196 Cpn1 19 carboxypeptidase N, polypeptide 1 1.4687 0.0085 1.9251 0.0040
Chrom indicates the chromosome on which the gene is found, and FC indicates fold change (this also applies for Tables 5-4 and 5-5).144
Table 5-4: Genes with altered expression at E11.5 following multiple testing correction
Ensembl ID: Symbol: Chrom: Description: Log2FC: adj.P.Val:
ENSMUSG00000026678 Rgs5 1
regulator of G-protein
signaling 5
-2.0388 0.0340
ENSMUSG00000019906 Lin7a 10
lin-7 homolog A (C.
elegans)
-1.5660 0.0179
ENSMUSG00000027463 Slc52a3 2
solute carrier protein
family 52, member 3
-1.3710 0.0287
ENSMUSG00000035551 Igfbpl1 4
insulin-like growth factor
binding protein-like 1
-1.3022 0.0009
ENSMUSG00000020061 Mybpc1 10
myosin binding protein
C, slow-type
-1.2496 0.0303
ENSMUSG00000024868 Dkk1 19
dickkopf homolog 1
(Xenopus laevis)
-1.2324 0.0127
ENSMUSG00000018893 Mb 15 Myoglobin -1.1955 0.0059
ENSMUSG00000025488 Cox8b 7
cytochrome c oxidase,
subunit VIIIb
-1.1717 0.0323
ENSMUSG00000019787 Trdn 10 triadin -1.0781 0.0024
ENSMUSG00000033737 Fndc3c1 X
fibronectin type III
domain containing 3C1
-1.0672 0.0354
ENSMUSG00000059742 Kcnh7 2
potassium voltage-gated
channel, subfamily H
(eag-related), member 7
-0.9919 0.0354
ENSMUSG00000031558 Slit2 5
slit homolog 2
(Drosophila)
-0.9871 0.0003
ENSMUSG00000074491 Clec4g 8
C-type lectin domain
family 4, member g
-0.9857 0.0203
ENSMUSG00000039579 Grin3a 4
glutamate receptor
ionotropic, NMDA3A
-0.9720 0.0024
ENSMUSG00000052516 Robo2 16
roundabout homolog 2
(Drosophila)
-0.9067 0.0201
ENSMUSG00000044067 Gpr22 12
G protein-coupled
receptor 22
-0.8386 0.0188
ENSMUSG00000073764 Gm12888 4 predicted gene 12888 -0.8374 0.0282
ENSMUSG00000007653 Gabrb2 11
gamma-aminobutyric
acid (GABA) A receptor,
subunit beta 2
-0.8214 0.0292
ENSMUSG00000023328 Ache 5 acetylcholinesterase -0.7994 0.0497
ENSMUSG00000039057 Myo16 8 myosin XVI -0.7174 0.0446
ENSMUSG00000029322 Plac8 5 placenta-specific 8 1.8213 0.0077
ENSMUSG00000027942
4933434E
20Rik
3
RIKEN cDNA 4933434E20
gene
1.7283 0.0396
ENSMUSG00000027861 Casq2 3 calsequestrin 2 1.6910 0.0003
ENSMUSG00000026471 Mr1 1
major histocompatibility
complex, class I-related
1.2335 0.0028
ENSMUSG00000022103 Gfra2 14
glial cell line derived
neurotrophic factor
family receptor alpha 2
1.1899 0.0108
ENSMUSG00000058952 Cfi 3
complement component
factor i
1.1009 0.0446
ENSMUSG00000053519 Kcnip1 11
Kv channel-interacting
protein 1
0.9434 0.0287145
ENSMUSG00000021219 Rgs6 12
regulator of G-protein
signaling 6
0.8952 0.0061
ENSMUSG00000070933 Speer4d 5
spermatogenesis
associated glutamate
(E)-rich protein 4d
0.8779 0.0445
ENSMUSG00000070867 Trabd2b 4 predicted gene 12824 0.8600 0.0048
ENSMUSG00000020427 Igfbp3 11
insulin-like growth factor
binding protein 3
0.8543 0.0453
ENSMUSG00000095241 Gm5478 15 0.7317 0.0322
ENSMUSG00000029309 Sparcl1 5 SPARC-like 1 0.7226 0.0433
Table 5-5: Genes with altered expression at E13.5 following multiple testing correction
Ensembl ID: Symbol: Chrom: Description: Log2FC: adj.P.Val:
ENSMUSG00000073007 Fam46d X
family with sequence
similarity 46, member D
-1.1136 0.0425
ENSMUSG00000069792 Wfdc17 11 predicted gene 11428 1.6059 0.0367
ENSMUSG00000055312
0610012H
03Rik
2
RIKEN cDNA
0610012H03 gene
0.9106 0.0273
5.1.3 qRT-PCR shows similar trends for dysregulated genes to the microarray datasets
To validate the microarray datasets, further samples of RNA were collected from dissected
Chd7
fl/fl;Mesp1-Cre and Chd7
+/+;Mesp1-Cre hearts at both E11.5 and E13.5. Again, RNA from 4
hearts for each genotype at each developmental stage were compared. Following reverse
transcription to cDNA, quantitative real-time PCR (qRT-PCR) analysis was performed on a panel
of 39 genes that were found to be differentially regulated in the microarray datasets, using
custom-designed TaqMan® Array Micro Fluidic Cards.
Figures 5-3 and 5-4 show the results of the qRT-PCR experiments alongside the log2FC values
calculated from the microarrays. Overall there was very good agreement between the trends
seen in up- or downregulation of each gene: at both time points the qRT-PCR data showed the
same direction of gene expression change for 33 out of the 39 genes tested. Using a null
hypothesis that there is no correlation between the microarray and qRT-PCR data, Chi-squared
analysis indicated that this is a highly significant level of correlation (p < 0.0001). At E11.5,
major differences in the direction of gene change were seen for Gabrb3, Myom2, Plxna2 and
Thbs2, whilst smaller changes (log2FC < 0.5 in both datasets) were seen for Hand1 and Slit3. At
E13.5, large changes were seen with Edn1, Myom2 and Slit3, and smaller changes with Kitl,
Nedd4l and Robo1. However, overall the strong agreement between log2FC values in both the
microarray and qRT-PCR datasets increases our confidence in the microarray experiments.146
Figure 5-3: Comparison of gene expression changes identified at E11.5 through microarray
and TaqMan qRT-PCR analysis
Calculated log2FC values from the microarray (red) and qRT-PCR (blue) experiments are shown for the
panel of genes tested, which are listed along the x-axis of the graph. Error bars are not included for
log2FC values, as comparison focussed on the direction of gene expression change.
Figure 5-4: Comparison of gene expression changes identified at E13.5 through Microarray
and TaqMan qRT-PCR analysis
Calculated log2FC values from the microarray (red) and qRT-PCR (blue) experiments are shown for the
panel of genes tested, which are listed along the x-axis of the graph. Error bars are not included for
log2FC values, as comparison focussed on the direction of gene expression change.147
5.1.4 GO term analysis reflects processes associated with heart development
To further elucidate pathways that could be disrupted in Chd7
fl/fl;Mesp1-Cre hearts, the 100
significantly-altered genes with the highest fold changes from each up- or downregulated list
from the microarrays was uploaded to the DAVID Bioinformatics resource for gene ontology
(GO) analysis (Huang et al., 2009). The resulting GO term clusters are shown in Tables 5-6 to 5-
9. This analysis highlighted a number of processes relevant for later cardiac development and
the defects observed in the Chd7
fl/fl;Mesp1-Cre hearts. Interestingly, many of the GO clusters
involved extracellular signalling pathways, rather than direct transcriptional regulators, such as
cell surface receptor linked signal transduction, G-protein coupled receptor signalling
pathways, Integrin-mediated signalling pathways, and negative regulation of signal
transduction.
A number of clusters were directly relevant for the innervation and coronary vein defects seen
in Chd7
fl/fl;Mesp1-Cre hearts, including neuron projection development, axonogenesis,
regulation of neuron differentiation, regulation of neurotransmitter levels, and blood vessel
development. These clusters contain many components of the Semaphorin and Slit-Robo
signalling pathways, which beyond their guidance roles in neuronal and vascular development
also have further key roles during heart development. In particular, Semaphorin 3C signalling is
crucial for OFT development (Feiner et al., 2001), whilst deletion of various combinations of
Slit and Robo genes leads to VSDs (Mathilda Mommersteeg, personal communication).
Furthermore, Sema3A, Slit2 and Robo2 were significantly downregulated following multiple
testing correction. These pathways were therefore selected for further investigation in
Chd7
fl/fl;Mesp1-Cre embryos (see sections 5.2 and 5.3).
Regulation of muscle contraction also appeared in the GO analysis of the clusters from the
heat map shown in Figure 5-2. Again, aberrant expression of Trdn and Casq2, which encode
key components at the sarcoplasmic reticulum for excitation-contraction coupling of
cardiomyocytes, was seen following multiple testing correction (Tables 5-3 and 5-4). A number
of further genes involved in calcium handling were also disrupted, so this was also investigated
further in Chd7
fl/fl;Mesp1-Cre cardiomyocytes (see section 5.4).
Whilst the microarray data and GO analysis suggested multiple relevant genes and pathways
for a number of the defects seen in Chd7
fl/fl;Mesp1-Cre hearts, they did not reveal expression
changes in genes with known roles in inflow tract development. This indicates that the
transcriptional changes underlying the lack of vestibular spine and DILVs seen in these hearts
occur earlier than E11.5. This will be addressed further in section 5.5.148
Table 5-6: GO Term Clusters for Genes Downregulated at E11.5 in Chd7
fl/fl;Mesp1-Cre Hearts
GO Term: Count: P Value: Genes:
Neuron projection development 5 0.022988 ROBO2, SEMA3A, LMX1A, GRIN3A, SLIT2
Leukocyte differentiation 4 0.033534 CALCR, IKZF1, MITF, IL15
Hemopoiesis 5 0.035969 CALCR, IKZF1, MITF, IL15, MB
Regulation of neurotransmitter
levels
3 0.037981 ACHE, SNAP25, LIN7A
Eye development 4 0.043124 ACHE, CHD7, IKZF1, MITF
Axonogenesis 4 0.047306 ROBO2, SEMA3A, LMX1A, SLIT2
Forebrain development 4 0.050202 DKK1, IKZF1, LMX1A, NR2F1
Hemopoietic or lymphoid organ
development
5 0.050824 CALCR, IKZF1, MITF, IL15, MB
Negative regulation of signal
transduction
4 0.053183 DKK1, RGS5, RGS18, FRZB
Brain development 5 0.054712 DKK1, IKZF1, ROBO2, LMX1A, NR2F1
Neuron projection
morphogenesis
4 0.057027 ROBO2, SEMA3A, LMX1A, SLIT2
Myeloid cell differentiation 3 0.082361 CALCR, MITF, MB
Cell morphogenesis involved in
differentiation
4 0.088384 ROBO2, SEMA3A, LMX1A, SLIT2
Lymph node development 2 0.090398 IKZF1, IL15
Regulation of neuron
differentiation
3 0.091322 ROBO2, SEMA3A, LMX1A149
Table 5-7: GO Term Clusters for Genes Upregulated at E11.5 in Chd7
fl/fl;Mesp1-Cre Hearts
GO Term: Count: P Value: Genes:
Tissue development 10 0.00112
SHOX2, ALDH1A2, ADM, RXFP1, HOXA5,
IRF6, EDN1, SPRR2B, MET, NR4A3
G-protein coupled receptor
signalling pathway
16 0.007626
RXFP1, PTH2R, OLFR538, OLFR1413,
EDN1, OLFR559, OLFR735, OLFR1309,
SSTR4, OLFR1042, OLFR1156, RGS6,
OLFR878, OLFR1126, OLFR429, OLFR366
Cell surface receptor linked
signal transduction
19 0.009247
PTH2R, RXFP1, OLFR538, OLFR1413, MET,
EDN1, OLFR559, OLFR735, OLFR1309,
SSTR4, SFRP5, OLFR1042, OLFR1156,
RGS6, OLFR1126, OLFR878, OLFR429,
GFRA2, OLFR366
Mesenchyme development 3 0.018267 ALDH1A2, HOXA5, EDN1
Epithelium development 5 0.025821 ALDH1A2, ADM, HOXA5, IRF6, SPRR2B
Sensory perception 12 0.026766
OLFR1042, OLFR1156, TRPM8, OLFR538,
OLFR1413, OLFR559, OLFR878, OLFR1126,
OLFR429, OLFR1309, OLFR735, OLFR366
Embryonic organ morphogenesis 4 0.029166 SHOX2, HOXA5, EDN1, NR4A3
Cartilage development 3 0.041613 SHOX2, HOXA5, EDN1
Gland development 4 0.048366 RXFP1, HOXA5, IRF6, MET
Myotube differentiation 2 0.048767 MET, MYH9
Mammary gland development 3 0.049603 RXFP1, IRF6, MET
Negative regulation of cell
proliferation
4 0.065965 IRF6, HMOX1, IGFBP3, ALOX8
Tissue morphogenesis 4 0.076102 ALDH1A2, ADM, HOXA5, NR4A3
Lung development 3 0.077653 ALDH1A2, RXFP1, HOXA5
Blood vessel development 4 0.080648 ALDH1A2, HMOX1, EDN1, MYH9150
Table 5-8: GO term Clusters for Genes Downregulated at E13.5 in Chd7
fl/fl;Mesp1-Cre Hearts
GO Term: Count: P Value: Genes:
Blood coagulation 6 3.07E-05 F2RL2, GP5, PLEK, P2RX1, TREML1, GP9
Platelet activation 3 0.003065 PLEK, P2RX1, TREML1
Cell surface receptor linked
signal transduction
23 0.006099
CALCR, F2RL2, GABRG3, ADAMTS19,
GABRA1, PLEK, GABRA4, FST, BEX1,
MSTN, RGS18, ITGB3, GPRC6A, OLFR173,
GPR22, FZD10, CHRM2, P2RY1, MTNR1B,
CNTN1, ANGPT1, ITGA2B, CLEC1B
Axonogenesis 5 0.010275 SLITRK3, ETV1, SEMA3A, NRN1, SLITRK5
Platelet degranulation 2 0.010403 PLEK, P2RX1
Cell morphogenesis in neuron
differentiation
5 0.014903 SLITRK3, ETV1, SEMA3A, NRN1, SLITRK5
Regulation of receptor recycling 2 0.025809 ACHE, GRIA2
Regulation of hair follicle
development
2 0.035948 INHBA, FST
Blood vessel development 5 0.038304 CHD7, MEOX2, PRRX1, SEMA3C, ANGPT1
Generation of neurons 7 0.044383
SLITRK3, BEX1, ETV1, SEMA3A, NRN1,
SLITRK5, NR2F1
Integrin-mediated signalling
pathway
3 0.059648 ADAMTS19, ITGB3, ITGA2B
Inorganic anion transport 3 0.069607 GABRG3, GABRA1, GABRA4
Blood vessel morphogenesis 4 0.084404 MEOX2, PRRX1, SEMA3C, ANGPT1
Branching in salivary gland
morphogenesis
2 0.089884 SEMA3C, SEMA3A
Positive regulation of ion
transport
2 0.099366 P2RX1, P2RY1
Blood coagulation 6 3.07E-05 F2RL2, GP5, PLEK, P2RX1, TREML1, GP9
Table 5-9: GO Term Clusters for Genes Upregulated at E13.5 in Chd7
fl/fl;Mesp1-Cre Hearts
GO Term: Count: P Value: Genes:
Unsaturated fatty acid metabolic
process
3 0.008325 EPHX2, ALOX8, MGST2151
5.2 Semaphorin Signalling
5.2.1 Roles of Class 3 Semaphorins during heart development
The Semaphorin family of glycoproteins can be divided into eight classes based on structural
similarities (Semaphorin Nomenclature Committee, 1999). All members share a highly
conserved 500 amino acid Sema domain near the N-terminus, which determines their binding
specificity and is essential for their signalling function (Gherardi et al., 2004). They were first
identified as axon guidance factors, which induce the collapse of neuronal growth cones
(Kolodkin et al., 1992; Luo et al., 1993). Many further roles for Semaphorin signalling have
since been discovered, including in angiogenesis, axon attraction and repulsion, immune
response, organogenesis, and tumour suppression and promotion (Roth et al., 2009; Staton,
2011; Takamatsu and Kumanogoh, 2012; Yazdani and Terman, 2006). The Class 3 Semaphorins
are the only soluble secreted Semaphorin proteins, the other classes being either
transmembranous or anchored to the membrane following glycophosphatidylinositol (GPI)
post-translational modification. There are seven members of the Class 3 Semaphorins, of
which both Semaphorin 3A and 3C are known to be important during cardiovascular
development.
Semaphorin 3A is a potent neural chemorepellant for sensory and sympathetic neurons
(Tanelian et al., 1997). Strong expression of Sema3a is seen in the cardiac ventricles at E12.0,
which then decreases with an inverse relationship to the increase in sympathetic innervation
as the heart develops (Ieda et al., 2007). Innervation patterning is disrupted in homozygous
null Sema3a
-/- mice leading to sinus bradycardia, so most Sema3a
-/- mice die within the first
postnatal week and only 20% survive until weaning (Taniguchi et al., 1997). Meanwhile,
transgenic mice with cardiac-specific overexpression of Sema3a, driven by the α-myosin heavy 
chain promoter, also displayed reduced sympathetic innervation and susceptibility to
ventricular tachycardia (Ieda et al., 2007). Therefore the correct levels of Sema3a expression
during heart development are essential for cardiac innervation and control of heart rate.
Semaphorin 3C is required for OFT development and aortic arch patterning: homozygous
ablation of Sema3c in mice results in a range of structural cardiac defects, including common
arterial trunk (CAT), interrupted aortic arch (predominantly type B, but also type C), VSD and
DORV (Feiner et al., 2001). Sema3c is expressed in the OFT and subpulmonary myocardium
between E10.5 and E12.5, during the key period of OFT septation and remodelling, as well as
in the condensed mesenchyme of the cardiac outflow tract, which is populated by NCCs
(Brown et al., 2001). Overlapping expression of Sema3C and the Semaphorin receptor PlexinA2152
is seen in cardiac NCCs, and in Sema3C
-/- mutant embryos PlexinA2 expressing cells are
abnormally patterned: they do not reach as far distally within the OFT mesenchyme, and do
not form the characteristic condensed clusters of mesenchyme (Brown et al., 2001). It is
therefore proposed that Semaphorin 3C/PlexinA2 signalling affects the migration and
positioning of NCCs in the OFT, contributing to the morphogenesis of the OFT and aortic arch
(Brown et al., 2001; Feiner et al., 2001). Both PlexinA2 expression in the cardiac neural crest
and Sema3C expression in neural crest and OFT myocardium are directly regulated by the
transcription factor GATA6, with mutations to GATA6 disrupting Semaphorin-Plexin signalling
and leading to OFT malformations (Kodo et al., 2009; Lepore et al., 2006).
Two further Semaphorin receptors have key roles during cardiovascular development,
PlexinD1 and Neuropilin-1. PlexinD1 and Npn-1 knock-out mutants show very similar OFT and
aortic arch defects to Sema3C mutant mice (Gitler et al., 2004; Gu et al., 2003), and a
combination of genetic and biochemical studies suggest that Semaphorin signalling to
PlexinD1-Neuropilin complexes in endothelial cells, in concert with Vegf/KDR/Neuropilin-1
paracrine signalling, is required for OFT septation and great vessel remodelling (Figure 5-5).
Figure 5-5: Model for integrated Semaphorin and VEGF signalling during cardiovascular
development
Neuropilin receptors (Npn-1 and Npn-2) form heterodimers with either PlexinD1 or the VEGF receptor
KDR in endothelial cells. OFT development requires signalling through these neuropilin-containing
complexes, mediated by both Vegf165/KDR and Sema3C/PlexinD1. Sema3A signalling via a Npn-1-
PlexinD1 receptor complex is also required for atrial development.
Figure from Gitler et al. (2004)153
5.2.2 Sema3A and Sema3C are downregulated in Chd7
fl/fl;Mesp1-Cre hearts
Table 5-10 shows the microarray results for Sema3A and Sema3C, showing significant
downregulation of both genes in Chd7
fl/fl;Mesp1-Cre hearts at E11.5 and E13.5. Sema3E was
also slightly upregulated at E13.5. qRT-PCR analysis confirmed reduction of expression of
Sema3C and Sema3A at both time points, and although calculation of p-values using the two-
tailed Student’s t-Test did not find significance for Sema3A at E11.5, the trend of
downregulation is still seen (Figure 5-6). The slight increase in Sema3E expression at E13.5 was
not seen in qRT-PCR dataset, and no change in expression was seen for the closely related
Sema3D gene either. Therefore, CHD7 activity appears to be specifically affecting the
Semaphorin 3A and 3C members of the Class 3 Semaphorin family, and is required for their
correct expression during heart development, although whether this regulation is direct or
indirect remains unclear.
Table 5-10: Microarray results for Semaphorin pathway genes
Symbol: Gene name:
E11.5
log2FC:
E11.5
P Value:
E13.5
log2FC:
E13.5
P Value:
Sema3A semaphorin 3A -0.89409 9.87E-07 -0.70435 1.63E-05
Sema3C semaphorin 3C -0.63997 0.001107 -0.65304 0.000936
Sema3E semaphorin 3E NS NS 0.554481 0.030159
NS indicates not significant
Figure 5-6: qRT-PCR analysis of Semaphorin gene expression in E11.5 and E13.5 hearts
Sema3A, Sema3C, Sema3D and Sema3E mRNA expression levels were compared in Chd7
+/+;Mesp1-Cre
(blue) and Chd7
fl/fl;Mesp1-Cre (red) hearts. Data were normalised to Gapdh expression, and Chd7
expression levels are shown to confirm its reduction in Chd7
fl/fl;Mesp1-Cre hearts. * p < 0.05, ** p < 0.01.154
5.2.3 Sema3A expression in the trabeculae is reduced after Chd7 ablation in the
mesoderm
The microarray and qRT-PCR experiments provide useful quantitative analysis for the levels of
mRNA expression of genes that potentially lie downstream of CHD7 activity in the heart.
However, they do not provide data on the specific location of the differentially-expressed
genes within the heart. This can also be informative, for example in identifying the specific cell
populations in which gene expression is affected. In situ hybridisation was therefore used to
compare a number of genes of interest from the microarrays, to look at their specific
expression in control Chd7
fl/fl and mutant Chd7
fl/fl;Mesp1-Cre hearts.
Figure 5-7 shows that Sema3A is expressed specifically in the trabeculae of E13.5 hearts, which
is consistent with previous reports (Ieda et al., 2007). Throughout the ventricles, this
trabecular expression was lost in Chd7
fl/fl;Mesp1-Cre hearts, confirming the microarray and
qRT-PCR data. Given the reported role of Sema3A in the sympathetic innervation of the heart
(Ieda et al., 2007), it may be that this downstream loss of Sema3A expression is contributing to
the innervation defects seen in Chd7
fl/fl;Mesp1-Cre hearts. Alternatively, given the location of
its expression, it may be influencing the trabeculation and compaction of the ventricles, which
are also affected in Chd7
fl/fl;Mesp1-Cre hearts.
Figure 5-7: Sema3A expression in the trabeculae is lost in Chd7
fl/fl;Mesp1-Cre hearts
Sema3A ISH revealed strong expression in the trabeculae of E13.5 Chd7
fl/fl control hearts (A and B),
whilst this expression was clearly reduced in Chd7
fl/fl;Mesp1-Cre hearts (red stars, A’ and B’). The two
panels (A,A’ and B,B’) are from two separate repeats of the ISH experiment.
Scale bars represent 0.2mm. Rv indicates right ventricle; lv, left ventricle.155
5.2.4 Expression of Sema3C is lost in the myocardial cuff of the distal OFT
ISH was also used to examine the expression of Sema3C in Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre
hearts (Figure 5-8). Sema3C was seen in the SHF-derived myocardial cuff of the OFT and in the
NCC population in the distal endocardial cushions in E11.5 Chd7
fl/fl hearts, again consistent
with previously published data (Brown et al., 2001). Interestingly, at the proximal end of the
OFT the expression of Sema3C appeared to be unchanged in Chd7
fl/fl;Mesp1-Cre hearts.
However, at the distal end of the OFT a striking reduction in Sema3C expression can be seen in
the myocardial cuff, indicating a spatial restriction on the region in which CHD7 activity affects
Sema3C transcription.
As previously discussed, Semaphorin 3C-PlexinA2 signalling between the myocardium and
migratory cardiac NCCs is crucial for OFT development, and when it is disrupted this results in
a range of overlapping defects with the Chd7
fl/fl;Mesp1-Cre mice, including CAT, DORV, IAA-B
and VSDs (Brown et al., 2001; Feiner et al., 2001). Furthermore, distal-proximal migration of
NCCs in the OFT appears to be abrogated in Chd7
fl/fl;Mesp1-Cre hearts, as shown by PlexinA2
ISH (see Figure 3-13), which is also noted in Sema3C
-/- embryos (Brown et al., 2001).
Downregulation of Sema3C expression in the distal OFT as a result of loss of CHD7 activity
therefore is likely to be contributing to the disruption to NCC migration in Chd7
fl/fl;Mesp1-Cre
OFTs, which leads to the overlapping structural defects.156
Figure 5-8: Sema3C expression is reduced specifically in the distal OFT
(A, B) Sema3C ISH on coronal sections through the distal OFT of an E11.5 Chd7
fl/fl embryos shows strong
expression in the myocardial cuff (blue arrows, A-A’’), as well as in NCCs in the cushions (white arrows).
In Chd7
fl/fl;Mesp1-Cre embryos, the myocardial cuff expression is almost entirely lost (red arrows, B-B’’),
whilst there is also some reduction in the NCC expression (white arrows).
(C, D) At the proximal end of the OFT, the myocardial expression of Sema3C appears the same in both
Chd7
fl/fl (blue arrows, C-C’) and Chd7
fl/fl;Mesp1-Cre (blue arrows, D-D’) hearts.
Scale bars represent 0.2mm. oft indicates outflow tract; rv, right ventricle; lv, left ventricle.157
5.2.5 Epistasis between Chd7 and Sema3C could not be detected in the mesoderm
To investigate further the link between Chd7 and Sema3C during OFT development, a
conditional Sema3C allele was utilised to look for genetic interaction between these genes.
Initially, heterozygous conditionally-ablated Chd7
fl/+;Sema3C
fl/+;Mesp1-Cre embryos were
generated. Neither Chd7
fl/+;Mesp1-Cre or Sema3C
fl/+;Mesp1-Cre embryos present with a
cardiac phenotype, so if any defects were seen in Chd7
fl/+;Sema3C
fl/+;Mesp1-Cre embryos this
would indicate a synergistic relationship between these genes. However, examination of
Chd7
fl/+;Sema3C
fl/+;Mesp1-Cre embryos at E13.5 (n=2) and at E15.5 (n=8) did not reveal any
cardiac defects (data not shown).
To increase the level of Chd7 ablation, the conditional Chd7
fl allele was replaced with the
Chd7
Whi allele, so offspring would be constitutively heterozygous for Chd7. Whilst
Sema3C
fl/+;Chd7
Whi/+; Mesp1-Cre embryos were difficult to generate due to the parent mice not
breeding well, five embryos of the required genotype were collected at E15.5. Just one of
these embryos showed a VSD, and no OFT or great vessel defects were seen (Figure 5-9).
However, the VSD can be attributed to the presence of Chd7
Whi allele, as a previous study
found 3 out of 5 Chd7
Whi/+ embryos examined showed a VSD (Bosman et al., 2005), so
additional cardiac defects would need to be seen to indicate that Sema3C and Chd7 are in
epistasis. Therefore, it seems that conditional ablation of Sema3C in the cardiogenic
mesoderm, even on a constitutively heterozygous Chd7 background, is not sufficient to show
an epistatic relationship between these genes.158
Figure 5-9: Lack of epistasis between Sema3C and Chd7
(A) H&E staining on transverse sections through E15.5 Sema3C
fl/+;Mesp1-Cre embryos (n=3) were
examined for cardiac defects, for comparison to Sema3C
fl/+;Chd7
Whi;Mesp1-Cre hearts. No embryos of
this genotype showed any abnormalities.
(B) Hearts of Sema3C
fl/+;Chd7
Whi/+ embryos (n=2) were also examined, which looked anatomically
normal. Although none were seen here, previous reports have shown VSDs are observed in Chd7
Whi/+
embryos.
(C-D) One Sema3C
fl/+;Chd7
Whi;Mesp1-Cre heart out of five showed a small VSD (blue arrow, C’), but was
otherwise normal.All other Sema3C
fl/+;Chd7
Whi;Mesp1-Cre hearts showed normal septation of the OFT
and cardiac chambers (D-D’).159
5.3 Slit-Robo Signalling
5.3.1 Slit-Robo signalling during cardiac development
The Slit-Robo pathway was originally described as an extracellular signalling guidance system
for axon pathfinding, promotion of axon branching and controlling neuronal migration (Brose
et al., 1999). The Robo proteins are transmembrane receptors with large extracellular domains
composed of immunoglobulin and fibronectin domains, whilst the Slit family act as ligands for
these receptors (Fujiwara et al., 2006). It is now known that these two protein families can
participate together in either repulsive or attractive signalling to a range of migrating cells,
including neurons, leukocytes and muscle precursor cells (Kramer et al., 2001; Rothberg et al.,
1988; Wu et al., 2001). Slit-Robo signalling is also now thought to be involved in signalling to
migrating endothelial cells, implicating a role in angiogenesis: Robo4 is found expressed at
sites of active angiogenesis (Huminiecki et al., 2002), with Slit2-Robo4 signalling thought to be
an inhibitory cell migratory signal (Park et al., 2003), whilst Slit3 promotes angiogenesis during
development (Zhang et al., 2009).
Several studies have highlighted roles for Slit-Robo signalling during early cardiac
morphogenesis in Drosophila. Slit and Robo proteins are found at the dorsal midline at the
time of linear tube formation by myocardial progenitors, and manipulation of localisation or
overexpression of Slit results in defective heart tube alignment and assembly (Qian et al.,
2005). Loss of Slit protein results in disruption to migration, cardiac cell alignment and cell-
polarity marker localisation in the myocardium, whilst Robo2 mutants show a similar
phenotype, with fewer migration defects (MacMullin and Jacobs, 2006). Furthermore, Slit-
Robo signalling is important for development of the cardiac lumen during early heart tube
formation: the lumen is created by the preferential attachment of the dorsal and ventral edges
of the pairs of cardiogenic progenitors either side of the dorsal midline, and Slit-Robo signalling
leads to the selected inhibition of E-cadherin adhesion in the central luminal domain (Medioni
et al., 2008; Santiago-Martinez et al., 2008).
In the mouse, Slit1, Slit2 and Slit3 are expressed in the heart and pharyngeal region during
development, along with Robo1 and Robo2 (Medioni et al., 2010). Slit2/3-Robo1/2 signalling
has been shown to regulate cardiac cushion formation, through its effects on Notch signalling
(Mathilda Mommersteeg, Weinstein conference 2014 abstract and personal communication).
Robo1 and Robo2, along with their ligands Slit2 and Slit3, are expressed in or adjacent to the
cardiac cushions. Robo1 knockout mice displayed membranous VSDs, and whilst knockout of
Robo2 did not result in similar defects, Robo1;Robo2 double mutants showed increased160
incidence and severity in VSDs. Slit3 mutants also showed VSDs, whilst Slit2 mutants showed
VSDs at E14.5 but these were all closed at E18.5. Furthermore, valve defects were observed in
Slit2, Slit3 and Robo1;Robo2 mutants. Downregulation of Notch and downstream Hey and Hes
genes was seen in Robo1 mutants, which have well established roles in the development of the
cardiac cushions and valves (Zhou and Liu, 2014). Slit-Robo signalling is also involved in
development of the pericardium, the sinus horn myocardium and alignment of the caval veins.
Loss of Slit3-Robo1 signalling causes impaired cardiac NCC survival, adhesion and migration,
leading to pericardial defects (Mommersteeg et al., 2013).
5.3.2 Slit2, Robo2 and Slitrks are downregulated following mesodermal Chd7 ablation
Significant downregulation of Robo2 and Slit2 were identified in the microarray experiment in
E11.5 Chd7
fl/fl;Mesp1-Cre hearts, and the downregulation of Slit2 continued at E13.5 (Table 5-
11). A number of Slitrk genes were also downregulated at E13.5. The Slitrk family of
transmembrane proteins (Slitrk1-6) all contain an extracellular domain with two lycine-rich
repeats (LRR) that are highly homologous to the LRR regions of Slit molecules (Aruga and
Mikoshiba, 2003). The Slitrks are expressed predominantly in neural tissues, and are thought
to function in the development of specific aspects of neuronal development (Beaubien and
Cloutier, 2009). This data suggests they may have a role in cardiac innervation, or an additional
different function in cardiovascular development.
qRT-PCR was again used to validate the aberrant gene expression of Slit-Robo pathway genes
at E11.5 and E13.5 (Figure 5-10). Significant downregulation of Robo2 was replicated at E11.5,
and it appeared to be reduced at E13.5 as well, although this did not reach significance.
Similarly, downregulation of Slit2 at both time points can be seen on the graphs, although
these did not quite reach significance (at E13.5, p = 0.57). Slitrk genes also showed reduced
expression in Chd7
fl/fl;Mesp1-Cre hearts, further validating their expression downstream of
CHD7 activity in the developing heart. It would have been interesting to examine the spatial
expression of some of these Slitrk genes in the developing heart by ISH, and to see if their
downregulation could be validated further. Unfortunately, however, attempts to generate
specific ISH probes for several Slitrk genes were unsuccessful, so this was not pursued further.161
Table 5-11: Microarray results for Slit-Robo pathway genes
Symbol: Gene name:
E11.5
log2FC
E11.5
P Value
E13.5
log2FC
E13.5
P Value
Robo2 roundabout homolog
2 (Drosophila)
-0.90673 2.38E-05 NS NS
Slit2 slit homolog 2
(Drosophila)
-0.98707 2.44E-08 -0.53024 4.66E-05
Slitrk3 SLIT and NTRK-like
family, member 3
NS NS -0.65121 0.018027
Slitrk4 SLIT and NTRK-like
family, member 4
NS NS -0.54174 0.01459
Slitrk5 SLIT and NTRK-like
family, member 5
NS NS -0.67045 1.35E-05
NS indicates not significant
Figure 5-10: qRT-PCR analysis of Slit-Robo gene expression in E11.5 and E13.5 hearts
Robo2, Slit2, Slitrk5 and Slitrk6 mRNA expression levels were compared in Chd7
+/+;Mesp1-Cre (blue) and
Chd7
fl/fl;Mesp1-Cre (red) hearts. Data were normalised to Gapdh expression, and Chd7 expression levels
are shown to confirm its reduction in Chd7
fl/fl;Mesp1-Cre hearts. * p < 0.05, ** p < 0.01.162
5.3.3 Slit2 and Robo2 are downregulated by ISH
At E8.5 and E9.5, Slit2 is expressed in the pharyngeal surface ectoderm, whilst at E12.5 it is
strongly expressed in the trabecular region of the ventricles (Medioni et al., 2010). Slit2
expression was compared by ISH in Chd7
fl/fl and Chd7
fl/fl;Mesp-Cre hearts at both E11.5 and
E13.5. At the earlier time point, no difference was seen in the weak Slit2 expression in the
trabeculae of Chd7
fl/fl and Chd7
fl/fl;Mesp-Cre hearts (Figure 5-11, panel A). However, at E13.5
much stronger expression was seen in Chd7
fl/fl hearts, again in the trabeculae, which was
strongly downregulated in Chd7
fl/fl;Mesp-Cre hearts (Figure 5-11, panel B). This indicates that
expression of the Slit2 ligand is disrupted following ablation of Chd7 in the cardiogenic
mesoderm.
Figure 5-11: Reduction in Slit2 expression is seen at E13.5
(A) Slit2 ISH on coronal sections through the heart at E11.5 show some trabecular expression in the
ventricular chambers (blue arrows), but there is no difference detected between the Chd7
fl/fl (A) and
Chd7
fl/fl;Mesp1-Cre hearts (A’).
(B) At E13.5, strong Slit2 expression is seen specifically in the trabeculae on transverse sections through
the heart (B), with downregulation in both the dominant left ventricle and under-developed right
ventricle of the Chd7
fl/fl;Mesp1-Cre heart (red stars, B’).
Scale bars represent 0.2mm. Oft indicates outflow tract; rv, right ventricle; lv, left ventricle.163
Previous studies have shown Robo2 is expressed at the venous pole of the linear heart tube at
E8.5, in both atria at E10.5, and in the aorta and pulmonary trunk at E12.5 (Medioni et al.,
2010). Consistent with this, at E11.5 Robo2 expression was clearly seen in the endocardial
cushions throughout the OFT in Chd7
fl/fl hearts, in a pattern that distally looks to be in the two
characteristic ‘prongs’ of cardiac NCCs, and becomes more diffuse throughout the cushions at
the proximal end of the OFT (Figure 5-12, A-F). However, whilst the more distal expression is
maintained in Chd7
fl/fl;Mesp1-Cre hearts, the expression throughout the cushions in the
proximal OFT is lost in mutant hearts (Figure 5-12, G-L). As with Sema3C, the region of Robo2
expression affected by Chd7 ablation is therefore restricted to a very distinct portion of the
OFT.
Figure 5-12: Robo2 expression is lost in the proximal OFT at E11.5
Robo2 ISH was performed on coronal sections through the hearts of E11.5 Chd7
fl/fl (A-F) and
Chd7
fl/fl;Mesp1-Cre (G-L) hearts. In Chd7
fl/fl hearts, expression is seen distally in two distinct ‘prongs’,
likely overlapping with NCCs (A,B). More proximally, it becomes more diffuse, and is seen in the
endocardial cushions as the OFT connects to the RV. In Chd7
fl/fl;Mesp1-Cre hearts, similar expression is
seen in the distal OFT (G-I), however at the distal end of the OFT the more diffuse Robo2 expression is
lost (J-L).
Scale bars represent 0.2mm.164
In order to confirm the specificity of CHD7 activity on individual Slit-Robo pathway genes,
Robo1 ISH was also performed on Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre E13.5 hearts, when it is seen
at the base of the great arteries, at the tip of the inter-ventricular septum, and around the AV
valves (Figure 5-13). This expression was not affected in the Chd7
fl/fl;Mesp1-Cre heart, which is
consistent with no significant change being seen in the microarray and qRT-PCR analysis.
Therefore, CHD7 activity lies upstream of the Robo2 and Slit2 expression in the developing
heart, but not other Slit-Robo genes such as Robo1.
Figure 5-13: Robo1 expression is unaffected in Chd7
fl/fl;Mesp1-Cre hearts
Transverse sections through E13.5 hearts showed Robo1 expression (blue arrows) at the base of the
great arteries, the tip of the interventricular septum and the AV valves in both Chd7
fl/fl (A) and
Chd7
fl/fl;Mesp1-Cre (B) hearts.
Scale bars represent 0.2mm. ao indicates aorta; pt, pulmonary trunk; rv, right ventricle; lv, left ventricle.165
5.4 Calcium Handling
5.4.1 The importance of calcium in cardiomyocyte function
In addition to the complex morphological events underlying structural development of the
heart, the ability of cardiomyocytes to undergo excitation-contraction coupling is essential for
cardiovascular function. This process links the electrical stimulation of cardiomyocytes to the
activation of myofilaments that cause contraction, so that cardiomyocyte contractions are
coordinated and the heart can act as an efficient pump (reviewed in (Bers, 2002)).
The ubiquitous messenger Ca
2+ is the key signalling molecule for this excitation-contraction
coupling. Figure 5-14 summarises the process. Briefly, during the cardiac action potential,
voltage-sensitive L-type Ca
2+ channels (LTCCs) are activated by the depolarisation of the
sarcolemmic membrane, producing a Ca
2+ current into the cardiomyocyte cytoplasm. This Ca
2+
influx triggers Ca
2+ release from the sarcoplasmic reticulum (SR), and the combination of these
two sources raises the intracellular Ca
2+ concentration sufficiently to bind to the myofilament
protein Troponin C. This binding activates the contractile machinery. For relaxation to occur,
Ca
2+ must dissociate from Troponin C, so the intracellular Ca
2+ concentration needs to be
rapidly reduced. This is achieved by the active transport of Ca
2+ out of the cytoplasm by the SR
Ca
2+-ATPase, which restores SR Ca
2+ levels, sarcolemmal Na
+/Ca
2+ exchange, sarcolemmal Ca
2+
ATPase or mitochondrial Ca
2+ uniport. These processes and transport systems are tightly inter-
linked and highly dynamic.
The release of calcium from the SR in response to the Ca
2+ influx – termed calcium-induced
calcium release (CICR) – provides a crucial functional link between the depolarisation of the
sarcolemmal membrane upon excitation and the contraction of the myofilaments. The SR Ca
2+-
release channel Ryanodine Receptor (RyR) is centrally involved in this process. The main RyR
isoform in cardiomyocytes is RyR2. RyRs form homotetrameric channels that sit within
complex macromolecular structures on the SR membrane, which contain multiple regulatory
components that affect RyR function (Bers, 2004). LTCCs and RyRs are organised into
structures known as Ca
2+-release units (CRUs). As well as an LTCC and RyR channel, CRUs also
contain the SR docking protein Junctophilin, the internal Ca
2+-binding protein Calsequestrin,
and Triadin and Junctin, which mediate the Calsequestrin-RyR interaction (reviewed in
(Wehrens et al., 2005)). When CICR or excitation-contraction coupling is disrupted, this leads
to contractile dysfunction and arrhythmias in many pathological conditions (Pogwizd et al.,
2001).166
Figure 5-14: Calcium signalling during cardiac excitation-contraction coupling
The key processes in excitation-contraction coupling all involve Ca
2+ movement and signalling, from the
initial Ca
2+ influx, calcium-induced calcium release at the SR, activation of myofilaments, and active
transport of intracellular Ca
2+ either back into the SR, out of the cell or into the mitochondria.
The inset shows the relationship between the time courses of an action potential (black line),
intracellular free Ca
2+ levels (blue line) and cardiomyocyte contraction (red dashed line) in a rabbit
ventricular cardiomyocyte at 37°C.
Figure from Bers (2002). NCX indicates Na
+/Ca
2+ exchange; ATP, ATP-ase; PLB, phospholamban; RyR,
ryanodine receptor; SR sarcoplasmic reticulum.
5.4.2 Calcium handling genes are dysregulated
The lists of microarray genes that were significantly dysregulated following multiple testing
correction (Table 5-3 and 5-4) contained both Trdn and Casq2, which encode the sarcoplasmic
reticulum (SR) membrane-associated proteins Triadin and Calsequestrin. Transcripts of further
genes, including the voltage-dependent calcium channels Cacng7, Cacna2d3 and Cacna1e,
were also affected (Table 5-12). These genes are all associated with Ca
2+ handling during
cardiomyocyte excitation-contraction coupling. At E13.5, a slight downregulation of Ryr3 was
also seen in the microarray data, which encodes the Ryanodine Receptor 3 (RyR3). Whilst RyR2
is the main isoform found in cardiac muscle, RyR3 is also weakly expressed in cardiac tissue
(Bers, 2004; Nakashima et al., 1997). qRT-PCR confirmed that both Ryr3 and Trdn were
downregulated in Chd7
fl/fl;Mesp1-Cre hearts at E11.5 and E13.5 (Figure 5-15).167
Table 5-12: Microarray results for genes associated with Ca
2+ handling
Symbol: Gene name:
E11.5
Log2FC:
E11.5
P Value:
E13.5
log2FC:
E13.5
P Value:
Cacna1e calcium channel,
voltage-dependent, R
type, alpha 1E subunit
-0.504 0.000393 NS NS
Cacna2d3 calcium channel,
voltage-dependent,
alpha2/delta subunit 3
-0.69777 0.004466 NS NS
Cacng7 calcium channel,
voltage-dependent,
gamma subunit 7
-0.60886 0.0016 NS NS
Casq2 calsequestrin 2 1.691003 1.98E-08 0.556697 0.003187
Trdn triadin -1.0781 6.84E-07 -0.8 2.28E-05
Ryr3 ryanodine receptor 3 NS NS -0.52855 0.000215
NS indicates not significant
Figure 5-15: qRT-PCR analysis of calcium handling genes in E11.5 and E13.5 hearts
Ryr3 and Trdn mRNA expression levels were compared in Chd7
+/+;Mesp1-Cre (blue) and Chd7
fl/fl;Mesp1-
Cre (red) hearts. Data were normalised to Gapdh expression, and Chd7 expression levels are shown to
confirm its reduction in Chd7
fl/fl;Mesp1-Cre hearts. * p < 0.05, ** p < 0.01.168
5.4.3 Culture of embryonic cardiomyocytes
To determine whether the transcriptional changes to Ca
2+ handling genes seen in
Chd7
fl/fl;Mesp1-Cre hearts resulted in any functional effect, a protocol was developed for live
imaging of Ca
2+ transients in embryonic cardiomyocytes. Cardiomyocytes were isolated from
E13.5 hearts, as more cardiomyocytes could be collected at this stage than at E11.5, but the
hearts were not yet becoming necrotic as they may have been by E15.5. Several methods were
tested for dissociating the cells of the dissected hearts, including incubation with Pancreatin,
Collagenase or Trypsin-EDTA at 37°C. Treatment with 0.05% Trypsin-EDTA containing 10µg ml
-1
DNase I was chosen, as this provided sufficient digestive activity for cells to be well dissociated
but was not too damaging to the resulting cardiomyocyte cultures. An additional step was
used whereby cells were plated for 1.5 hours to allow adherence of fibroblasts, which spread
and adhere faster than cardiomyocytes, before re-plating of the supernatant to enrich the
culture for cardiomyocytes. The full protocol can be found in the Experimental Procedures,
section 2.6.1.
Following overnight culture at 37°C, 5% CO2, cells could be seen beating in the culture dish.
Whilst this was already convincing evidence that these were successfully-isolated
cardiomyocytes, immunocytochemistry was also used to show expression of the cardiac
transcription factor NKX2-5 and the cardiac-specific myosin heavy-chain 6 in cultured
cardiomyocytes (Figure 5-16).
Figure 5-16: E13.5 embryonic cardiomyocytes
Immunocytochemistry showed cardiac-specific myosin heavy chain 6 (MHC6) and nuclear NKX2-5 levels
in isolated E13.5 cardiomyocytes from CD1 embryos.
Scale bars represent 0.1mm.169
5.4.4 Excitation-contraction coupling is defective in Chd7
fl/fl;Mesp1-Cre
cardiomyocytes
In order to visualise Ca
2+ transients in the cultured E13.5 cardiomyocytes, cells were loaded
with the calcium-sensitive fluorogenic dye Cal-520
TM, which fluoresces green when bound to
Ca
2+ (Kd 320nM). Live imaging using confocal microscopy meant cells that were producing Ca
2+
transients could be randomly selected for analysis, and these transients were recorded over
time by rapid line scan analysis.
Initial trials of this technique showed that whilst Ca
2+ transients could be recorded in both
control Chd7
fl/fl and mutant Chd7
fl/fl;Mesp1-Cre cardiomyocytes, there was a very high level of
variation in the frequency of the Ca
2+ transients between all cells, regardless of genotype. For
most cells the Ca
2+ peaks were unevenly paced across the 40 seconds they were measured,
such as the example in the top panel of Figure 5-17. This high variance would have made
analysis and identification of any difference in Chd7
fl/fl;Mesp1-Cre cardiomyocytes compared to
controls extremely difficult. Therefore, to overcome this issue, electrical pacing by field
stimulation at 1Hz was introduced, in order to regulate the Ca
2+ transients produced by
cardiomyocytes (Figure 5-17).
Figure 5-17: Cardiomyocytes could be paced by field stimulation
Rapid line scan analysis of Ca
2+ transients over 40s in individual cells showed irregular cardiomyocyte
contractions and high variation between all cells (top panel). Pacing of cells using electrical field
stimulation at 1Hz by platinum electrodes meant that Ca
2+ peaks could be regulated.170
Comparison of the response to electrical pacing by control Chd7
fl/fl or Chd7
fl/+ cells with
Chd7
fl/fl;Mesp1-Cre cardiomyocytes revealed a striking difference. 95% (n=22) of control
cardiomyocytes responded to electrical pacing with regular Ca
2+ transients recorded at the
expected 1s intervals, as seen in Figure 5-17. However, only 39% (n=23) of Chd7
fl/fl;Mesp1-Cre
cells could be paced in this way (p<0.0001, Figure 5-18). This indicates the excitation-
contraction coupling mechanism in cardiomyocytes is defective following ablation of Chd7 in
the cardiac mesoderm, which is likely due, at least in part, to the aberrant expression of Ca
2+
handling genes.
Figure 5-18: Excitation-contraction coupling is disrupted in Chd7
fl/fl;Mesp1-Cre
cardiomyocytes
(A) Comparison of 10 representative control Chd7
fl/+ or Chd7
fl/fl line scans (top panel) with
Chd7
fl/fl;Mesp1-Cre (bottom panel) showed a range of pacing defects in Chd7
fl/fl;Mesp1-Cre
cardiomyocytes. Only 1 control cell did not pace fully (far right, top panel).
(B) Significantly fewer Chd7
fl/fl;Mesp1-Cre cells responded to the electrical pacing compared to control
cells. *** p < 0.0001.171
5.5 Earlier transcriptional changes underlying the DILV phenotype
As previously mentioned, genes with known roles in early venous pole development were not
identified in the E11.5 and E13.5 microarray datasets. Whilst the microarrays carried out
provided much valuable information, with additional time and resources another microarray
experiment at E9.5 may have identified disrupted genes and pathways that are important for
AV canal septation and that may be contributing to the DILV phenotype see in Chd7
fl/fl;Mesp1-
Cre embryos. It was recently reported that BMP activity is abrogated in the AV canals of Chd7
-/-
mutant embryos around E10.0 (Liu et al., 2014). BMP signalling has a key role in development
of the vestibular spine (Briggs et al., 2013), so it is likely that this disruption to BMP activity in
the early heart tube following Chd7 ablation is contributing to the DILV defect seen in all
Chd7
fl/fl;Mesp1-Cre hearts.
To investigate further transcriptional changes that could also be affecting venous pole and
vestibular spine development, two candidate genes were also tested by ISH at E9.5. Tgfbr2 and
Wnt2 are both expressed in the early inflow tract, and their disruption during development
can lead to DILVs and septation defects of the AV canal (Bartram et al., 2001; Jiao et al., 2006;
Tian et al., 2010). However, preliminary ISH experiments indicated that there was no
difference in their cardiac expression between Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre embryos,
although quite a lot of background staining occured (Figure 5-19). This would indicate that
CHD7 activity does not lie upstream of Wnt2 or Tgfbr2 expression during inflow tract
development, although microarray or real-time data would be required to confirm this
proposal. Therefore, loss of BMP signalling following Chd7 ablation in the AV canal remains the
most likely reason for the DILV phenotype, as observed in Chd7
-/- hearts (Liu et al., 2014).172
Figure 5-19: Wnt2 and Tgfbr2 expression are not altered in E9.5 Chd7
fl/fl;Mesp1-Cre hearts
(A) Wholemount ISH on E9.5 embryos showed similar expression of Wnt2 in the sinus venosus and early
atrial chamber in both Chd7
fl/fl (A) and Chd7
fl/fl;Mesp1-Cre (A’) hearts, highlighted by blue arrows.
(B) Tgfbr2 ISH showed expression throughout the heart in both Chd7
fl/fl (B) and Chd7
fl/fl;Mesp1-Cre (B’)
hearts, again highlighted by blue arrows.
Scale bars represent 1mm. v indicates ventricle; a, atrium; sv, sinus venosus.173
5.6 Discussion
This chapter has addressed the transcriptional changes caused by loss of CHD7 activity in the
cardiogenic mesoderm, and linked them to the phenotypes seen in Chd7
fl/fl;Mesp1-Cre hearts.
Microarrays were performed at E11.5 and E13.5, when key septation events are taking place in
the developing heart, and differentially-expressed gene lists were analysed for over-
represented gene ontology (GO) terms. Many of these related to the structural, innervation
and vascular defects seen in Chd7
fl/fl;Mesp1-Cre hearts, including Class 3 Semaphorin and Slit-
Robo pathway genes. qRT-PCR and ISH were used to validate a selection of these genes, and
provide detailed spatial information on the cardiac regions in which CHD7 activity affects
expression of these genes. Furthermore, Ca
2+ handling genes with aberrant expression in the
microarrays were also validated, and this was demonstrated to affect the excitation-
contraction coupling function of Chd7
fl/fl;Mesp1-Cre cardiomyocytes.
5.6.1 Loss of CHD7 affects extracellular signalling pathways
Conditional ablation of Chd7 has allowed elucidation of some of the later genes affected by
CHD7 activity during cardiogenesis. Notably, these include many signalling and calcium
handling genes, as opposed to master-regulator transcription factors such as NKX2-5, which is
regulated in the early heart tube (Liu et al., 2014). This indicates a switch in the types of genes
CHD7 regulates as cardiogenesis progresses. Other signalling pathways have also been shown
to be affected by CHD7 activity: Chd7 haploinsufficiency results in reduced Fgf8 expression in
the isthmus organiser during early cerebellar development (Yu et al., 2013) and misexpression
of Bmp4 in the forebrain (Jiang et al., 2012). Furthermore, CHD7 directly regulates the retinoic
acid receptors Rarb and Rxrg in neural stem and progenitor cells, with cooperation between
CHD7 and retinoic acid signalling important for inner ear development (Micucci et al., 2014).
Multiple downregulated genes were identified in the E11.5 and E13.5 microarray datasets with
known signalling roles in ventricular septation, alignment and septation of the OFT, and great
vessel remodelling. Of these, further work focussed on components of the Semaphorin and
Slit-Robo extracellular signalling pathways. Semaphorin 3C, which was downregulated at both
time points, is a secreted glycoprotein that was proposed to act as a guidance molecule to
migratory NCCs expressing semaphorin receptors such as PlexinA2 (Brown et al., 2001; Feiner
et al., 2001). Sema3C
-/- mice have defects in the morphogenetic patterning of the aortic arch
and OFT, such as IAA-B, CAT and DORV (Feiner et al., 2001). It is therefore likely that
diminished Semaphorin 3C signalling contributes to the very similar defects seen in
Chd7
fl/fl;Mesp1-Cre and Chd7
Whi/fl;Mesp1-Cre hearts. Unpublished work on conditional Sema3C174
mutants in our lab has shown that Sema3C expression is required in both cardiac NCCs and in
the SHF-derived myocardial cuff for OFT septation, which signals to endothelial cells via Nrp1
receptors to promote endothelial-mesenchymal transitions for the formation of the OFT
endocardial cushions (Amelie Calmont and Catherine Roberts, personal communication). This
is consistent with the loss of Sema3C expression seen in the myocardial cuff of the OFT of
Chd7
fl/fl;Mesp1-Cre hearts contributing to the OFT defects seen in these hearts.
To test the hypothesis that the Chd7 and Sema3C genes epistatically interact in the cardiogenic
mesoderm, compound conditional heterozygotes were generated. It was disappointing that
these offspring did not exhibit any notable cardiac defects when examined at E13.5 or E15.5.
This could indicate that further genes important for OFT development are affected by the loss
of CHD7 and also contribute to the OFT defects observed in Chd7
fl/fl;Mesp1-Cre hearts, so
looking for epistasis with Sema3C alone was insufficient to reproduce defects. Alternatively, it
could be that the levels of ablation of Chd7 and Sema3C ablation in the models tested were
not efficient enough to produce an epistatic effect, although the use of the Chd7
Whi allele
should have reduced the possibility of this. Constitutively heterozygous Chd7
+/-;Sema3C
+/-
mutants are now being generated to see if extending the knockdown of both genes to multiple
tissues will produce an epistatic effect, either on OFT development or great vessel remodelling,
as it is clear that Sema3C expression is affected by the loss of CHD7 activity.
Sema3A was also downregulated following mesodermal Chd7 ablation, with ISH showing its
trabecular expression was clearly reduced in Chd7
fl/fl;Mesp1-Cre hearts. Sema3A has a well-
characterised role in the regulation of sympathetic innervation of the heart, which is crucial for
the maintenance of a normal heart rhythm. The developing heart is extremely sensitive to
Sema3A dosage: transgenic mice with cardiac-specific Sema3A overexpression demonstrate
sudden death and susceptibility to ventricular tachycardia, whilst Sema3A
-/- mice show sinus
bradycardia, right ventricular hypertrophy and a dilated right atrium, and usually die before P7
(Behar et al., 1996; Ieda et al., 2007; Taniguchi et al., 1997). Therefore, loss of Sema3A
expression very likely underlies the sympathetic cardiac innervation defects seen in
Chd7
fl/fl;Mesp1-Cre hearts.
Loss-of-function mutations of SEMA3A are associated with human Kallmann syndrome
(Hanchate et al., 2012), a disorder characterised by defects overlapping with CHARGE. Non-
synonymous SEMA3A variations have been found in 3 of 45 CHD7-negative CHARGE patients,
and Sema3A expression is lost after morpholino-knockdown of Chd7 in Xenopus (Schulz et al.,
2014b). Hypomorphic mutation of SEMA3A has also been reported in a patient with short
stature, thoracic abnormalities, and a small self-healing atrial septal defect (Hofmann et al.,175
2013). This work therefore strengthens the link between CHD7 and SEMA3A and indicates it is
relevant in the context of heart development. Furthermore, it is in agreement with and
extends a recent report that Sema3A and Sema3C have diminished expression in whole E9.5
Chd7
-/- embryos (Schulz et al., 2014b).
The Slit-Robo pathway is important for endocardial cushion formation and ventricular
septation, with membranous VSDs observed at E14.5 in Slit2, Slit3, Robo1 and Robo1;Robo2
mutant mice (Mathilda Mommersteeg, personal communication). Downregulation of Slit2 and
Robo2 expression is therefore likely to be contributing to the septation defects observed in the
conditional Chd7 mutant embryos. Slit-Robo signalling to endothelial cells is also implicated in
vascular development (Park et al., 2003; Zhang et al., 2009). Therefore, the observation of
truncated coronary veins after mesodermal, but not endothelial, ablation of Chd7 may at least
in part also be attributed to downregulation of Slit-Robo signalling from cardiomyocytes to
migratory endothelial cells. Furthermore, Class 3 Semaphorins and Slit-Robo signalling have
been shown to act together for directional control of neuronal migration, in the context of
both ventral forebrain and corneal innervation (Hernandez-Miranda et al., 2011; Kubilus and
Linsenmayer, 2010). The compound effect of disruption to components of both pathways
could therefore contribute to the innervation defects present in Chd7
fl/fl;Mesp1-Cre hearts.
Given the highly-penetrant haemorrhagic phenotype in Chd7
fl/fl;Mesp1Cre embryos and the
disruption to coronary vessel development, it was interesting to see not only Slit-Robo genes
dysregulated, but other factors associated with angiogenesis. Angiopoietin-1, which is
downregulated in the E11.5 and E13.5 microarray datasets, is a secreted glycoprotein growth
factor and a key regulator of blood vessel development, along with its receptor Tie2: Angpt-1
-/-
and Tie2
-/- mice show early embryonic lethality due to severe vascular defects (Sato et al.,
1995; Suri et al., 1996). Cardiomyocyte-specific deletion using Nkx2.5Cre also results in
embryonic lethality and almost identical phenotype, with vascular remodelling defects seen
from E10.5 occurring secondary to cardiac trabeculation defects observed from E9.5, indicating
that the vascular abnormalities may be caused by abnormal flow and hemodynamics (Jeansson
et al., 2011). Although the phenotypes seen in these knockout studies occur earlier in
development than the vascular defects seen in Chd7
fl/fl;Mesp1Cre mice, this could be due to a
dosage effect, with a smaller reduction in Angpt-1 expression when CHD7 activity is lost
compared to its complete ablation in knockout mice. Poor trabeculation and myocardial
compaction is also seen in Chd7
fl/fl;Mesp1Cre hearts, so loss of Angiopoietin-1 signalling may be
contributing to this. Similarly, the endogenous inhibitor of angiogenesis Thrombospondin-2
(Streit et al., 1999) is upregulated in the Chd7
fl/fl;Mesp1Cre hearts, so disruption to a176
combination of vascular development genes may be affecting the development of the
coronary vasculature.
Finally, consistent with the loss of innervation of Chd7
fl/fl;Mesp1-Cre hearts, a large number of
genes associated with neuronal function were also downregulated in Chd7
fl/fl;Mesp1-Cre
hearts. Multiple genes for subunits of the GABA A receptor, a chloride channel that mediates
inhibitory synaptic transmission, were all downregulated in mutant hearts. This included
Gabrb2, which was significantly downregulated following multiple testing correction at both
E11.5 and E13.5. Ache also passed multiple testing correction at E11.5, which encodes
acetylcholinesterase, a hydrolase for the synaptic junction neurotransmitter acetylcholine.
Many ion channels associated with propagation of electrical signals in neuronal axons were
also seen in the lists of downregulated genes. The cardiac sympathetic neurons are derived
from the cardiac neural crest (Hasan, 2013), so will not have Cre-driven Chd7 ablation in
Chd7
fl/fl;Mesp1-Cre embryos. The reduction of mRNA transcripts for these genes seen in the
microarrays is therefore most likely reflecting the absence of neuronal axons in Chd7
fl/fl;Mesp1-
Cre hearts, which would usually be expressing these genes, rather than a role for CHD7 in the
transcriptional regulation of these genes.
5.6.2 Direct regulation of Sema3C expression in vivo
The microarray datasets have provided interesting insights into the pathways disrupted in
Chd7
fl/fl;Mesp1-Cre hearts, which can be linked with the defects observed. However, the direct
targets of CHD7 in the cardiogenic mesoderm still cannot be determined: the differentially-
expressed genes identified in the microarrays may be CHD7 targets, with CHD7 binding at their
enhancer or promoter regions for direct transcriptional regulation through chromatin
remodelling activity, or they may be downstream effects of other CHD7-DNA binding events.
Interrogation of CHD7 occupancy across the genome by chromatin immunoprecipitation (ChIP)
followed by high-throughput DNA sequencing (ChIP-seq) would be extremely informative for
addressing this issue. CHD7 binding sites in the heart at E11.5 and E13.5 could be compared to
the genes with aberrant expression in Chd7
fl/fl;Mesp1-Cre hearts. Unfortunately, despite the
use of several antibodies, attempts at genome-wide ChIP-seq by other lab members have not
produced an adequate signal-to-noise ratio, either in vitro or in vivo. This is discussed further in
section 6.2.1. However, using chromatin extracted from CD1 E11.5 hearts, it was possible to
perform a ChIP experiment followed by qRT-PCR (ChIP-PCR) to show that CHD7 is located
specifically at the promoter of Sema3C. Primer pairs were designed along the Sema3C locus to
overlap with areas of DNase I hypersensitivity and histone modification marks associated with177
suspected promoter and enhancer regions, based on ENCODE datasets (Figure 5-20, panel A).
Enrichment for CHD7 was seen specifically at the promoter region of Sema3C (Figure 5-20,
panel B).
Furthermore, DNase I hypersensitivity assays were designed to test the accessibility of this
region of DNA, giving a readout of chromatin remodelling activity. Sensitivity to increasing
concentrations of DNase I was significantly reduced in Chd7
fl/fl;Mesp1-Cre samples compared
to control Chd7
fl/fl samples (Figure 5-20, panel C). The promoters of Gapdh and Nanog were
largely unchanged, with the former demonstrating a greater overall level of hypersensitivity
(as a reflection of “housekeeping” gene expression). This assay indicates that DNA proximal to
the Sema3C promoter is in a more condensed conformation when CHD7 activity is abolished.
This is consistent with the loss of Sema3C expression in the distal OFT of Chd7
fl/fl;Mesp1-Cre
hearts. We therefore propose that CHD7 localises to the Sema3C promoter during OFT
development, where it functions in remodelling the chromatin to ensure transcriptional
machinery accessibility.
Figure 5-20: CHD7 localises to the Sema3C promoter in vivo
(A) ENCODE data around the Sema3c locus was used to design primer sets (denoted in red) around
potential enhancer and known promoter sites.
(B) ChIP-PCR demonstrated CHD7 binding around the promoter using Primer 1.
(C) DNase hypersensitivity assay showed greater chromatin compaction in Chd7
fl/fl;Mesp1-Cre hearts
(dotted line) than littermate controls (solid line) at the Sema3c promoter. Little change was seen at
the Gapdh or Nanog promoters, although Gapdh displayed greater hypersensitivity, correlating with its
constitutive expression. Individual replicates are shown, due to extreme biological variability.
Figure taken from manuscript by Payne et al. (submitted to Circulation Research), experiments carried
out by Matthew Burney and included with his permission.178
5.6.3 CHD7 activity impacts on excitation-contraction coupling
Following mesodermal ablation of Chd7, gene expression alterations were also detected that
are associated with Ca
2+ signalling, resulting in functional defects in the ability of embryonic
cardiomyocytes to respond to electrical pacing in vitro. This indicated a failure of the key
process of excitation-contraction coupling. The developing mouse heart beats from about E8.5,
and it is uncertain whether membrane voltage-activated Ca
2+ channels or spontaneous Ca
2+
release from SR stores in cardiomyocytes drives this process (Rapila et al., 2008). Either way,
genes encoding both Ca
2+ channels and key components involved in Ca
2+-induced Ca
2+ release
(CICR) from the SR were dysregulated in Chd7
fl/fl;Mesp1-Cre hearts. The loss of coordinated
excitation-contraction coupling is therefore likely a contributing cause of the cardiac failure
leading to the severe oedema seen in Chd7
fl/fl;Mesp1-Cre embryos and embryonic lethality.
This oedema was not seen in Tie2-Cre embryos and is therefore not likely to be secondary to a
role for CHD7 in vascular endothelial cells. Furthermore, it is becoming evident that
coordinated Ca
2+ release is itself an important factor in regulating cardiac morphogenesis, for
example through secretion of signalling molecules and force generation (Puceat and Jaconi,
2005). Therefore, the disruption to Ca
2+ handling may have relevance for the structural
malformations observed in Chd7
fl/fl;Mesp1-Cre mice.
The low expression of L-type voltage-dependent Ca
2+ channels in Chd7
fl/fl;Mesp1-Cre
cardiomyocytes likely results in the inability to generate a sufficient Ca
2+ influx at the
sarcolemmal membrane in response to electrical excitation. This would lead to the observed
phenotype in which immature Chd7
fl/fl;Mesp1-Cre cardiomyocytes could not be fully paced by
electrical field stimulation. Whilst some mutant cardiomyocytes did not appear to respond at
all to the electrical pacing, continuing to show apparently random Ca
2+ transient peaks, many
appeared to respond to alternate electrical stimuli – i.e. peaks were seen every 2 seconds
instead of every second- for at least some of the period of observation (see bottom panel,
Figure 5-18). This would be consistent with a situation in which two membrane depolarisations
are required for sufficient Ca
2+ current into the cell to raise the intracellular Ca
2+ to a level to
trigger CICR from the SR stores. The variation between the severity of the phenotype between
Chd7
fl/fl;Mesp1-Cre cardiomyocytes probably reflects varying levels of reduction of gene
expression between cells, as well as the presence of cardiomyocytes of varying maturity within
the population of isolated cells. It is possible that the overall population of Chd7
fl/fl;Mesp1-Cre
cardiomyocytes was less developmentally mature than the Chd7
fl/fl controls, which could also
explain the differences in excitation-contraction coupling, but if so then the disruption to the
Ca
2+ handling genes would still likely be involved in this maturity delay.179
Figure 5-21: The cardiac Ryanodine Receptor structure at the SR membrane
The Ryanodine Receptor is shown at the SR membrane with six predicted transmembrane regions and a
large cytoplasmic domain. It is associated at the SR membrane with both Triadin and Junctin, and the SR
protein Calsequestrin. Phosphorylation sites and sites of interaction with ancillary proteins in the
cytoplasmic domain are also shown.
Figure from Priori and Napolitano (2005). PP indicates protein phosphatase; P, phosphorylation site;
CaM, Calmodulin; CaMKII, Calmodulin-dependent protein kinase II.
Transcripts for key SR proteins involved in CICR were also dysregulated, which would
exacerbate the disruption to excitation-contraction coupling. At the SR membrane,
Calsequestrin 2, Triadin and Junction form a complex that helps regulate SR Ca
2+ release
through interactions with the cardiac Ryanodine Receptor (RyR) 2 channel (see Figure 5-21)
(Zhang et al., 1997). Calsequestrin 2 and Triadin transcripts were aberrantly expressed in
Chd7
fl/fl;Mesp1-Cre hearts, along with RyR3. Mutations to Casq2 and Trdn are both associated
with inherited arrhythmogenic diseases, showing their importance for excitation-contraction
coupling (Lahat et al., 2001; Roux-Buisson et al., 2012). Furthermore, Triadin has been shown
to have an additional role in maintaining the structural integrity of the cardiac calcium release
unit (CRU), with its ablation leading to impaired excitation-contraction coupling (Chopra et al.,
2009). Downregulation of these genes in Chd7
fl/fl;Mesp1-Cre hearts is therefore also likely
making a significant contribution to the observed Ca
2+ handling defect.
This work has identified a novel role for CHD7 activity upstream of the expression of multiple
components critical for the coordinated excitability of cardiomyocytes. To the author’s
knowledge, dysregulation of these components has not been remarked upon in any other
transcriptomics analysis of hearts mutant for chromatin regulators. Interestingly, however,180
embryos mutant for the splicing regulator SRp38 also show disruption to Triadin and
Calsequestrin 2 expression, leading to cardiac defects and abnormal Ca
2+ release from the SR
(Feng et al., 2009). This was shown to be due to altered splicing of Triadin pre-mRNAs in the
absence of SRp38. Ca
2+ transients were examined in similar primary cultures of embryonic
cardiomyocytes from E14.5 hearts, although this analysis focussed on the properties of the
Ca
2+ sparks, which are the elementary Ca
2+ release events from the SR that underlie excitation-
contraction coupling (Cheng et al., 1993). Spark frequency was significantly increased in SRp38
-
/- cardiomyocytes compared to wild-type controls, whilst the amplitude was reduced,
demonstrating disruption to the Ca
2+ handing at the SR. It would have been interesting to look
at Ca
2+ sparks in the Chd7
fl/fl;Mesp1-Cre cardiomyocytes as well, to see if a similar disruption
could be detected: Ca
2+ sparks were noted in both Chd7
fl/fl and Chd7
fl/fl;Mesp1-Cre cells, but no
quantitative analysis was carried out to compare their frequency between genotypes. Cardiac
defects were also noted in SRp38
-/- embryos, including severe oedema, thin and disorganised
myocardial walls, and AVSDs, which are markedly similar to those seen in Chd7
fl/fl;Mesp1-Cre
cells. This again supports the hypothesis that the disruption to Ca
2+ handling and the
coordination of cardiomyocyte contractions contributes to the structural malformations seen
in Chd7
fl/fl;Mesp1-Cre mice.
5.6.4 Disruption to NKX2.5 activity and BMP signalling likely underlies the DILV
phenotype
CHD7 has previously been shown to interact with BMP-activated SMAD1/5/8 during early
cardiogenesis, to regulate directly the cardiac differentiation marker Nkx2.5 (Liu et al., 2014).
BMP activity was abrogated in the AV canals of Chd7 mutant embryos around E10.0, leading to
reduced myocardial proliferation and defective cushion formation. BMP signalling is vital for
development of the vestibular spine and AV septation: conditional deletion of the BMP
receptor Alk3 in the SHF leads to impaired formation of the vestibular spine and ostium
primum defects, caused by a lack of expansion of the SHF-derived vestibular spine population
at the venous pole (Briggs et al., 2013). Disruption to NKX2-5-mediated BMP signalling in the
early heart tube following Chd7 ablation therefore offers a likely molecular basis for the
common AV valves and DILVs seen in Chd7
fl/fl;Mesp1-Cre hearts. However, aberrant expression
of Nkx2.5 was not identified in the E11.5 and E13.5 microarrays, although it is known to still be
expressed in the atrial and ventricular chambers at E12.5 (Lints et al., 1993), so it seems that
later in cardiac development CHD7 no longer regulates Nkx2.5 expression.181
Other pathways at E9.5 with known roles in venous pole development were also examined.
TGFβ signalling is important for endocardial cushion development and myocardialisation of the 
developing heart (Azhar et al., 2003). Endocardial inactivation of the Tgfbr2 receptor provides
a model for DILV (Jiao et al., 2006), whilst homozygous mutation of Tgfb2 can result in DILV
and AVSDs (Bartram et al., 2001). Wnt2 expression in the posterior second heart field is also
crucial for correct development of the inflow tract, with Wnt2
-/- mutants also displaying AVSDs
(Tian et al., 2010). However, neither Tgfbr2 or Wnt2 expression was affected at E9.5,
indicating that disruption to BMP signalling, as described by Liu and colleagues, is most likely
the major contributor to the venous pole component of the Chd7
fl/fl;Mesp1-Cre cardiac
phenotype.
It would be useful to perform genome-wide transcriptional analysis at E9.5, to confirm that
BMP signalling is disrupted, as well as to identify any additional pathways or transcription
factors that lie downstream of CHD7 activity in the early heart tube. It would be preferable to
use RNA-sequencing (RNA-Seq) technology for transcriptome profiling of Chd7
fl/fl and
Chd7
fl/fl;Mesp1-Cre hearts. RNA-Seq uses deep-sequencing technology rather than the
hybridisation methods used in the DNA microarray. A population of RNA molecules can be
converted to a library of cDNA fragments that have adaptors added to one or both ends, and
then each individual molecule is sequenced and compared to a reference genome. The result is
a genome-scale transcriptional map with information on both transcriptional structure and the
level of expression for each gene, which has less background signal and a much higher dynamic
range compared with DNA microarray (Wang et al., 2009). Furthermore, the bias caused by
probe specificity and binding strength during hybridisation in microarrays is not an issue with
RNA-seq, and it is able to measure non-coding RNAs. At the time of performing the E11.5 and
E13.5 microarrays presented here, protocols for the analysis of microarray datasets were
better established than for RNA-Seq datasets. However, better tools and standardised
protocols are now available for this analysis (Anders et al., 2013; Luo and Brouwer, 2013;
Ramsköld, 2012).
Overall, this chapter has shown genome-wide analysis of differential transcription in
Chd7
fl/fl;Mesp1-Cre hearts at two developmental time points. Of particular interest, Slit-Robo
and Semaphorin extracellular signalling pathway genes with known roles in heart development
were found to be aberrantly expressed, and were validated further. Functional analysis of Ca
2+
transients in Chd7
fl/fl;Mesp1-Cre cardiomyocytes was also performed, showing that differential
expression of Ca
2+ handling genes affects the excitation-contraction coupling capability of
mutant cardiomyocytes. Together, these gene expression changes correlate well with the
cardiac malformations seen in Chd7
fl/fl;Mesp1-Cre hearts.182
CHAPTER SIX
OVERALL DISCUSSION AND FUTURE WORK
6.1 Final discussion and conclusions
Chromatin remodelling allows the dynamic regulation of gene expression programmes, which
is required for the complex morphological changes that occur with both temporal and spatial
precision in the developing heart. The ATP-dependent chromatin remodeller CHD7 has been
shown here to be present throughout the early heart until around E13.5, with its activity in the
cardiogenic mesoderm crucial for formation of cardiac structures, heart function, and
embryonic survival. CHD7 activity affects transcription of a large number of genes instrumental
for cardiovascular development, including components of the Slit-Robo and Semaphorin
signalling pathways and the excitation-contraction coupling machinery. Thus, it is clear that
transcriptional regulation by CHD7 in the cardiogenic mesoderm and its derivatives is crucial
during heart development.
Correct alignment and septation of the developing cardiac components ensures the complete
separation of the pulmonary and systemic circulations, which is vital for effective
cardiovascular function. Mesodermal Mesp1-Cre-driven deletion of Chd7 produced a serious
defect combining DILV and DORV with spiralling arterial trunks. This is analogous to the
“Holmes heart” seen in humans, although in the heart initially described by Holmes the
ventriculo-arterial trunks, whilst spiralling, were concordantly connected in the heart (Dobell
and Van Praagh, 1996). Common AV junction, caused at least in part by failure of the
formation of the vestibular spine and disorganisation of the AV endocardial cushions, and
great vessel defects were also frequently observed. Many of these defects had not been
previously described in Chd7 mutant mice due to the p53-dependent severe growth delay
observed in constitutive mutants (Van Nostrand et al., 2014). This bypass of early lethality
through the use of conditional Chd7 ablation has therefore allowed the exploration of more
specific effects on heart development. Furthermore, the cardiovascular defects described in
Chd7
fl/fl;Mesp1-Cre embryos correlate well with the malformations seen in CHARGE patients, in
which AVSDs and OFT defects are common (Corsten-Janssen et al., 2013a), supporting the
importance of CHD7 activity in the cardiogenic mesoderm.
Investigation into other conditional Chd7 mutants, driven by Nkx2.5-Cre, Mef2c-Cre and Tie2-
Cre, demonstrated a requirement for Chd7 activity in multiple lineages within the cardiogenic183
mesoderm. Each cross resulted in a milder subset of the cardiac defects observed after
mesodermal ablation, with varying severity and penetrance. Chd7
fl/fl;Nkx2.5-Cre embryos
showed the most similar cardiac defects to Chd7
fl/fl;Mesp1-Cre embryos, which was reflected in
the perinatal lethality for this genotype. However, it appears ablation in both endocardial and
myocardial precursors is required to produce the characteristic combination of DORV and DILV
seen in Chd7
fl/fl;Mesp1-Cre embryos. Meanwhile, the interrupted aortic arch phenotype can be
attributed to loss of CHD7 activity in the anterior SHF, as Chd7
fl/fl;Mef2c-Cre recapitulated the
great vessel defects. This requirement for Chd7 in multiple lineages derived from Mesp1-
expressing progenitors is consistent both with the presence of CHD7 throughout the
developing heart until E13.5, and with the range of cardiovascular defects observed in
Chd7
fl/fl;Mesp1-Cre embryos affecting structures derived from various cardiac tissues.
Datasets generated by microarray experiments showed aberrant expression of a large number
of genes in the heart following ablation of Chd7 in the cardiogenic mesoderm. This is
consistent with previous reports that CHD7 acts as a ‘transcriptional rheostat’ to modulate the
expression of its target genes in either a positive or negative direction (Schnetz et al., 2010).
Downregulation of Sema3C in the distal OFT of Chd7
fl/fl;Mesp1-Cre hearts is likely contributing
to the alignment and septation defects observed at the arterial pole, whilst loss of Sema3A in
the trabeculae may be contributing to the severe truncation of sympathetic neurons seen on
the dorsal side of these hearts or to the thin myocardial walls. Disruption to the Slit-Robo
pathway may also be exacerbating this innervation defect, as well as contributing to the
endocardial cushion defects, which are linked to the septation defects observed. Extracellular
signalling is vital during development for cells to communicate and direct key processes such
as migration, differentiation, proliferation or apoptosis, so it is unsurprising that loss of key
extracellular signals such as the Semaphorins can disrupt multiple components of
cardiovascular development.
Disruption to the expression of genes associated with excitation-contraction coupling in
cardiomyocytes was also seen in the microarray data, and this was shown to be having a
functional affect through the analysis of Ca
2+ transients in primary embryonic cardiomyocyte
cultures. Loss of coordinated cardiomyocyte contractility due to aberrant Ca
2+ handling would
severely reduce cardiac function. This could have impacted on the structural cardiac
malformations observed, in addition to contributing to the severe oedema seen from E13.5 in
Chd7
fl/fl;Mesp1-Cre embryos.
Elucidating the roles of CHD7 in mesodermal derivatives alters our perspective on the etiology
of the cardiovascular malformations associated with CHARGE syndrome. Whilst an additional184
requirement for CHD7 in NCCs is not ruled out, the classification of CHARGE as a
neurocristopathy appears to be an over-simplification, at least with regard to the heart
defects. Furthermore, conditional deletion of Chd7 has also allowed identification of some of
the genes affected by CHD7 activity later during cardiogenesis than was possible with Chd7
-/-
embryos. Notably, these included extracellular signalling and calcium handling genes, as
opposed to master-regulator transcription factors such as NKX2-5, suggesting a switch in the
types of genes CHD7 regulates as cardiogenesis progresses. Overall, this work provides novel
insights into the tissue-specific requirement and roles of CHD7 during cardiovascular
development.185
6.2 Future work
The work presented in this thesis has characterised the cardiovascular phenotype following
various lineage-specific conditional ablations of Chd7, and addressed the transcriptional
changes that occur in the developing heart when CHD7 activity is lost. This final section will
briefly highlight a number of more general questions that remain in our understanding of the
role of CHD7 during cardiovascular development.
6.2.1 Where does CHD7 bind on a genome-wide scale in the cardiogenic mesoderm?
As discussed in section 5.6.2, despite seeing major cardiovascular malformations when Chd7 is
ablated in the developing heart, we have little information about CHD7 genome occupancy in
the cardiogenic mesoderm. The optimal way to address this issue would be by genome-wide
chromatin immunoprecipitation (ChIP) followed by high-throughput DNA sequencing (ChIP-
seq), which would allow global comparison of CHD7 binding sites with altered gene expression.
This has been attempted by other lab members, both in vitro and in vivo. Attempts in vitro
involved utilising an ESC line transformed with a BAC construct expressing CHD7 with a C-
terminal TAP tag, which contains three FLAG tags and two calmodulin-binding proteins for
tandem affinity purification, that would be differentiated to a cardiomyocyte lineage. This was
based on several recent studies that tracked epigenetic and transcriptional changes as ESCs
were differentiated through a series of defined states to a cardiomyocyte lineage (Paige et al.,
2012; Wamstad et al., 2012). However, this in vitro work was hampered by the fact that pure
populations of cardiomyocytes cannot be generated through differentiation of ESCs.
Unfortunately, attempts at labelling cells with fluorescently-tagged cardiomyocyte-specific
proteins, to allow them to be sorted by FACS, were unsuccessful, so efforts were instead
focussed on in vivo experiments.
The in vitro work did allow optimisation of the CHD7 ChIP protocol sufficiently to perform the
ChIP-PCR experiment shown in Figure 5-20, which demonstrated localisation of CHD7
specifically at the Sema3C promoter at E11.5 in vivo. A key modification was the use of
disuccinimidyl glutarate (DSG) rather than formamide for the fixation step in the ChIP protocol,
as this fixative has a range of ~8Å, which is four times greater than formamide. The
requirement for DSG fixation reflects the fact that CHD7 is thought to interact with histone
modifications via its chromodomains, so the majority of this large protein is not in direct
contact with the DNA. However, attempts at genome-wide ChIP-seq in vivo using chromatin
extracted from approximately 50 wild-type hearts were unsuccessful, as insufficient material
was retrieved for sequencing, so the resulting signal-to-noise ratio was too low (Matthew186
Burney, personal communication). In the future, it could be useful to repeat this experiment
with a significant increase in the number of hearts from which chromatin collected, to attempt
to overcome this issue. Notably, the only ChIP-seq datasets that have been published for CHD7
were produced by Schnetz and colleagues on ESCs and other in vitro cell lines, using an Abcam
antibody that is no longer available, so this appears to be a common problem for researchers
working on CHD7 (Schnetz et al., 2009; Schnetz et al., 2010).
As an alternative to ChIP-seq, it would be interesting to compare Chd7
fl/fl and Chd7
fl/fl;Mesp1-
Cre samples using genome-wide mapping of DNase I or MNase hypersensitivity sites. A DNase I
hypersensitivity assay was already successfully carried out specifically at the Sema3C locus, as
discussed in section 5.6.2, with a reduction in DNase I hypersensitiy seen in Chd7
fl/fl;Mesp1-Cre
hearts indicating a more closed chromatin conformation in the absence of CHD7. To extend
this, these endonuclease assays can be followed by massively-parallel sequencing to give an
indication of the accessibility of regions of DNA on a genome-wide scale (Crawford et al.,
2006). The loci of genes differentially regulated in Chd7
fl/fl;Mesp1-Cre hearts could therefore be
interrogated for changes in their chromatin structure and accessibility when CHD7 activity is
ablated, to identify potential regulatory elements. A more recently-developed, highly sensitive
assay for transposase-accessible chromatin using sequencing (ATAC-seq) could also be
informative: this protocol is based on direct in vitro transposition of sequencing adaptors into
native chromatin to capture open chromatin sites, so it could be utilised to compare cultured
embryonic cardiomyocytes (Buenrostro et al., 2013).
Whilst the identification of genomic loci with altered chromatin structure in Chd7
fl/fl;Mesp1-Cre
heart would not confirm direct CHD7 binding, they could still be extremely useful for
identifying further candidate genes that may be directly regulated by CHD7 in the cardiogenic
mesoderm, as CHD7 activity involves the repositioning of nucleosomes. The identification of
possible regulatory elements at which CHD7 is located would be extremely useful, as in the
absence of ChIP-seq data, the next best option is ChIP-PCR at candidate genes. However, this
technique requires prediction of the exact locus where CHD7 potentially binds, as primers
need to be designed to test these sites by qRT-PCR following the CHD7 ChIP. This can be
extremely challenging, and is an obvious limitation of this technique, so if data is available on
loci with altered chromatin structure, primers could be designed around these sites to look for
CHD7 enrichment using ChIP-PCR.187
6.2.2 What are the interaction partners of CHD7 during cardiogenesis?
Genome-wide data on CHD7 binding sites would not only be informative for correlating the
direct CHD7 cardiovascular targets versus downstream effects of CHD7 activity, but could also
help to identify interaction partners for CHD7 during cardiogenesis. DNA-interacting proteins
that overlap with CHD7 on the genome or are in close proximity may be in a common complex,
or be involved in the recruitment of CHD7 to target loci on the genome. Therefore, the regions
around CHD7 binding sites could be interrogated for known transcription factor binding sites
or other regulatory sequences, using motif-finding software such as TFM-Scan, which utilises
Position Weight Matrices to locate large sets of putative transcription factor binding sites on a
DNA sequence (Liefooghe A., 2006). This analysis could focus particularly on the regions
surrounding differentially-expressed genes identified in Chd7
fl/fl;Mesp1-Cre hearts.
ENCODE datasets from other ChIP-seq experiments focussing on cardiogenic factors could also
be compared to CHD7 ChIP-seq data, to identify overlapping binding sites. For example, ChIP-
seq data is available for the genome occupancy of the cardiac transcription factors GATA4,
Nkx2-5, Tbx5, SRF and Mef2A in the HL1 cell line (He et al., 2011), as well as predicted cardiac
enhancers based on p300 genome occupancy in E11.5 hearts (Blow et al., 2010). Candidate
genes identified through this bioinformatics approach could then be tested by co-
immunoprecipitation, in vitro using the tagged constructs previously mentioned, or in vivo
using native protein extracted from dissected embryonic hearts.
In the absence of CHD7 ChIP-seq data, a yeast two-hybrid assay could be performed using a
Chd7 bait construct. This has been carried out for a number of other proteins important for
cardiovascular development, such as TBX20 and SMAD1, with screening libraries generated
from cDNA isolated from embryonic hearts (Debenedittis et al., 2011; Liu et al., 2014).
Alternatively, immunoprecipitation of CHD7 followed by mass spectrometry would be a
sensitive and accurate method for identification of protein complexes and interaction partners
(ten Have et al., 2011). Obtaining information about proteins that interact with CHD7 during
cardiogenesis would further our understanding about the mechanisms through which
specificity for CHD7 localisation on the genome is achieved, and how CHD7 activity influences
the transcriptional networks that regulates cardiovascular development. As previously
mentioned, it appears that CHD7 regulates master transcription factors such as Nkx2-5 early in
cardiogenesis, but later affects the transcription of intra- and extracellular signalling pathways.
This switch could be through the recruitment of CHD7 to target genes by different protein
complexes, which are cell-type and stage-specific during cardiovascular development. CHD7
binding on the genome has previously been shown to be cell-type specific (Schnetz et al.,188
2009), and whilst this was associated with changes in H3K4me patterns, interactions between
CHD7 and other nuclear proteins may also play a key role in this specificity.
6.2.3 Is CHD7 required in other tissues for cardiovascular development?
Tissue-specific ablation of Chd7 in the cardiogenic mesoderm, cardiomyocytes, SHF and
endothelial cells has been demonstrated here to be sufficient to produce a range of
cardiovascular defects of varying severity and penetrance. This alters our perspective on the
etiology of CHARGE syndrome, which has traditionally been considered a neurocristopathy, by
showing that CHD7 activity plays a key role in the cardiogenic mesoderm. However, this work
does not rule out an additional role for Chd7 in cardiac NCCs, which could be contributing to
the heart defects seen in CHARGE patients.
Conditional ablation of Chd7 in NCCs, driven by Wnt1-Cre, has been described recently by
Sperry and colleagues. Whilst major craniofacial defects were observed in Chd7
fl/fl;Wnt1-Cre
embryos, consistent with the known contribution of NCCs to the cartilage and bones during
craniofacial morphogenesis (Cordero et al., 2011), cardiac defects were not identified. Hearts
were examined for pharyngeal arch artery defects at E10.5, and great vessel defects or
septation defects at E16.5, but all hearts examined looked normal (Sperry et al., 2014). This
would indicate that Chd7 is not required in cardiac NCCs for heart or great vessel
development. However, Chd7
fl/fl;Wnt1-Cre embryos were also examined in our lab, and
although great vessel defects were also absent, a number of these embryos showed VSDs and
one had a common arterial trunk (Karen McCue, personal communication). This indicates that
CHD7 activity is required in NCCs as they contribute to the septation of the OFT and ventricles.
Further work is therefore required to resolve this contradiction, and to identify genes
potentially regulated by CHD7 activity in cardiac NCCs.
Given the importance of both Chd7 and Tbx1 dosage in the pharyngeal surface ectoderm for
great vessel development (Randall et al., 2009), it would also be interesting to investigate the
cardiovascular phenotype in mice with Chd7 ablation driven by AP2αIRES-Cre. There is
currently not a Cre line available that is active only in the pharyngeal surface ectoderm, but
AP2αIRES-Cre drives recombination in both NCCs and the pharyngeal ectoderm. Any additional
defects seen in Chd7
fl/fl;  AP2αIRES-Cre  embryos compared to Chd7
fl/fl;Wnt1-Cre embryos
therefore could be attributed to the loss of Chd7 in the ectoderm.189
6.2.4 What happens if Chd7 is reactivated after myocardial injury?
In Chapter Three, the possibility that Chd7 expression could be reactivated in pathological
situations was discussed. This was hypothesised based on the similarity in embryonic, but not
postnatal, cardiac expression between Chd7 and Brg1, and their similar chromatin remodelling
activity. Briefly, Brg1 has been found to be re-expressed in hypertrophic hearts in response to
cardiac stresses, which induces a pathological switch between adult and fetal myosin heavy
chain isotopes (Hang et al., 2010). If Chd7 were also re-activated, this could identify it as a new
therapeutic target. Another intriguing research question that arises from the work presented
in this thesis is whether CHD7 reactivation following myocardial injury would have a
therapeutic benefit. Novel roles have been identified for CHD7 upstream of cardiac
innervation, coronary venous development and calcium handling in cardiogenic progenitors,
which are all processes that could aid with the repair of damaged tissue following infarction.
Many recent studies have focussed on reprogramming of non-myocytes into cardiomyocytes
by inducing expression of key transcription factors or miRNAs with known roles during heart
development (reviewed in (Xin et al., 2013)). Similarly, the actin sequestering protein thymosin
β4 (Tβ4) was found to regulate coronary vasculature development during embryogenesis and 
stimulate neovascularisation following myocardial infarction and ischaemia (Smart et al.,
2007). Re-expression of a chromatin remodeller such as CHD7, itself affecting multiple gene
expression programmes, could have a broad effect on gene expression programmes to help
stimulate cardiac regeneration and repair.190
6.3 Summary
Chromatin remodelling activity by CHD7 plays a crucial role in the cardiogenic mesoderm for
the transcriptional regulation of multiple genes involved in cardiovascular development.
Serious cardiac malformations result from conditional ablation of Chd7 in the cardiogenic
mesoderm, which are analogous to the rare human Holmes heart, leading to cardiac failure
and embryonic lethality around E15.5. CHD7 activity lies upstream of Class 3 Semaphorin and
Slit-Robo signalling in the developing heart, as well as components critical for the excitation-
contraction coupling of cardiomyocytes. Together, these molecular changes contribute to the
range of defects seen in conditional Chd7 mutants. This work therefore furthers our
understanding of both the tissue-specific requirements for Chd7 during cardiovascular
development and the downstream transcriptional changes caused by loss of CHD7 activity.191
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APPENDIX A – FIGURE LEGENDS FOR MOVIES
Movie 1 – Normal OFT septation in an E13.5 Chd7
Whi/+ heart
OPT movie through a Chd7
Whi/+ heart (transverse plane) shows septation of the OFT into the
separate aorta and pulmonary trunk. The AV cushions have not quite fused to close the
embryonic interventricular communication, although the alignment of the chambers is normal,
with separate right and left AV junctions. The venous valves are normally formed. See Figure
3-10 for labelling of the aorta and pulmonary trunk.
Movie 2 – Common arterial trunk and double inlet left ventricle in an E13.5 Chd7
Whi/fl;Mesp1-
Cre heart
OPT movie through a Chd7
Whi/fl;Mesp1-Cre heart shows a common arterial trunk (CAT) arising
from an incomplete right ventricle. The CAT shows pulmonary dominance, whilst the aortic
component is hypoplastic and interrupted, supplying only the common carotid arteries. The
atrial chambers connect through a common AV valve to the dominant left ventricle, and it can
clearly be seen there is no connection between the incomplete right ventricle and the atria.
The venous valves are grossly hypoplastic, and the vestibular spine has failed to form.
Movie 3 – Vestibular spine formation and normal endocardial cushion alignment in an E11.5
Chd7
fl/fl heart
OPT movie through a control E11.5 heart (transverse plane) shows formation of the primary
atrial septum and vestibular spine, which fuses with the inferior AV endocardial cushion. As
the movie plays the superior endocardial cushion is seen first, followed by the inferior cushion.
See Figure 3-14 for labelling of key structures.
Movie 4 – Absence of the vestibular spine and abnormal positioning of the endocardial
cushions in an E11.5 Chd7
fl/fl;Mesp-Cre heart
OPT movie through a Chd7
fl/fl;Mesp-Cre heart, in which the primary atrial septum can be seen,
but the vestibular spine is completely absent. This means the atrial septum and endocardial
cushions are not brought together for septation of the AV canal. Furthermore, both the
superior and inferior AV endocardial cushions are seen adjacent in the same transverse plane,
highlighting their abnormal position when compared to the control heart.220
APPENDIX B – E11.5 AND E13.5 MICROARRAY GENE LISTS
Tables B1-B4 contain lists of genes downregulated or upregulated in Chd7
fl/fl;Mesp1-Cre hearts
compared to Chd7
+/+;Mesp1-Cre hearts, based on microarray analysis at two time points using
GeneChip® Mouse Gene 1.0 ST Arrays. Only genes with Log2FC > 0.7, and p value < 0.05, are
included.
For each table, Chrom indicates the chromosome on which the gene is found, and FC indicates fold
change.
Table B1: Genes downregulated in the heart at E11.5 following mesodermal ablation of Chd7
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000026678 Rgs5 1 regulator of G-protein signaling 5 -2.0388 6.76E-05
ENSMUSG00000041235 Chd7 4
chromodomain helicase DNA
binding protein 7
-1.6829 6.11E-09
ENSMUSG00000028332 Hemgn 4 hemogen -1.6068 0.004013
ENSMUSG00000019906 Lin7a 10 lin-7 homolog A (C. elegans) -1.5660 1.80E-05
ENSMUSG00000027463 Slc52a3 2 solute carrier protein family 52,
member 3
-1.3710 4.54E-05
ENSMUSG00000035551 Igfbpl1 4
insulin-like growth factor binding
protein-like 1 -1.3022 1.08E-07
ENSMUSG00000012405 Rpl15 14 ribosomal protein L15 -1.2700 0.001382
ENSMUSG00000038997 Asb17 3
ankyrin repeat and SOCS box-
containing 17
-1.2556 0.000156
ENSMUSG00000020061 Mybpc1 10
myosin binding protein C, slow-
type
-1.2496 5.32E-05
ENSMUSG00000069171 Nr2f1 13
nuclear receptor subfamily 2, group
F, member 1 -1.2412 4.09E-05
ENSMUSG00000045573 Penk 4 preproenkephalin -1.2337 0.002035
ENSMUSG00000024868 Dkk1 19
dickkopf homolog 1 (Xenopus
laevis)
-1.2324 1.13E-05
ENSMUSG00000018893 Mb 15 Myoglobin -1.1955 3.24E-06
ENSMUSG00000028132 Tmem56 3 transmembrane protein 56 -1.1809 0.005723
ENSMUSG00000025488 Cox8b 7 cytochrome c oxidase, subunit VIIIb -1.1717 6.16E-05
ENSMUSG00000068686 Cd59b 2 CD59b antigen -1.1620 0.006512
ENSMUSG00000039200 Atf7ip2 16
activating transcription factor 7
interacting protein 2
-1.1565 0.000397
ENSMUSG00000035158 Mitf 6 microphthalmia-associated
transcription factor
-1.1052 0.00042
ENSMUSG00000042219 Olfr631 7 olfactory receptor 631 -1.1040 0.006613
ENSMUSG00000031125
3830403N
18Rik
X RIKEN cDNA 3830403N18 gene -1.0910 0.025038
ENSMUSG00000035472 Slc25a21 12
solute carrier family 25
(mitochondrial oxodicarboxylate
carrier), member 21
-1.0866 0.014794
ENSMUSG00000019787 Trdn 10 triadin -1.0781 6.84E-07
ENSMUSG00000033737 Fndc3c1 X
fibronectin type III domain
containing 3C1
-1.0672 8.05E-05
ENSMUSG00000023964 Calcr 6 calcitonin receptor -1.0667 0.000169
ENSMUSG00000030762 Aqp8 7 aquaporin 8 -1.0530 0.013353221
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000026357 Rgs18 1 regulator of G-protein signaling 18 -1.0468 0.017992
ENSMUSG00000041324 Inhba 13 inhibin beta-A -1.0163 0.000459
ENSMUSG00000020460 Rps27a 11 ribosomal protein S27A -1.0159 0.00233
ENSMUSG00000059742 Kcnh7 2
potassium voltage-gated channel,
subfamily H (eag-related), member
7
-0.9919 8.03E-05
ENSMUSG00000031558 Slit2 5 slit homolog 2 (Drosophila) -0.9871 2.44E-08
ENSMUSG00000074491 Clec4g 8
C-type lectin domain family 4,
member g
-0.9857 2.52E-05
ENSMUSG00000042333 Tnfrsf14 4
tumor necrosis factor receptor
superfamily, member 14
(herpesvirus entry mediator)
-0.9821 0.010138
ENSMUSG00000036687 Tmem184
a
5 transmembrane protein 184a -0.9805 0.001076
ENSMUSG00000036446 Lum 10 lumican -0.9794 0.048496
ENSMUSG00000039579 Grin3a 4
glutamate receptor ionotropic,
NMDA3A -0.9720 6.21E-07
ENSMUSG00000075145 Olfr1155 2 olfactory receptor 1155 -0.9680 0.010133
ENSMUSG00000095528 Gm10375 14 predicted gene 10375 -0.9444 0.022939
ENSMUSG00000018659 Pnpo 11 pyridoxine 5'-phosphate oxidase -0.9249 0.004907
ENSMUSG00000026100 Mstn 1 myostatin -0.9244 0.013116
ENSMUSG00000053119 Chmp3 6
charged multivesicular body
protein 3 -0.9186 0.006818
ENSMUSG00000032028 Nxpe2 9
family with sequence similarity 55,
member B
-0.9170 0.022996
ENSMUSG00000061816 Myl1 1 myosin, light polypeptide 1 -0.9105 0.012749
ENSMUSG00000018983 E2f2 4 E2F transcription factor 2 -0.9097 0.000247
ENSMUSG00000052516 Robo2 16
roundabout homolog 2
(Drosophila) -0.9067 2.38E-05
ENSMUSG00000001542 Ell2 13
elongation factor RNA polymerase
II 2
-0.9039 0.001301
ENSMUSG00000000244 Tspan32 7 tetraspanin 32 -0.8990 0.016638
ENSMUSG00000090326 Gm17384 5 predicted gene, 17384 -0.8973 0.000603
ENSMUSG00000028883 Sema3a 5
sema domain, immunoglobulin
domain (Ig), short basic domain,
secreted, (semaphorin) 3A
-0.8941 9.87E-07
ENSMUSG00000031712 Il15 8 interleukin 15 -0.8940 0.00145
ENSMUSG00000029650 Slc46a3 5 solute carrier family 46, member 3 -0.8917 0.012711
ENSMUSG00000075307 Klhl41 2
kelch repeat and BTB (POZ) domain
containing 10
-0.8915 0.000816
ENSMUSG00000073938 Olfr632 7 olfactory receptor 632 -0.8909 0.004545
ENSMUSG00000030048 Gkn3 6 gastrokine 3 -0.8885 0.001937
ENSMUSG00000070890 Gm12794 4 predicted gene 12794 -0.8845 0.002194
ENSMUSG00000027620 Rbm39 2 RNA binding motif protein 39 -0.8815 0.000696
ENSMUSG00000026532 Spta1 1 spectrin alpha 1 -0.8765 0.031537
ENSMUSG00000060499 Rpl10l 12 ribosomal protein L10-like -0.8741 0.003779
ENSMUSG00000018654 Ikzf1 11 IKAROS family zinc finger 1 -0.8710 0.006988
ENSMUSG00000026686 Lmx1a 1
LIM homeobox transcription factor
1 alpha
-0.8684 0.008522
ENSMUSG00000053441 Adamts19 18
a disintegrin-like and
metallopeptidase (reprolysin type)
with thrombospondin type 1 motif,
19
-0.8653 0.000156222
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000036295 Lrrn3 12
leucine rich repeat protein 3,
neuronal
-0.8634 0.000156
ENSMUSG00000019890 Nts 10 neurotensin -0.8571 0.012237
ENSMUSG00000027559 Car3 3 carbonic anhydrase 3 -0.8550 0.029583
ENSMUSG00000026815 Gfi1b 2 growth factor independent 1B -0.8550 0.033986
ENSMUSG00000015354 Pcolce2 9 procollagen C-endopeptidase
enhancer 2
-0.854 0.000306
ENSMUSG00000058331 Zfp85-rs1 13
zinc finger protein 85, related
sequence 1
-0.8529 0.011325
ENSMUSG00000060636 Rpl35a 16 ribosomal protein L35A -0.8524 0.024588
ENSMUSG00000034810 Scn7a 2
sodium channel, voltage-gated,
type VII, alpha
-0.8463 0.016847
ENSMUSG00000047686 Zcchc5 X
zinc finger, CCHC domain
containing 5
-0.8452 0.008625
ENSMUSG00000037872 Darc 1
Duffy blood group, chemokine
receptor -0.8442 0.003441
ENSMUSG00000044067 Gpr22 12 G protein-coupled receptor 22 -0.8386 2.11E-05
ENSMUSG00000073764 Gm12888 4 predicted gene 12888 -0.8374 4.38E-05
ENSMUSG00000022309 Angpt1 15 angiopoietin 1 -0.8342 0.000677
ENSMUSG00000044921 Rassf9 10
Ras association (RalGDS/AF-6)
domain family (N-terminal)
member 9
-0.8295 0.003028
ENSMUSG00000007653 Gabrb2 11 gamma-aminobutyric acid (GABA)
A receptor, subunit beta 2
-0.8214 5.02E-05
ENSMUSG00000001348 Acp5 9
acid phosphatase 5, tartrate
resistant -0.8145 0.034052
ENSMUSG00000024448 H2-M10.1 17
histocompatibility 2, M region locus
10.1
-0.8144 0.007766
ENSMUSG00000014980 Tsen15 1
tRNA splicing endonuclease 15
homolog (S. cerevisiae)
-0.8107 0.003469
ENSMUSG00000027500 Stmn2 3 stathmin-like 2 -0.8079 0.008879
ENSMUSG00000059371 Olfr427 1 olfactory receptor 427 -0.8042 0.000692
ENSMUSG00000027820 Mme 3 membrane metallo endopeptidase -0.8010 0.001894
ENSMUSG00000023903 Mmp25 17 matrix metallopeptidase 25 -0.8000 0.000335
ENSMUSG00000023328 Ache 5 acetylcholinesterase -0.7994 0.000137
ENSMUSG00000079363 Gbp4 5 guanylate binding protein 4 -0.7937 0.010563
ENSMUSG00000059674 Cdh24 14 cadherin-like 24 -0.7912 0.001852
ENSMUSG00000061923 Odf1 15 outer dense fiber of sperm tails 1 -0.7904 0.001316
ENSMUSG00000057778 Cyb5d2 11
cytochrome b5 domain containing
2
-0.7896 0.036574
ENSMUSG00000034566 Atp5h 11
ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit
d
-0.7862 0.010195
ENSMUSG00000035031 C8a 4
complement component 8, alpha
polypeptide
-0.7774 0.005477
ENSMUSG00000056853 Olfr765 10 olfactory receptor 765 -0.773 0.013631
ENSMUSG00000063297 Luzp2 7 leucine zipper protein 2 -0.7728 0.017801
ENSMUSG00000068617 Efcab1 16 EF hand calcium binding domain 1 -0.7721 0.003809
ENSMUSG00000027004 Frzb 2 frizzled-related protein -0.7716 0.001185
ENSMUSG00000053897 Slc39a8 3
solute carrier family 39 (metal ion
transporter), member 8
-0.7691 0.007979
ENSMUSG00000004552 Ctse 1 cathepsin E -0.7681 0.022571
ENSMUSG00000027273 Snap25 2
synaptosomal-associated protein
25
-0.7678 0.000898223
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000022658 Tagln3 16 transgelin 3 -0.7668 0.000616
ENSMUSG00000034555 Tex16 X testis expressed gene 16 -0.7646 0.000735
ENSMUSG00000019659 Ccdc12 9 coiled-coil domain containing 12 -0.7630 0.009235
ENSMUSG00000020638 Cmpk2 12
cytidine monophosphate (UMP-
CMP) kinase 2, mitochondrial
-0.7625 0.021755
ENSMUSG00000059898 Dsc3 18 desmocollin 3 -0.7577 0.000348
ENSMUSG00000054626 Xlr X
X-linked lymphocyte-regulated
complex -0.7567 0.04652
ENSMUSG00000071493 Vmn1r208 13 vomeronasal 1 receptor 208 -0.7565 0.013412
ENSMUSG00000096747 Olfr823 10 olfactory receptor 823 -0.7547 0.022869
ENSMUSG00000025573
6030468B
19Rik
11 RIKEN cDNA 6030468B19 gene -0.7510 0.023917
ENSMUSG00000023093 Gm7257 9 predicted gene 7257 -0.7503 0.00032
ENSMUSG00000051361
6030498E
09Rik X RIKEN cDNA 6030498E09 gene -0.7437 0.00289
ENSMUSG00000078942 Naip6 13
NLR family, apoptosis inhibitory
protein 6
-0.7312 0.001002
ENSMUSG00000035875 AI182371 2 expressed sequence AI182371 -0.7292 0.001658
ENSMUSG00000057170 Prl3d1 13
prolactin family 3, subfamily d,
member 1
-0.7242 0.008561
ENSMUSG00000055026 Gabrg3 7
gamma-aminobutyric acid (GABA)
A receptor, subunit gamma 3 -0.7237 0.000183
ENSMUSG00000006235 Epor 9 erythropoietin receptor -0.7210 0.025758
ENSMUSG00000039057 Myo16 8 myosin XVI -0.7174 0.000113
ENSMUSG00000048697 Vmn1r26 6 vomeronasal 1 receptor 26 -0.7169 0.003378
ENSMUSG00000030222 Rerg 6 RAS-like, estrogen-regulated,
growth-inhibitor
-0.7159 0.021202
ENSMUSG00000060044 Tmem26 10 transmembrane protein 26 -0.7135 0.002711
ENSMUSG00000016998 Svs4 2 seminal vesicle secretory protein 4 -0.7134 0.010077
ENSMUSG00000073680 Tmem88b 4 transmembrane protein 88B -0.7093 0.004922
ENSMUSG00000027555 Car13 3 carbonic anhydrase 13 -0.7091 0.000803
ENSMUSG00000072774 Zfp951 5 zinc finger protein 951 -0.7029 0.005338
ENSMUSG00000020020 Usp44 10 ubiquitin specific peptidase 44 -0.7012 0.000345
ENSMUSG00000041216 Clvs1 4 clavesin 1 -0.7007 0.000285224
Table B2: Genes upregulated in the heart at E11.5 following mesodermal ablation of Chd7
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000020891 Alox8 11 arachidonate 8-lipoxygenase 0.7030 0.013438
ENSMUSG00000075144 Olfr1156 2 olfactory receptor 1156 0.7055 0.016192
ENSMUSG00000049350 Zg16 7 zymogen granule protein 16 0.7056 0.001515
ENSMUSG00000095180 Rhox5 X reproductive homeobox 5 0.7060 0.000503
ENSMUSG00000079015 Serpina1c 12
serine (or cysteine) peptidase
inhibitor, clade A, member 1C
0.7075 0.009398
ENSMUSG00000009376 Met 6 met proto-oncogene 0.7145 0.000382
ENSMUSG00000003541 Ier3 17 immediate early response 3 0.7193 0.040657
ENSMUSG00000068947 Olfr366 2 olfactory receptor 366 0.7215 0.007234
ENSMUSG00000029309 Sparcl1 5 SPARC-like 1 0.7226 0.000106
ENSMUSG00000043421 Hilpda 6
hypoxia inducible lipid droplet
associated 0.7263 0.011431
ENSMUSG00000028128 F3 3 coagulation factor III 0.7282 0.019032
ENSMUSG00000095241 Gm5478 15 0.7317 5.85E-05
ENSMUSG00000018822 Sfrp5 19
secreted frizzled-related sequence
protein 5
0.7334 0.002257
ENSMUSG00000056158 Car10 11 carbonic anhydrase 10 0.7354 0.000179
ENSMUSG00000038092 Hsd3b5 3
hydroxy-delta-5-steroid
dehydrogenase, 3 beta- and steroid
delta-isomerase 5
0.7414 0.02908
ENSMUSG00000097451 Rian NA NA 0.7457 8.35E-05
ENSMUSG00000065353 Snora73b 4
small nucleolar RNA, H/ACA box
73b 0.7490 0.022449
ENSMUSG00000053420 Gm4792 10 predicted gene 4792 0.7503 0.000753
ENSMUSG00000021638 Ocln 13 occludin 0.7548 0.001376
ENSMUSG00000005413 Hmox1 8 heme oxygenase (decycling) 1 0.7569 0.009623
ENSMUSG00000093007 Mir15a 14 microRNA 15a 0.7577 0.011795
ENSMUSG00000024479 Mal2 15 mal, T cell differentiation protein 2 0.7583 0.029476
ENSMUSG00000074158
9830147E
19Rik 7 RIKEN cDNA 9830147E19 gene 0.7669 0.003389
ENSMUSG00000023043 Krt18 15 keratin 18 0.7683 0.008522
ENSMUSG00000013584 Aldh1a2 9
aldehyde dehydrogenase family 1,
subfamily A2
0.7697 0.003966
ENSMUSG00000051940 5031410I0
6Rik
5 RIKEN cDNA 5031410I06 gene 0.7762 0.001219
ENSMUSG00000039215 Svs1 6 seminal vesicle secretory protein 1 0.7815 0.014586
ENSMUSG00000058904 Olfr1413 1 olfactory receptor 1413 0.7827 0.003613
ENSMUSG00000074968 Ano3 2 anoctamin 3 0.7834 0.000396
ENSMUSG00000066363 Serpina3f 12
serine (or cysteine) peptidase
inhibitor, clade A, member 3F
0.7851 0.010171
ENSMUSG00000030787 Lyve1 7 lymphatic vessel endothelial
hyaluronan receptor 1
0.7874 0.001096
ENSMUSG00000046210 Olfr735 14 olfactory receptor 735 0.7882 0.000877
ENSMUSG00000066677 Pydc3 1 pyrin domain containing 3 0.7965 0.002785
ENSMUSG00000070529 Wfdc10 2 WAP four-disulfide core domain 10 0.8057 0.011004
ENSMUSG00000055780 Usp26 X ubiquitin specific peptidase 26 0.8135 0.000713
ENSMUSG00000040405 Havcr1 11 hepatitis A virus cellular receptor 1 0.8153 0.038827
ENSMUSG00000049528 Olfr429 1 olfactory receptor 429 0.8199 0.004907225
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000096819 Srsy Y
Serine-rich secreted Y-linked
protein
0.8223 0.002995
ENSMUSG00000061126 Cyp4f39 17
cytochrome P450, family 4,
subfamily f, polypeptide 39
0.8271 0.000437
ENSMUSG00000009654 Oit3 10 oncoprotein induced transcript 3 0.8320 0.005785
ENSMUSG00000021367 Edn1 13 endothelin 1 0.8365 0.005362
ENSMUSG00000056973 Ces1d 8 carboxylesterase 1D 0.8474 0.000698
ENSMUSG00000020427 Igfbp3 11
insulin-like growth factor binding
protein 3
0.8543 0.00012
ENSMUSG00000070867 Trabd2b 4 predicted gene 12824 0.8600 2.19E-06
ENSMUSG00000028341 Nr4a3 4
nuclear receptor subfamily 4, group
A, member 3
0.8613 0.011819
ENSMUSG00000070933 Speer4d 5
spermatogenesis associated
glutamate (E)-rich protein 4d
0.8779 0.00011
ENSMUSG00000024395 Lims2 18
LIM and senescent cell antigen like
domains 2 0.8783 0.018917
ENSMUSG00000005125 Ndrg1 15
N-myc downstream regulated gene
1
0.8825 0.047623
ENSMUSG00000054966 Ifltd1 6
intermediate filament tail domain
containing 1
0.8839 0.000238
ENSMUSG00000054258 Gm5082 13 predicted gene 5082 0.8924 0.022338
ENSMUSG00000024273
2700062C
07Rik 18 RIKEN cDNA 2700062C07 gene 0.8932 0.001515
ENSMUSG00000050092 Sprr2b 3 small proline-rich protein 2B 0.8939 0.000757
ENSMUSG00000021219 Rgs6 12 regulator of G-protein signaling 6 0.8952 4.07E-06
ENSMUSG00000061306 Slc38a10 11 solute carrier family 38, member 10 0.8953 0.001151
ENSMUSG00000022949 Clic6 16 chloride intracellular channel 6 0.9168 0.000488
ENSMUSG00000021943 Gdf10 14 growth differentiation factor 10 0.9221 0.000475
ENSMUSG00000096109 Olfr1537 9
olfactory receptor 1537,
pseudogene 1
0.9242 0.003063
ENSMUSG00000053519 Kcnip1 11 Kv channel-interacting protein 1 0.9434 4.62E-05
ENSMUSG00000035165 Kcne3 7
potassium voltage-gated channel,
Isk-related subfamily, gene 3
0.9551 0.028108
ENSMUSG00000020159 Gabrp 11
gamma-aminobutyric acid (GABA)
A receptor, pi 0.9618 0.014963
ENSMUSG00000070686 C87414 5 expressed sequence C87414 0.9826 0.001085
ENSMUSG00000075202 Olfr1042 2 olfactory receptor 1042 0.9863 0.003242
ENSMUSG00000065944 Rnu2-10 11 U2 spliceosomal RNA 0.9884 0.030422
ENSMUSG00000039145 Camk1d 2
calcium/calmodulin-dependent
protein kinase ID
0.9985 0.000176
ENSMUSG00000024087 Cyp1b1 17
cytochrome P450, family 1,
subfamily b, polypeptide 1
1.0252 0.000516
ENSMUSG00000051663 Pcdhb1 18 protocadherin beta 1 1.0293 0.000159
ENSMUSG00000027833 Shox2 3 short stature homeobox 2 1.0311 0.004779
ENSMUSG00000038253 Hoxa5 6 homeobox A5 1.0373 0.001617
ENSMUSG00000031461 Myom2 8 myomesin 2 1.0488 0.000249
ENSMUSG00000066747 Olfr878 9 olfactory receptor 878 1.0570 0.001186
ENSMUSG00000058952 Cfi 3 complement component factor i 1.1009 0.000113
ENSMUSG00000066272 Olfr559 7 olfactory receptor 559 1.1289 0.006041
ENSMUSG00000040621 Gemin8 X
gem (nuclear organelle) associated
protein 8
1.1387 0.01319
ENSMUSG00000023885 Thbs2 17 thrombospondin 2 1.1814 0.002338
ENSMUSG00000094637 Vmn1r204 13 vomeronasal 1 receptor 204 1.1849 0.000483226
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000022103 Gfra2 14
glial cell line derived neurotrophic
factor family receptor alpha 2
1.1899 8.69E-06
ENSMUSG00000030790 Adm 7 adrenomedullin 1.2141 0.001756
ENSMUSG00000095901 Olfr538 7 olfactory receptor 538 1.2193 0.009645
ENSMUSG00000026471 Mr1 1
major histocompatibility complex,
class I-related
1.2335 1.12E-06
ENSMUSG00000024164 C3 17 complement component 3 1.2641 0.02604
ENSMUSG00000074852 Hpse2 19 heparanase 2 1.4621 0.000145
ENSMUSG00000025196 Cpn1 19 carboxypeptidase N, polypeptide 1 1.4687 6.39E-06
ENSMUSG00000053930 Shisa6 11 shisa homolog 6 (Xenopus laevis) 1.4714 0.000489
ENSMUSG00000027861 Casq2 3 calsequestrin 2 1.6910 1.98E-08
ENSMUSG00000027942
4933434E
20Rik
3 RIKEN cDNA 4933434E20 gene 1.7283 9.34E-05
ENSMUSG00000029322 Plac8 5 placenta-specific 8 1.8213 5.56E-06227
Table B3: Genes downregulated in the heart at E13.5 following mesodermal ablation of Chd7
Ensembl ID: Symbol: Chrom: Description: Log2FC P.Value
ENSMUSG00000039114 Nrn1 13 neuritin 1 -1.7590 0.000601
ENSMUSG00000041235 Chd7 4
chromodomain helicase DNA
binding protein 7
-1.5832 1.41E-08
ENSMUSG00000069171 Nr2f1 13 nuclear receptor subfamily 2, group
F, member
-1.4321 8.43E-06
ENSMUSG00000023964 Calcr 6 calcitonin receptor -1.3886 1.04E-05
ENSMUSG00000061816 Myl1 1 myosin, light polypeptide 1 -1.3862 0.000619
ENSMUSG00000026357 Rgs18 1 regulator of G-protein signaling 18 -1.1937 0.008457
ENSMUSG00000029372 Ppbp 5 pro-platelet basic protein -1.1640 0.007009
ENSMUSG00000000320 Alox12 11 arachidonate 12-lipoxygenase -1.1156 0.005136
ENSMUSG00000073007 Fam46d X
family with sequence similarity 46,
member D
-1.1136 1.24E-05
ENSMUSG00000019906 Lin7a 10 lin-7 homolog A (C. elegans) -1.0430 0.000947
ENSMUSG00000073414 AU023871 17 expressed sequence AU023871 -1.0338 0.000555
ENSMUSG00000039070 Cpa4 6 carboxypeptidase A4 -1.0257 0.002821
ENSMUSG00000030054 Gp9 6 glycoprotein 9 (platelet) -1.0243 0.004286
ENSMUSG00000036295 Lrrn3 12 leucine rich repeat protein 3,
neuronal
-1.0178 2.86E-05
ENSMUSG00000046080 Clec9a 6
C-type lectin domain family 9,
member a -0.9958 0.001965
ENSMUSG00000023993 Treml1 17
triggering receptor expressed on
myeloid cells-like 1
-0.9882 0.001068
ENSMUSG00000031712 Il15 8 interleukin 15 -0.9556 0.000839
ENSMUSG00000034028 Cd226 18 CD226 antigen -0.9521 0.001591
ENSMUSG00000018893 Mb 15 myoglobin -0.9403 4.81E-05
ENSMUSG00000027559 Car3 3 carbonic anhydrase 3 -0.9383 0.018601
ENSMUSG00000016255 Tubb1 2 tubulin, beta 1 class VI -0.9360 0.010849
ENSMUSG00000049630 C1ql3 2 C1q-like 3 -0.9282 0.000148
ENSMUSG00000059742 Kcnh7 2
potassium voltage-gated channel,
subfamily H (eag-related), member
7
-0.9195 0.000171
ENSMUSG00000090326 Gm17384 5 predicted gene, 17384 -0.8545 0.000917
ENSMUSG00000007682 Dio2 12 deiodinase, iodothyronine, type II -0.8515 0.000568
ENSMUSG00000026824 Kcnj3 2 potassium inwardly-rectifying
channel, subfamily J, member 3
-0.8471 0.000328
ENSMUSG00000021675 F2rl2 13
coagulation factor II (thrombin)
receptor-like 2 -0.8339 0.045735
ENSMUSG00000007653 Gabrb2 11
gamma-aminobutyric acid (GABA)
A receptor, subunit beta 2
-0.8292 4.54E-05
ENSMUSG00000026100 Mstn 1 myostatin -0.8267 0.023805
ENSMUSG00000033737 Fndc3c1 X
fibronectin type III domain
containing 3C1
-0.8239 0.000895
ENSMUSG00000020120 Plek 11 pleckstrin -0.8206 0.006375
ENSMUSG00000069515 Lyz1 10 lysozyme 1 -0.8151 0.01912
ENSMUSG00000030159 Clec1b 6
C-type lectin domain family 1,
member b
-0.8114 0.017341
ENSMUSG00000019787 Trdn 10 triadin -0.8000 2.28E-05
ENSMUSG00000034664 Itga2b 11 integrin alpha 2b -0.7963 0.010892
ENSMUSG00000028132 Tmem56 3 transmembrane protein 56 -0.7850 0.049338
ENSMUSG00000020061 Mybpc1 10
myosin binding protein C, slow-
type
-0.7775 0.003493228
Ensembl ID: Symbol: Chrom: Description: Log2FC P.Value
ENSMUSG00000027022 Xirp2 2
xin actin-binding repeat containing
2
-0.7727 0.001448
ENSMUSG00000030513 Pcsk6 7
proprotein convertase
subtilisin/kexin type 6
-0.7685 0.000395
ENSMUSG00000006389 Mpl 4
myeloproliferative leukemia virus
oncogene
-0.7675 0.001706
ENSMUSG00000051361
6030498E
09Rik
X RIKEN cDNA 6030498E09 gene -0.7666 0.002309
ENSMUSG00000001865 Cpa3 3 carboxypeptidase A3, mast cell -0.7648 0.043466
ENSMUSG00000081420 Olfr29-ps1 4
olfactory receptor 29, pseudogene
1
-0.7625 0.007148
ENSMUSG00000044573 Acp1 12 acid phosphatase 1, soluble -0.7608 0.007456
ENSMUSG00000055026 Gabrg3 7
gamma-aminobutyric acid (GABA)
A receptor, subunit gamma 3
-0.7523 0.000125
ENSMUSG00000076009 Mir688 15 microRNA 688 -0.7502 0.013937
ENSMUSG00000021613 Hapln1 13
hyaluronan and proteoglycan link
protein 1
-0.7425 0.002363
ENSMUSG00000036144 Meox2 12 mesenchyme homeobox 2 -0.7408 0.045293
ENSMUSG00000021765 Fst 13 follistatin -0.7367 0.002261
ENSMUSG00000045613 Chrm2 6
cholinergic receptor, muscarinic 2,
cardiac
-0.7344 0.001451
ENSMUSG00000022129 Dct 14 dopachrome tautomerase -0.7333 0.018173
ENSMUSG00000027971 Ndst4 3
N-deacetylase/N-sulfotransferase
(heparin glucosaminyl) 4
-0.7284 0.008727
ENSMUSG00000044067 Gpr22 12 G protein-coupled receptor 22 -0.7236 9.98E-05
ENSMUSG00000010803 Gabra1 11 gamma-aminobutyric acid (GABA)
A receptor, subunit alpha 1
-0.7212 0.00565
ENSMUSG00000094808
1810009J0
6Rik 6 RIKEN cDNA 1810009J06 gene -0.7082 0.004729
ENSMUSG00000028883 Sema3a 5
sema domain, immunoglobulin
domain (Ig), short basic domain,
secreted, (semaphorin) 3A
-0.7044 1.63E-05229
Table B4: Genes upregulated in the heart at E13.5 following mesodermal ablation of Chd7
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000024935 Slc1a1 19
solute carrier family 1
(neuronal/epithelial high affinity
glutamate transporter, system
Xag), member 1
0.7050 0.00653
ENSMUSG00000090084 Srpx X sushi-repeat-containing protein 0.71538 0.011908
ENSMUSG00000094637 Vmn1r204 13 vomeronasal 1 receptor 204 0.71874 0.016967
ENSMUSG00000023885 Thbs2 17 thrombospondin 2 0.7229 0.04108
ENSMUSG00000054272 Zscan4c 7
zinc finger and SCAN domain
containing 4C
0.7360 0.037541
ENSMUSG00000022180 Slc7a8 14
solute carrier family 7 (cationic
amino acid transporter, y+ system),
member 8
0.7479 0.000112
ENSMUSG00000024395 Lims2 18
LIM and senescent cell antigen like
domains 2
0.7641 0.037096
ENSMUSG00000000983 Wfdc18 11 extracellular proteinase inhibitor 0.7653 0.024953
ENSMUSG00000074604 Mgst2 3 microsomal glutathione S-
transferase 2
0.7662 0.003838
ENSMUSG00000053930 Shisa6 11 shisa homolog 6 (Xenopus laevis) 0.7694 0.035461
ENSMUSG00000039304 Tnfsf10 3
tumor necrosis factor (ligand)
superfamily, member 10
0.7708 0.016122
ENSMUSG00000073530 Pappa2 1 pappalysin 2 0.7767 0.011317
ENSMUSG00000058147 Xlr3c X X-linked lymphocyte-regulated 3C 0.7880 0.039376
ENSMUSG00000090166 Ear10 14 eosinophil-associated, ribonuclease
A family, member 10
0.7931 0.010262
ENSMUSG00000040564 Apoc1 7 apolipoprotein C-I 0.7975 0.010643
ENSMUSG00000022949 Clic6 16 chloride intracellular channel 6 0.7985 0.001558
ENSMUSG00000028415 Spink4 4
serine peptidase inhibitor, Kazal
type 4
0.8016 0.000465
ENSMUSG00000039145 Camk1d 2
calcium/calmodulin-dependent
protein kinase ID
0.8113 0.001127
ENSMUSG00000022661 Cd200 16 CD200 antigen 0.8163 0.001337
ENSMUSG00000073811 Ifna12 4 interferon alpha 12 0.8216 0.027747
ENSMUSG00000052217 Hbb-bh1 7
hemoglobin Z, beta-like embryonic
chain
0.8421 0.015833
ENSMUSG00000032496 Ltf 9 lactotransferrin 0.8481 0.018048
ENSMUSG00000021638 Ocln 13 occludin 0.8496 0.000507
ENSMUSG00000026471 Mr1 1 major histocompatibility complex,
class I-related
0.8561 7.08E-05
ENSMUSG00000029088 Kcnip4 5 Kv channel interacting protein 4 0.8600 0.004185
ENSMUSG00000074852 Hpse2 19 heparanase 2 0.8635 0.009457
ENSMUSG00000020891 Alox8 11 arachidonate 8-lipoxygenase 0.8728 0.003362
ENSMUSG00000022902 Stfa2 16 stefin A2 0.8830 0.012863
ENSMUSG00000031461 Myom2 8 myomesin 2 0.8968 0.000998
ENSMUSG00000021367 Edn1 13 endothelin 1 0.9035 0.003137
ENSMUSG00000055312
0610012H
03Rik
2 RIKEN cDNA 0610012H03 gene 0.9106 3.92E-06
ENSMUSG00000058952 Cfi 3 complement component factor i 0.9620 0.000408
ENSMUSG00000023078 Cxcl13 5 chemokine (C-X-C motif) ligand 13 1.0092 0.031794
ENSMUSG00000056054 S100a8 3
S100 calcium binding protein A8
(calgranulin A)
1.0283 0.007609230
Ensembl ID: Symbol: Chrom: Description: Log2FC: P.Value:
ENSMUSG00000069041 Slc25a31 3
solute carrier family 25
(mitochondrial carrier; adenine
nucleotide translocator), member
31
1.0969 0.03699
ENSMUSG00000073125 Xlr3b X X-linked lymphocyte-regulated 3B 1.1154 0.013755
ENSMUSG00000017737 Mmp9 2 matrix metallopeptidase 9 1.1458 0.000173
ENSMUSG00000072601 Ear1 14
eosinophil-associated, ribonuclease
A family, member 1
1.1506 0.001791
ENSMUSG00000031362 Xlr4c X X-linked lymphocyte-regulated 4C 1.1589 0.005512
ENSMUSG00000059657 Stfa2l1 16 stefin A2 like 1 1.1889 0.004943
ENSMUSG00000071561 BC100530 16 cDNA sequence BC100530 1.2444 0.01268
ENSMUSG00000054258 Gm5082 13 predicted gene 1.2495 0.002798
ENSMUSG00000032484 Ngp 9 neutrophilic granule protein 1.3976 0.012473
ENSMUSG00000022487 Gtsf1 15 gametocyte specific factor 1 1.4706 3.09E-05
ENSMUSG00000029322 Plac8 5 placenta-specific 8 1.5681 2.99E-05
ENSMUSG00000069792 Wfdc17 11 predicted gene 11428 1.6059 7.76E-06
ENSMUSG00000025196 Cpn1 19 carboxypeptidase N, polypeptide 1 1.9251 2.32E-07